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“Yes, I think it’s ambivalent, because on the one hand, if my child gets a medicine that 
has never been tested, I think that’s bad. But on the other hand, I also find it very bad 
when my child ... that he will test that medicine.”  
 Mother, focus group (chapter 6)
This mother is spot-on. I interviewed her in one of the empirical studies in this thesis. 
She describes the ethical dilemma that ethicists, philosophers, researchers, physicians, 
members of research ethics committees and other professionals have been wrestling 
with for many years regarding performing clinical research involving children. How can 
we conduct clinical research to advance scientific knowledge and develop much-needed 
treatment options for children while protecting children against harm from research? In 
this thesis, I aim to contribute to finding a balance in this dilemma.
eThical Dilemma in PeDiaTric clinical research
The core ethical dilemma in pediatric clinical research centers on finding a balance 
between advancement and protection.1 2 It is not one or the other but a balancing act 
that will allow us to advance science and maximally protect children.
We need to realize that without clinical research, every treatment in daily practice is 
actually an experiment. Clinical research with children is essential; otherwise, children 
turn into ‘therapeutic orphans’.3 Clinical research generates new data that we can use to 
develop new treatments for children, and these treatments are much needed. A lack of 
knowledge about drugs and other treatments in children may cause treatment failure 
and adverse events in children in clinical practice.4 5 There are some unfortunate ex-
amples, such as the treatment failure that was observed in neonates on extracorporeal 
membrane oxygenation (ECMO) with disseminated herpes simplex virus infection after 
they were given unresearched doses of acyclovir.6 7 There are no alternatives: performing 
research involving adults and extrapolating these data to children is not the solution 
either. Children are not small adults. For example, treatment of neonates with doses of 
chloramphenicol that were derived from research results in adults caused gray baby 
syndrome and even death in neonates.8 9
Fortunately, there are some initiatives to stimulate pediatric clinical drug research. In 
2006, the European Commission launched a directive that offered incentives to pharma-
ceutical companies to generate data in children.10 A similar initiative was set up in the 
United States (US).11 Unfortunately, these initiatives have not resulted in the expected 
reduction in off-label drug use in children for which they were designed.12 13 Off-label use 
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of drugs in children in diverse hospital settings still ranges from 10 to 65%.14 In children 
admitted to the Pediatric Intensive Care Unit (PICU) and in neonates, these numbers 
even go up to 70-90%.15 16 It seems there is still a discrepancy between the therapeutic 
needs and therapeutic offers, due to a lack of clinical research in children. 17 Therefore, 
clinical research is essential to provide safe and effective treatments for children.
At the same time, children need and deserve protection against the harm associated 
with research participation. In addition, this protection is and should be more stringent 
for them than for adults.1 2 Children are more vulnerable, as their distinct physiology 
puts them at increased risk of being harmed during research. Moreover, children are 
(relatively) incapable of protecting their own interests because of their dependency on 
others and due to their developing decision-making capacities. Because of this fact and 
a lack of legal competence, children (partly) rely on their parents to make decisions for 
them. Their parents decide for them, while the children are the ones participating in the 
research.
informeD consenT in PeDiaTric clinical research
Before children can participate in research, someone needs to make decisions about 
their research participation and consent to their participation. For children, this some-
one, in most cases, is their parent. To be precise, both parents need to consent to their 
child’s participation, and children need to co-consent or assent to research participa-
tion. An informed consent process empowers parents and children to make an informed 
decision about participation in clinical research. The importance of informed consent in 
pediatric clinical research is hardly ever questioned, but its effectiveness and validity are 
always a concern in practice. To illustrate these, I distinguish three values of informed 
consent in pediatric clinical research: legal, moral and instrumental values.
LegaL vaLue of informed consent in Pediatric cLinicaL research
The legal value of informed consent in pediatric clinical research concerns the arrange-
ment of the rights and duties between (the parents of ) the pediatric research participants 
and researchers. What then has been laid down in legislation about informed consent for 
pediatric research? Variation exists in the national legislative requirements for informed 
consent in pediatric clinical research worldwide.18 However, there are some common 
core elements. The core guideline concerning clinical research is as follows: no participa-
tion without prior informed consent of the research participant.1 2 19-21 Children have a 
special position in this issue. As mentioned earlier, children generally cannot make an 
autonomous, well-considered decision concerning research participation on their own 
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and therefore cannot consent to research. Their parents (or legal guardians)1i need to 
consent for them, which is called proxy consent. In the Netherlands, proxy consent is 
arranged in the Medical Research (Human Subjects) Act (WMO), precisely art. 6:1.21
How the views of children themselves are being taken into consideration in informed 
consent requirements differs by country. In many countries, an assent procedure is used 
for children. This means that although children cannot consent for themselves, to re-
spect children’s developing autonomy, they do need to assent to research participation. 
However, assent is very differently used in daily practice, and no consensus exists on an 
operational definition in legislation and guidelines.22
In the Netherlands, we go a step further in recognizing children’s decision-making 
capacities.23 In the Netherlands, children aged 12 years and older also need to officially 
consent for themselves next to their parents’ consent (art. 6:1.b WMO 1998). This is called 
dual consent or co-consent.23 For children below 12 years of age, researchers do not have 
to ask official consent but must ensure that children are informed about the research by 
an appropriately trained person in a manner befitting their ability to understand (art. 6:7 
WMO 1998). For this purpose, authors have suggested using illustrations or even comic 
strips to support the informed consent process for children.24 Children’s willingness 
to participate is also respected and reflected in a clause that states that when a child 
objects to or resists research procedures, the research will not commence or will not be 
continued (art 10.a:1 WMO 1998). During the time of the research on which this thesis 
is based, the legal age of consent for clinical research in the Netherlands shifted from 
18 years of age to 16 years of age.ii This revision of the WMO came into force in March 
2017 (art 6:1 WMO 1998) and was a result of a long-lasting discussion that had started 
with the ‘Committee Doek’ in 2009.25 26 This shift brought the age threshold in line with 
the thresholds used in the Dutch Medical Treatment Contracts act and incorporated new 
insights into children’s developing decision-making capacities.23 27
These legal requirements are, of course, crucial, but too much focus on the legal value 
of informed consent creates an informed consent process that is actually just a one-time 
achievement and, moreover, creates informed consent documents and conversations 
with complex scientific terminology, technical jargon and information that is irrelevant 
for decision-making but required from a legal perspective.28-30 In that way, the informed 
i   In the remainder of this chapter, whenever there is mention of ‘parents’, one can also read this term as ‘parents 
or legal guardians’.
ii  At the time of the empirical work presented in this thesis, the former legislation was still in force and dual 
consent of both the child and the parents was needed for 16- and 17-year-olds. As a result, the perspectives 
of (the parents of ) children who are 16 and 17 years of age are included in the empirical work in this thesis.
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consent process might be legally correct but often is inadequate in moral and instru-
mental terms.
moraL vaLue of informed consent in Pediatric cLinicaL research
The moral value of informed consent in general is the implementation of the ethical 
principle ‘respect for persons’. Respect for persons means that people are treated as 
autonomous agents and that people with diminished autonomy have a right to pro-
tection.19 To reach a complete meaningful and valid consent, five elements are distin-
guished: transmission of information, comprehension of this information, voluntariness 
(no coercion by others), competence to make a decision, and actual consent.31 These 
moral elements are particularly under pressure in pediatric clinical research.
The information related to clinical research is very complex: Advances in medicine have 
created complex clinical research protocols resulting in elaborate and complicated 
information to be conveyed to potential research participants and their parents during 
an informed consent process.28 30 32 Comprehension of such information is difficult for 
both the child and the parent.32-37 A study in the Netherlands indicated that material 
targeted to children was difficult for even adults to read and understand.32 In a study 
by Unguru and colleagues, half of the children were unaware that their treatment was 
in fact a research intervention.37 Chappuy and colleagues showed that after informed 
consent, half of the parents were not able to explain the aim of the research their child 
was participating in or to describe the potential benefit for their child.34 Furthermore, 
the competence of children varies greatly due to children’s developing decision-making 
capacities.38 Finally, due to children’s lack of legal competence, the actual consent for 
research is arranged by proxy consent of their parents. All these factors make the in-
formed consent process more complicated for pediatric clinical research than for clinical 
research with adults.23 39
instrumentaL vaLue of informed consent in Pediatric cLinicaL 
research
The instrumental value of informed consent in pediatric clinical research lies in the effect 
that informed consent can have on participation. Whereas the participation of children 
in pediatric research is a prerequisite for successful research, pediatric trials often have 
recruitment problems. One-third of RCTs in the PICU are generally terminated before the 
needed sample size is reached.40 An adequate informed consent process can increase 
the willingness to participate and decrease drop-out rates during participation in re-
search.41 42 When parents and children are not threatened by the complexity and amount 
of information but receive information that they consider helpful for their decision, they 
are probably more willing to participate, thereby increasing participation rates. By creat-
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ing realistic expectations of research participation during the informed consent process, 
potential participants and their parents know what they are getting themselves into, 
and the risk of surprises during the research is minimized.
informeD consenT anD moTivaTions in PeDiaTric clinical 
research
This thesis focuses mainly on the moral and instrumental values of informed consent 
in pediatric clinical research and seeks a way to tailor the process of recruitment and 
informed consent to the perspectives and needs of children and their parents. I would 
not state it as boldly as Waisel did in an editorial: “Let the patient drive the informed 
consent process: ignore legal requirements”.43 However, in my opinion, the legal value of 
informed consent should be the operationalization of the moral and instrumental value. 
In legislation, we lay down the requirements that are needed to achieve our moral and 
instrumental aims of informed consent.
Most national legislation specifies which aspects a person needs to be informed about 
when asked about research participation. For example, the Dutch WMO prescribes 
that people need to be explicitly informed about the objectives, nature and duration 
of the trial; the risks that the trial would present to the participant’s health; the risks 
that premature termination of the trial would present to the participant’s health; and 
the possible burden of the trial on the participant (art 6:5 WMO 1998). The rationale 
behind this requirement is that we see these aspects as crucial elements that must be 
understood in order to give meaningful and valid informed consent. However, are these 
the informational aspects that parents and children actually use in their decision? If they 
attach importance to completely different things and use other aspects in their decision 
but haven’t been informed about those other aspects, can we still call their agreement 
informed consent?
To learn to what parents and their children attach importance to, we should learn more 
about their motivations to participate in research. If we learn the motivating and dis-
couraging factors for their decision, we will know what information they use in their 
decision and about what factors they should be informed. This approach increases both 
the moral and instrumental value of informed consent; we obtain more informed con-
sent and probably more informed consent. During the course of this research, legislation 
in the US changed. Formerly, the prerequisite for valid informed consent consisted of 
only a list of facts that needed to be provided. Now the information that people use in 
their decision and the reason why they participate are central for informed consent.44 45 
14 Chapter 1
US legislation concerning clinical research (The Common Rule) now explicitly states 
the following: “Informed consent as a whole must present information in sufficient detail 
relating to the research, and must be organized and presented in a way that does not merely 
provide lists of isolated facts, but rather facilitates the prospective subject’s or legally au-
thorized representative’s understanding of the reasons why one might or might not want 
to participate…” (XIV.116.a.5i 49 CFR Part 11 2017).45 This legislation operationalizes the 
moral and instrumental value of informed consent by incorporating the motivations of 
potential participants directly into the legal requirements for informed consent.
In this thesis, I use a similar approach to optimize the recruitment and informed consent 
process in pediatric clinical research and tailor the process to the needs and perspec-
tives of children and their parents. I study and incorporate their views, motivations and 
expectations in the recruitment and informed consent process for pediatric clinical 
research. This analysis teaches us what information parents and children want and need 
to make a valid informed decision.
scoPe of This Thesis
With this thesis, I aim to contribute to the optimal inclusion of children in pediatric 
clinical research in such a way that we can further clinical research to advance scientific 
knowledge and develop much-needed treatment options for children while protecting 
children against harm from research.
Ethicists, researchers and physicians have extensively discussed the precarious balance 
between advancement and protection in pediatric research. However, how do children 
and their parents view this balance? Do they also weigh the possible harm against the 
benefits when they are approached for participation in clinical research? Or do they 
have other reasons and put other factors into the equation? Because children and their 
parents are the key decision-makers and children are ultimately the ones participating 
and undergoing the risk and burden of the research, it seems obvious that their views 
about this balance are crucial.
Why do children and parents want to participate (or not)? What are their motivations 
and what is important to them in their decision? What expectations do they have of 
participation? Answers to these questions are indispensable in order to incorporate 
their views into the pediatric research enterprise and tailor the process of recruitment 
and informed consent to their needs and perspectives. When we know why children and 
parents consent or dissent to research and what elements they use in their decision, we 
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know what they attach importance to in their decision. From this data, we learn which 
information they want and need to make a valid informed decision. This information 
helps us to increase both the moral and instrumental value of informed consent in 
pediatric clinical research.
research aims
Following the above, the main research aims of this thesis are as follows:
1. To explore children’s and their parents’ motivations, views and expectations during 
recruitment and informed consent processes in pediatric clinical research.
	 •  What are their motivations to consent/assent to participation in pediatric clini 
cal research? What factors influence their decisions?
	 • What are their views on recruitment and informed consent?
	 • What are their expectations of research?
2. To analyze these motivations, views and expectations and the factors that shape 
them from an ethical and legal perspective.
3. To develop a normative framework to support research professionals in the ethically 
sound inclusion of children in pediatric clinical research. This framework tailors the 
process of recruitment and informed consent to the perspective and the needs of 
children and their parents, who have the key role in decisions on research participa-
tion.
meThoDological aPProach
Combining normative thinking with empirical research has become increasingly com-
mon in bioethics.46 However, as much as its use has increased, this combination has also 
been criticized.47-49 As can be distilled from my introduction and research aims, I am 
not one of these critics. To achieve my research aims, I have used a variety of research 
methods by combining ethical theory with empirical research. Although I recognize that 
one cannot conclude that an action is in fact ethically right from an empirical finding 
that people believe the action is ethically right, in this thesis, I use results from empirical 
research others have carried out as well as the results of empirical research that I have 
performed myself to inform my normative reasoning.47 50 To explore and evaluate 
people’s moral beliefs, intuitions, behavior and reasoning in practice holds information 
that is meaningful for normative reasoning about that specific practice.51 To look into 
someone else’s views enables us to reflect on our own views and adapt them when nec-
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essary. Moreover, I believe this use of results from empirical research makes the results 
of my normative deliberation more ready for application in practice. It gives me insights 
in the practice I am reflecting on and trying to improve. In addition, this approach is 
imperative, especially in the field of research ethics, since the aim of research ethics is to 
evaluate research practices and to foster ethical research practices.52
It is, of course, crucial that the results extracted from empirical research are relevant 
and valid for my normative reasoning and are based on accepted standards of conduct 
for empirical research methods.53 54 Therefore, I have used several different types of 
research methods to collect relevant and valid qualitative and quantitative empirical 
results.50 I have collected morally relevant facts, studied morally relevant perspectives 
and combined them with relevant moral principles and background theories to achieve 
a reflective equilibrium.55 56
I have collected morally relevant facts among others by a review of the relevant rules 
and regulations concerning clinical research. For example, an evaluation of European 
pediatric research legislation (e.g., chapter 2) and guidelines concerning informed con-
sent/assent (e.g., chapter 3) are included.
I have studied morally relevant perspectives (e.g., motivations, views, expectations 
and intuitions) of children and their parents by performing a systematic review of the 
existing literature concerning motivations (chapter 4) and by performing two qualita-
tive studies: an interview study with children and parents from three hospital/research 
settings (chapters 5 and 8) and a focus group study with parents from the general public 
(chapter 6).
Relevant moral principles and background theories that I have used encompass, among 
others, the value of informed consent, the role of trust in decision-making (chapter 8) 
and the consequences and desirability of gatekeeping (chapter 7).
I have combined the above-mentioned empirical and normative elements into a reflec-
tive equilibrium to reach a coherent normative view that results in a normative frame-
work for an ethically sound recruitment and informed consent process for pediatric 
clinical research (chapter 9).
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ouTline of This Thesis
chapter 2 sketches the European regulatory landscape for pediatric clinical research 
and shows how specific ethical issues regarding clinical research with children, such as 
informed consent/assent and risk-benefit thresholds, are incorporated into the relevant 
legislation.
chapter 3 gives an overview of the ethical challenges that arise when planning and 
conducting clinical research with a specifically vulnerable group of children, namely, 
critically ill children in the PICU. This chapter discusses ethical challenges concerning 
study design, informed consent and risk and burden and proposes several solutions to 
these ethical challenges.
chapter 4 reviews the empirical literature concerning motivations of children and their 
parents to consent and dissent to pediatric clinical drug research. This chapter provides 
a comprehensive overview of the motivating and discouraging factors that influence 
children’s and their parents’ decisions to participate in pediatric clinical drug research 
reported in the empirical literature.
chapter 5 reports on a qualitative interview study aimed at gaining insight into chil-
dren’s and their parents’ motivations, views and expectations during the process of 
recruitment and informed consent for pediatric clinical research. This interview study 
presents perspectives from three different hospital settings: children and their parents 
in pediatric oncology, pediatric pulmonology (subdivision: cystic fibrosis) and the PICU.
chapter 6 reports on a qualitative focus group study aimed to explore parents’ perspec-
tives on decisions to participate in pediatric clinical research. This focus group study was 
performed with parents from the general public to add the intuitions and motivations 
of non-professionalized (non-hospitalized) parents to the body of empirical evidence.
chapter 7 discusses the phenomenon of gatekeeping in the recruitment for pediatric 
clinical research. Gatekeeping is a practice in which research professionals have implicit 
inclusion and exclusion criteria that lead to not approaching all eligible research par-
ticipants. This chapter argues that although this practice is understandable in pediatric 
clinical research, it is ethically undesirable.
chapter 8 discusses the different types of trust that children and their parents have in the 
research enterprise illustrated with empirical results from the interview study presented 
in chapter 5. This chapter also sketches how this trust influences their decision-making 
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and how it emphasizes the necessity of prior review of a research ethics committee and 
its filtering task.
chapter 9 concludes this thesis with a general discussion in which I combine the main 
findings of the preceding chapters into a normative framework for research profession-
als to include children in an ethically sound manner in pediatric clinical research. This 
framework tailors the process of recruitment and informed consent to the perspective 
and the needs of children and their parents.
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Over the past decades, clinical research has increasingly been subjected to ethical 
requirements and legal regulation. The specific focus of ethical and legal frameworks 
on competent adults (which serve as the paradigmatic research subject), however, has 
created an ambivalent attitude towards pediatric clinical research. On one hand, minors 
are regarded as a vulnerable population that deserves additional protection against the 
risks and burdens involved in clinical research. On the other hand, the population of mi-
nors should not be denied (or not get timely) access to the benefits of clinical research. 
In this chapter, we will explore the legal regulation and ethical guidance that currently 
governs pediatric clinical research in the European Union and discuss the future chal-
lenges in this field. In addition, we will discuss major ethical concerns in pediatric clinical 
research, with a focus on the acceptability of research risks and the informed consent 
process. In the discussion, we will address key concerns in both regulating pediatric 
clinical research and implementing ethical and legal requirement in the actual pediatric 
research conduct.
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inTroDucTion
Over the past decades, clinical research has increasingly been subjected to ethical re-
quirements and legal regulation. Since the Second World War, landmark codes of ethical 
research conduct have been drafted and legal regulation has been issued in the US, the 
European Union (EU), and many other countries. Despite the considerable diversity in 
ethical and legal requirements, there has always been consensus on the cornerstones 
of ethical research conduct. For example, the doctrine of informed consent, the premise 
that the interest of science and society should not prevail over those of the individual, 
and the fact that human subjects should never be exposed to unnecessary risks in clini-
cal research have been widely endorsed from the very start. 
The historical efforts to secure an adequate protection of human subjects in clinical re-
search have been grafted on a paradigmatic research subject: the competent adult. This 
specific focus, however, has created an ambivalent attitude towards pediatric clinical 
research. On the one hand, minors are regarded as a vulnerable population that deserves 
additional protection against the risks and burdens involved in clinical research. Such a 
protection could not be maximized further than in a full exclusion of minors from clinical 
research. On the other hand, the population of minors should not be denied (or not get 
timely) access to the benefits of clinical research. The impressive share of drugs that are 
prescribed off-label or off-license in pediatric practice,1 however, clearly indicates that 
research in competent adults does not automatically generates timely advancements in 
the diagnosis, care, and treatments for minors. Minors are not just small adults, and omit-
ting to conduct clinical trials in the population of minors turns minors into ‘therapeutic 
orphans’.2 3 By consequence, the conduct of pediatric clinical trials is indispensable to 
catch up with the lack of licensed drugs that are labelled for pediatric use. 
From an ethical and legal point of view, however, the conduct of pediatric clinical trials 
is a precarious enterprise, as it often remains difficult to balance scientific advancement 
with the adequate protection of minors.4 5 In addition, several hurdles such as difficult 
recruitment, market issues (e.g., a problematic return on investment for pediatric clini-
cal research), and restrictive regulation (e.g., risk thresholds for non-beneficial research) 
may be hard to surpass. 
In this chapter, we will explore the legal regulation and ethical guidance that currently 
governs pediatric clinical research and discuss the future challenges in this field. In this 
respect, it must be emphasized that the applicable ethical and legal frameworks are 
often formulated in general terms, while pediatric research is a very heterogeneous 
landscape. As such, these frameworks may fail to respond directly to the specific ethical 
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issues that come to the surface in practice. Certain issues therefore call for an appropri-
ate ethical approach, which cannot be derived easily from the available ethical and legal 
guidance. Table 1 lists a number of such issues. 
Table 1: Recognized problems from a clinical point of view in critically ill minors
recognized problems from a clinical point of view in critically ill minors
1.  The compassionate use at an individual base as a last resort drug (Imatinib) for pulmonary hypertension original 
labelled as an anti-cancer drug.
2.  The conduction of first in men studies such as new amino acid composition for parenteral nutrition in extreme low 
birthweight infants in the absence of adult data.
3.  The application of a therapeutic modality (for instance liquid ventilation with an organ preservation substance) in the 
absence of safety data.
4. Invasive fetal treatment modalities guided by industrial progress and not supported by properly designed RCTs.
5.  Opportunistic sampling of residual blood samples from routine laboratory test, as well as dry blood spot sampling 
with the aim to determine drug levels.
6.  Diagnostic procedures such as PET-scans to obtain normal values for the age-dependent distribution of opioid 
receptor isoforms in the central nervous system needed radioactive labelled substance.
The regulaTion of eThical issues in PeDiaTric clinical 
research in The eu
the LegaL reguLation governing Pediatric cLinicaL research in the eu
In the EU, various supranational and national regulations that have been promulgated 
by diverse legislative bodies over the past 15 years aim to harmonize existing standards 
of good clinical practice and to facilitate and encourage pediatric clinical research.6 At 
the supranational level, three different regulations govern pediatric research conduct. 
First, the Council of Europe issued the European Convention for the Protection of Hu-
man Rights and Dignity of the Human Being with Regard to the Application of Biology 
and Medicine in 1997 (further, the Oviedo Convention).7 In 2005, this convention was 
supplemented with an additional protocol on biomedical research.8 To date, the Oviedo 
Convention is binding for the 17 EU member states (and 12 countries outside the EU) 
that have signed and ratified it. The Convention specifically addresses the issue of pedi-
atric research in Article 17 (Table 2).
Second, Directive 2001/20/EC (further, the Clinical Trials Directive) mainly aims at a har-
monization of the provisions regarding good clinical practice and the facilitation of mul-
ticenter clinical trials across the borders of individual EU member states.9 All EU member 
states were bound to implement this directive into national law, with the freedom to 
adopt stricter provisions than those set down in the text of the directive (as long as the 
standards of protection and time limits captured in the directive were not violated). By 
consequence, there exists considerable variety among the national laws that implement 
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the Clinical Trials Directive. Obviously, differences in domestic requirements between 
EU member states must be taken into account when conducting a trial in a specific EU 
member state. The Clinical Trials Directive specifically addresses the issue of involving 
minors in research in Article 4 (Table 3).
Table 2: Oviedo Convention - Article 17
article 17: Protection of persons not able to consent to research
1.  Research on a person without the capacity to consent as stipulated in Article 5 may be undertaken only if all the 
following conditions are met:
 i. the conditions laid down in Article 16, sub-paragraphs i to iv, are fulfilled;
 ii. the results of the research have the potential to produce real and direct benefit to his or her health;
 iii. research of comparable effectiveness cannot be carried out on individuals capable of giving consent;
 iv. the necessary authorization provided for under Article 6 has been given specifically and in writing; and
 v. the person concerned does not object.
2.  Exceptionally and under the protective conditions prescribed by law, where the research has not the potential to 
produce results of direct benefit to the health of the person concerned, such research may be authorized subject 
to the conditions laid down in paragraph 1, sub-paragraphs i, iii, iv and v above, and to the following additional 
conditions:
 i.  the research has the aim of contributing, through significant improvement in the scientific understanding of the 
individual’s condition, disease or disorder, to the ultimate attainment of results capable of conferring benefit 
to the person concerned or to other persons in the same age category or afflicted with the same disease or 
disorder or having the same condition;
 ii. the research entails only minimal risk and minimal burden for the individual concerned.
Table 3: Clinical Trials Directive – Article 4
article 4: clinical trials on minors
In addition to any other relevant restriction, a clinical trial on minors may be undertaken only if:
a.  the informed consent of the parents or legal representative has been obtained; consent must represent the minor’s 
presumed will and may be revoked at any time, without detriment to the minor;
b.  the minor has received information according to its capacity of understanding, from staff with experience with 
minors, regarding the trial, the risks and the benefits;
c.  the explicit wish of a minor who is capable of forming an opinion and assessing this information to refuse 
participation or to be withdrawn from the clinical trial at any time is considered by the investigator or where 
appropriate the principal investigator;
d. no incentives or financial inducements are given except compensation;
e.  some direct benefit for the group of patients is obtained from the clinical trial and only where such research is 
essential to validate data obtained in clinical trials on persons able to give informed consent or by other research 
methods; additionally, such research should either relate directly to a clinical condition from which the minor 
concerned suffers or be of such a nature that it can only be carried out on minors;
f. the corresponding scientific guidelines of the Agency have been followed;
g.  clinical trials have been designed to minimize pain, discomfort, fear and any other foreseeable risk in relation to the 
disease and developmental stage; both the risk threshold and the degree of distress have to be specially defined and 
constantly monitored;
h.  the Ethics Committee, with pediatric expertise or after taking advice in clinical, ethical and psychosocial problems in 
the field of pediatrics, has endorsed the protocol; and 
i. the interests of the patient always prevail over those of science and society.
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Third, Regulation (EC) No. 1901/2006 (further, the Pediatric Regulation) requires that 
clinical trials in minors be planned and conducted for all new products entering the 
market.10 In this respect, sponsors must make a pediatric investigation plan after 
phase 1 trials in adults have been completed (in certain cases, waivers are possible). 
In return for the efforts to plan and conduct trials in minors, the Pediatric Regulation 
offers considerable rewards in the form of a prolongation of market exclusivity. The 
Pediatric Regulation also arranged the establishment of a pediatric committee within 
the European Medicines Agency that is (among other tasks) primarily responsible for 
the scientific assessment and agreement of pediatric investigation plans and for the 
system of waivers and deferrals thereof. In contrast to the European Convention and the 
European Directive, the Pediatric Regulation is exclusively dedicated to clinical research 
in minors. 
diversity and inconsistency of the current reguLation
Unfortunately, the legal frameworks that govern pediatric clinical research in the EU 
contain contradictory provisions and lack internal consistency in several matters. With 
regard to non-beneficial research, for example, Article 17.2 of the Oviedo Convention 
stipulates that in the absence of a direct benefit to the individual research participant, 
a minor can be involved in research only if the study entails minimal risks and minimal 
burdens, while Article 4e of the Clinical Trials Directive simply requires ‘some direct 
benefit’ to the research subject or a related group of beneficiaries. This indicates that the 
Oviedo Convention endorses a more restrictive policy than the Clinical Trials Directive 
and implies that early stage drug development may be compromised in member states 
that have signed and ratified the Oviedo Convention. Also with regard to the right of a 
minor to veto participation in clinical research, contradictory provisions exist: Article 4c 
of the Clinical Trials Directive stipulates that the (principal) investigator must consider 
the explicit wish of a minor to refuse or discontinue participation (given that the minor is 
capable of assessing information and forming an opinion), whereas Article 17.1v of the 
Oviedo Convention states that minors cannot be involved in a study when they object 
to research participation. Thus, the Oviedo Convention grants minors a more extensive 
decision-making capacity than the Clinical Trials Directive does. 
In addition to these contradictory provisions, the European legal framework contains 
numerous contingencies that require extensive interpretation. It is not clear, for ex-
ample, what must be understood to be an acceptable risk–benefit ratio, what it means 
to ‘consider’ the explicit dissent of a minor, how the capacity of minors to make decisions 
can be assessed, or why the Clinical Trials Directive refers to minor research participants 
as ‘patients’ and links benefits to the ‘group of patients’. The fact that many terms are not 
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clearly defined is likely to negatively affect the implementation of the European legal 
framework and creates the need for accurate guidance and support. 
At the level of domestic regulation, requirements for the inclusion of minors in clinical 
research (e.g., age criteria) vary from country to country, which obviously has profound 
implications for the conduct of multinational trials.11 The differences in interpretation 
and assessment of the acceptability of risks among European member states have im-
portant consequences. For example, trial protocols can be rejected in one member state 
because the risks or burdens exceed the applicable minimal risk and minimal burden 
thresholds, but still take place in other European member states, where these thresholds 
are not adopted into national law. Obviously, this may be very frustrating for researchers 
and minor patients and their parents who are committed to the trial. It also might con-
centrate certain types of non-beneficial research in a selected number of EU member 
states, while successful trials will result in drug licenses that cover all EU member states. 
This generates important justice-related issues. The premise that risks and burdens call 
for a proportionate counterpart, by preference in the form of a direct benefit to the 
research subject, challenges the involvement of minors in phase 1 research or the use of 
healthy controls in pediatric clinical trials. There is considerable controversy over the fact 
that some risks and burdens would not need any compensation and that mere altruism 
can have a place in clinical research.
eThical issues in PeDiaTric clinical research
The extensive body of legal regulation that has been developed over the past 15 years 
has not reduced the need for sound ethical reflection. In this chapter, we will discuss two 
major ethical concerns in pediatric clinical research: the acceptability of research risks 
and the informed consent process. 
accePtabiLity of research risks 
Clinical trials entail risks and burdens. Minors are a vulnerable population, and one 
should be vigilant to expose vulnerable subjects to risks and burdens. Therefore, pro-
cedures have been made to review the acceptability of risks and burdens in pediatric 
clinical trials, in which research ethics committees play a prominent role. The main ra-
tionale behind the assessment of research risks is that such risks call for compensation. 
This rationale is made operational in the principle of proportionality, according to which 
risks can be justified by a proportionate counterpart, for example in the form of a direct 
benefit to the research subject. Against this background, therapeutic research (research 
that is likely to generate a direct benefit for the subject involved) is often distinguished 
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from non-therapeutic research (research that is not likely to generate a direct benefit 
for the subject involved). While proportionality can be regarded as a general principle, 
exceptions are possible. Very small risks and burdens (often defined as ‘minimal risks’ 
and ‘minimal burdens’) for example can be deemed acceptable without a proportionate 
compensation in the form of a direct benefit to the research subject. 
In practice, deciding upon risks is a precarious enterprise. First, it is hard to measure 
benefit, risk, and burden and to assess their proportionality in a reliable way. Although 
risks may be determined using objective criteria or other systems for risk evaluation,12 
such criteria do not account for the subjective personal experience of risks, burdens, and 
benefits of research subjects, which may be closely related to their condition, disease, 
and personal experience. 
Second, also the review of risks and burdens by ethics committees is not a mechanical 
or fully objective procedure. Indeed, the deliberation of one and the same protocol by 
different ethics committees may have significantly different outcomes. Several factors, 
such as differences in the composition of ethics committees (which varies from country 
to country) or differences in the methods and procedures (e.g., for assessing risks), may 
nourish diversity in outcome. For example, in many European countries, non-beneficial 
research is subjected to a stringent minimal-risk- and minimal-burden threshold, while 
in others, no explicit distinction between therapeutic and non-therapeutic research is 
made by law, and proportionality between risks and benefits is not linked to specific risk 
thresholds. 
informed consent for Pediatric cLinicaL research 
The doctrine of informed consent has been widely used to serve two functions. Legally, 
informed consent settles the relationship between the researchers and the subjects 
participating in the research. Ethically, informed consent serves as an operational imple-
mentation of the principle of respect for persons. As such, informed consent is to protect 
research subjects from deception, coercion, and abuse.
In its original design, the doctrine of informed consent has been grafted on the paradig-
matic research subject of the competent adult. As such, valid decisions to participate in 
research must in principle be made voluntarily and by legally competent adults, after 
being duly informed on the nature, significance, implications, and risks and burdens 
of the research. For several reasons, this paradigm has serious workability problems 
when applied to the setting of pediatric clinical research. First, due to age restrictions, 
most minors are not capable of granting legally valid consent, as they may not have 
reached the age of medical majority (or have not been emancipated, e.g., by marriage).13 
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Second, the capacity to understand and assess information is often still underdeveloped 
in minor research subjects. As a result, minors may lack the competence necessary to 
make rational decisions and it may be difficult to inform minors duly. Third, parents 
enjoy considerable discretion in the way they raise their children and all the decisions 
that this entails. Against this background, parents are almost always involved in deci-
sions to enroll a minor in a clinical trial, even when the minor is mature enough to make 
decisions on his or her own. 
The involvement of a competent adult acting as a surrogate/ proxy decision-maker is 
thus most often required to enroll a minor in a clinical trial. Obviously, such involve-
ment of a proxy does not preclude minors from playing an active role in decisions about 
clinical trial participation. Quite the reverse, if parental consent is to be held to the same 
ethical standard as informed consent provided by a competent adult, the child who is 
participating in research must somehow be involved in the decision-making process. 
Several decision-making strategies, including: 1) Dual consent (by the minor and the 
proxy decision-maker); 2) Consent by the proxy and assent (affirmative agreement of 
a minor to participate in research) by the minor; 3) Respect for the dissent of the child, 
therefore aim at encouraging shared decision-making and a fair differentiation of deci-
sion authority between the proxy decision-maker and the minor research subject. 
vuLnerabiLities in the informed consent Process
Informed consent, proxy consent, assent, and dissent are simple in design. In practice, 
however, (proxy) informed consent, informed assent, and dissent are complex and pre-
carious processes, in which all involved face important obstacles.
First, informed consent is delicate because understanding what it means to participate 
in research appears hard to realize in practice. For example, research shows that par-
ents sometimes do not remember having consented to enroll their child in a clinical 
trial.14-16 Also the understanding of information and recalling what one has consented 
to are difficult. In this respect, Chappuy and colleagues have described an apparent 
discrepancy between the evaluation of the adequacy of information by parents, and the 
actual understanding and recalling of this information by these parents.16 Parents also 
tend to overestimate their understanding in comparison to an assessors’ estimation of 
parental understanding.17 In addition, specific elements, such as random allocation and 
potential risks, are difficult to understand for parents. The parental understanding of the 
concept of random assignment, for example, has been shown to be doubtful,18 19 and 
in a study done by Ballard and colleagues, only 5% of the parents who understood the 
study understood the potential risks.14 The poor understanding of information applies 
to the consent as well as to the assent process.20 21 
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Second, informed consent presupposes a distinction between research and therapy. 
In pediatrics, however, research does not necessarily start where therapy ends. This 
is particularly true for the setting of pediatric oncology, where nearly all patients are 
receiving their treatments in the context of a trial. But also in other settings, several 
factors may blur the theoretically rigid distinctions between therapy and research. For 
interventional studies, for example, it may not suffice for parents to be informed about 
the trial, the risks, and the benefits according to the specificities described in the study 
protocol. Rather, they may want to know why it would be worthwhile for their child to 
participate in this trial, taking the medical history and current treatment regimen into 
account. As such, trials may enter the therapeutic realm. In addition, minors and their 
parents often find it difficult to understand and keep in mind the difference between 
research and therapy, which may induce ‘therapeutic misconception’ in the informed 
consent process.22 Therefore, when research is framed in a therapeutic context, it is of 
key importance that research is also distinguished from therapy. In this respect, it is 
particularly important to communicate for example what the patient can expect after 
the trial has been terminated. 
Third, the considerable differentiation in expertise, tasks, and responsibilities among 
minors, their parents, and clinicians constitutes asymmetric relationships that compli-
cate decisions on clinical trial participation.23 This asymmetry creates a dependency of 
minors and their parents upon each other and upon clinicians to provide, explain, and 
frame information, which raises serious ethical concerns about conflicts of interests, 
uncritical loyalty towards physicians, and information bias.24-27 Nonetheless, all of these 
issues can be addressed adequately and need not be a hurdle to the establishment of 
relationships of mutual trust between all individuals involved in the decision.28 29 
Fourth, one should be vigilant that informed consent does not become mere ‘docu-
mented consent’. For several reasons, the signature of a document by no means guar-
antees a duly informed, well-considered, rational decision. First, the fact that informed 
consent is granted by competent persons does not imply that competences are actually 
used to take a stance towards a study protocol. Rationality is not necessarily the golden 
standard of all important decisions we make in life, and other factors (particularly tacit 
elements like hope, trust, or dependency) may shape decisions to grant informed con-
sent. Several studies indicate issues that work against rational decision-making, such as 
inadequacies in understanding the research,16-18 20 30 and emotional distress.31 Second, 
Pinxten suggested that consent discussions can be well-considered and rational deci-
sions, but might be a priori decisions as well, representing and confirming a positive (or 
negative) stance towards research that parents already had before recruitment.32 Third, 
time constraints and the urgency of the situation may influence the consent process, for 
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example in emergency settings, or when inclusion in the protocol must be completed 
shortly after the diagnosis of a serious disease. 
Discussion anD conclusion
Dealing with the ethical issues in pediatric clinical research is complex and delicate. Now 
that a growing body of ethical reflection and legal regulation aims to guide the ethical 
conduct of clinical trials in Europe for more than 10 years, it is important to reflect on 
how the available ethical and legal frameworks affect actual practice. For example, do 
the current ethical and legal frameworks adequately respond to the needs of the differ-
ent stakeholders involved in the actual conduct of pediatric clinical research? And (how) 
are available guidelines implemented in practice? When addressing these questions, 
several considerations should be taken into account. 
First, it must be emphasized that ethics, the law, and ethics committees do not establish 
ethical research conduct as such. Researchers and other health care professionals play a 
key role in the practical realization of ethical research conduct. The evolution of newer 
ways of data acquisition such as opportunistic sampling, dry blood spot technology, and 
the development of biobanks renders new challenges as well. Ethical requirements and 
legal regulations need to be interpreted and applied in practice, taking into account the 
heterogeneity of the pediatric population and the large diversity of research projects. 
Second, one should be vigilant not to confuse the operational implementation of ethical 
principles, with the successful approach of ethical concerns as such. For example, ob-
taining signed informed consent does not automatically imply respect for persons. 
Third, one should always keep in mind that it is all about the minor. In this respect, 
minors should not only get opportunities to participate in decisions concerning their 
health and/or participation in clinical research, they should also be given the freedom 
to take or leave these opportunities as they wish. For example, respect for minors may 
be fostered by maximizing their participation in the informed consent process (taking 
their understanding and maturity into account). Still, one should also consider the wish 
of a minor not to take part in the informed consent process, even if the minor concerned 
is sufficiently mature and capable of understanding what the trial is about. According 
to the current ethical and regulatory frameworks, however, this may not always be fully 
possible in practice, for example when assent or dual consent is explicitly required. 
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Finally, the challenge ahead is to foster ethical conduct in all involved. The mere existence 
of ethical reflection and legal regulation, by no means, implies a successful translation to 
practice. In addition, it would be unreasonable to expect from minors and their parents 
to just own the skills and know-how that are required to make well–considered deci-
sions on participation in a clinical trial. However, at present, easily accessible support 
for minors and their parents in deciding on research participation is still largely lacking. 
The same holds for the challenging tasks that researchers or other medical practitioners 
face in pediatric clinical trials. Therefore, efforts should be made to employ the vast 
and unexplored potential of empowering all involved for the advancement of ethical 
conduct in pediatric clinical research.
aDDenDum
The article, on which this chapter is based, was published in 2013. At that time the new 
European Clinical Trials Regulation was being drafted. On April 2nd 2014 the European 
Parliament approved the new Clinical Trials Regulation (Regulation No. 536/2014).33 As 
soon as it comes into force, expectedly in 2020, this regulation will repeal the Clinical 
Trials Directive (Directive 2001/20/EC)9 discussed in this chapter. The goal of the new 
Regulation is to simplify and harmonize the scientific and ethical review of clinical trials 
in the EU. In contrast to the current directive, in which EU member states are bound to 
implement the requirements from the directive into their national laws, the upcoming 
regulation has direct binding legal force in all EU member states.
Regarding pediatric clinical research, the new Regulation differs from the Directive in 
several respects. Some differences concern small details, while others are more substan-
tial. For pediatric clinical research the main differences are related to the risk and burden 
thresholds in research without a potential direct benefit and the informed consent 
process.
Concerning the informed consent process for example, the regulation now states that 
a child who reaches the age of legal competence during a trial explicitly needs to con-
sent before he can continue to participate (art 32:3 Clinical Trials Regulation). Another 
example, also relevant for pediatric clinical research, relates to new rules for informed 
consent in emergency situations. In contrast to the current regulation, article 35 of the 
Regulation now arranges conditions for the acceptability of deferred consent in emer-
gency situations.
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The main change concerning risk and burden thresholds in pediatric clinical research 
without a potential direct benefit can be found in article 32 of the new Regulation (table 
4), which is the counterpart of article 4 in the Clinical Trials Directive. As previously dis-
cussed in this chapter, the current Clinical Trials Directive does not provide limits regard-
ing the acceptable levels of risk and burden for pediatric research without a prospect of 
direct benefit; it doesn’t even distinguish between pediatric research with or without 
a prospect of direct benefit (art 4 Clinical Trials Directive). By contrast, the new Regula-
tion does make this distinction and sets limits to risk and burden in pediatric research 
without a prospect of direct benefit. It states that research with no direct benefit for the 
participating minor should have some benefit for the populations represented by the 
minor (group-relatedness) and may pose only minimal risk and burden to the minor in 
comparison with standard treatment of the minor’s condition (art 32:1:g:ii Clinical Trials 
Regulation). 
Due to the directly binding nature of the upcoming regulation to all EU member states 
the Dutch Medical Research (Human Subjects) Act (WMO) had to be adapted and aligned 
Table 4: Clinical Trials Regulation – Article 32
article 32: clinical trials on minors
1.  A clinical trial on minors may be conducted only where, in addition to the conditions set out in Article 28, all of the 
following conditions are met:
 a. the informed consent of their legally designated representative has been obtained;
 b.  the minors have received the information referred to in Article 29(2) in a way adapted to their age and mental 
maturity and from investigators or members of the investigating team who are trained or experienced in 
working with children;
 c.  the explicit wish of a minor who is capable of forming an opinion and assessing the information referred to 
in Article 29(2) to refuse participation in, or to withdraw from, the clinical trial at any time, is respected by the 
investigator;
 d.  no incentives or financial inducements are given to the subject or his or her legally designated representative 
except for compensation for expenses and loss of earnings directly related to the participation in the clinical 
trial;
 e.  the clinical trial is intended to investigate treatments for a medical condition that only occurs in minors or the 
clinical trial is essential with respect to minors to validate data obtained in clinical trials on persons able to give 
informed consent or by other research methods;
 f.  the clinical trial either relates directly to a medical condition from which the minor concerned suffers or is of 
such a nature that it can only be carried out on minors;
 g. there are scientific grounds for expecting that participation in the clinical trial will produce:
  i. a direct benefit for the minor concerned outweighing the risks and burdens involved; or
  ii.  some benefit for the population represented by the minor concerned and such a clinical trial will pose only 
minimal risk to, and will impose minimal burden on, the minor concerned in comparison with the standard 
treatment of the minor’s condition.
2. The minor shall take part in the informed consent procedure in a way adapted to his or her age and mental maturity.
3.  If during a clinical trial the minor reaches the age of legal competence to give informed consent as defined in the 
law of the Member State concerned, his or her express informed consent shall be obtained before that subject can 
continue to participate in the clinical trial.
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with the upcoming Regulation.34 Before March 1st 2017, the WMO held more restrictive 
risk and burden thresholds for pediatric clinical research without a prospect of direct 
benefit (former art 4:1 WMO) Currently, the adapted WMO holds the same thresholds 
as the upcoming regulation (new art 3:1:d WMO). In practice, this means that there has 
been a shift in the Netherlands towards allowing non-therapeutic research with more 
risk and burden to be offered to children and their parents than before. The old Dutch 
standard imposed a limit of minimal risk and burden, but the new puts the threshold 
at minimal risk and burden compared to standard treatment. How this comparator is 
going to be used is inevitably a topic of discussion. What if the standard is very burden-
some and risky, does that mean these children can be exposed to similar high risks and 
burden, for non-therapeutic research purposes?
In relation to the new Clinical Trials Regulation the European Commission expert group 
on clinical trials revised in 2017 the ‘Ethical considerations for clinical trials on medicinal 
products conducted with minors’.35 To draft this revision a working group lead by the 
Dutch Ministry of Health, Welfare and Sports was established.iii The main objective of 
this revision was to align the document with the upcoming Clinical Trials Regulation 
and with the latest scientific and ethical insights regarding research with children. The 
revised document is meant for all parties involved in research with children, including 
research professionals, RECs, other regulatory authorities and potential participants 
and their families. It gives guidance on various ethical aspects of pediatric clinical re-
search from birth up to the age of legal competence to provide informed consent. This 
guidance addresses among others: the informed consent process, risk thresholds, and 
required expertise for trial assessment. For example, based on new empirical and ethical 
insights elaborate changes have been made pertaining to the involvement of children 
in the decision-making process. The document also discusses new insights into how to 
minimize risk and burden for children participating in research. 
iii  I was a member of this working group. Insights from research presented in this thesis were implemented in 
the revision. They relate to taking into account motivations of parents and children not only in the recruit-
ment and informed consent process but also during the design of the research, the importance of focusing 
on (logistical) burden and methods of minimizing that burden.
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Critical illness and treatment modalities change pharmacokinetics and pharmacody-
namics of medications used in critically ill children, in addition to age-related changes in 
drug disposition and effect. Hence, to ensure effective and safe drug therapy, research 
in this population is urgently needed. However, conducting research in the vulnerable 
population of the pediatric intensive care unit (PICU) presents with ethical challenges. 
This chapter addresses the main ethical issues specific to drug research in these critically 
ill children and proposes several solutions.
The extraordinary environment of the PICU raises specific challenges to the design and 
conduct of research. The need for proxy consent of parents (or legal guardians) and the 
stress-inducing physical environment may threaten informed consent. The informed 
consent process is challenging because emergency research reduces or even eliminates 
the time to seek consent. Moreover, parental anxiety may impede adequate understand-
ing and generate misconceptions. Alternative forms of consent have been developed 
taking into account the unpredictable reality of the acute critical care environment.
As with any research in children, the burden and risk should be minimized. Recent devel-
opments in sample collection and analysis as well pharmacokinetic analysis should be 
considered in the design of studies.
Despite the difficulties inherent to drug research in critically ill children, methods are 
available to conduct ethically sound research resulting in relevant and generalizable 
data. This should motivate the PICU community to commit to drug research to ultimately 
provide the right drug at the right dose for every individual child.
Pediatric clinical research in the PICU: Ethical challenges and solutions 43
inTroDucTion
Drug research in children balances between the advancement of knowledge – and 
consequently improvement in clinical care – and protection of this vulnerable popula-
tion susceptible to harm and exploitation. Children are relatively incapable of protecting 
their own interests and therefore need additional protection as recognized in many 
international ethical and legal documents concerning research with humans.1-4 Specific 
provisions for minors, for example relating to the informed consent process and the 
acceptability of burden and risk have recently been reviewed by our group.5 These provi-
sions pose challenges to research in children. Failing to conduct clinical trials in minors 
turns children into ‘therapeutic orphans’ because the level of protection is not balanced 
with the need of generating knowledge to improve care.6
the need for drug research in chiLdren
We need to be aware that every medication used in clinical practice that has not been 
studied in clinical trials can be considered an experiment. Clinical drug trials in children 
are essential because data on effectiveness and safety often cannot reliably be derived 
from data in adults. Major changes in pharmacokinetics (PK) and pharmacodynamics 
(PD) occur with increasing age due to changes in body composition, ontogeny of drug 
metabolism and transport and renal function.7 The relative lack of knowledge on drug 
disposition can lead to treatment failure8 9 and adverse events as serious as fatalities.10 11 
It is known that extrapolation from adult data has caused harm in the past. For example, 
a lack of knowledge on ontogeny of enzymes responsible for conjugation caused grey 
baby syndrome in neonates treated with doses of chloramphenicol derived from adult 
studies.12 13 Similarly, drug choice and dosing for patients in the pediatric intensive care 
unit (PICU) cannot always be derived from research in the general pediatric popula-
tion because PK/PD is influenced by critical illness [e.g. inflammation, liver and renal 
failure)14-17 and its treatment modalities (e.g. extra corporeal membrane oxygenation 
(ECMO), hypothermia, continuous renal replacement therapy).18-20 
Some drugs (such as vasoactive and sedative drugs) are almost exclusively used in 
critically ill children, and therefore can only be researched in these patients. However, a 
large proportion of drugs used in pediatric practice has not been systematically tested 
in the pediatric population. To stimulate pediatric drug research the Best Pharmaceu-
ticals for Children Act in the US and a similar directive in Europe offered incentives to 
pharmaceutical companies to generate data in children.21 22 Regrettably, fewer than 50% 
of these studies and 26% of those focusing on safety were published in peer-reviewed 
journals. Moreover, studies on safe and efficient drugs were more likely to be published 
than studies resulting in negative labelling change, putting children at risk of inefficient 
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or unsafe prescriptions.23 Although these stimulating measures generated some useful 
safety and prescribing information in children, they did not result in the expected reduc-
tion of off-label use.24 25 Estimates of off-label use in the pediatric population still range 
from 10-65%.26 In the PICU, even up to 70% of drugs are unlicensed or off-label, which 
reflects the lack of knowledge on drug efficacy and safety in the PICU population.27-29 
chaLLenges of drug research in the Picu
The previous paragraph has made clear that drug research in the PICU is essential. 
But research in this population of critically ill children is precarious and raises specific 
ethical challenges. These challenges may be specific to culture and legislation of each 
individual country; this chapter focuses mainly on research in high income countries. 
The ethical dilemma of conducting research in the PICU is recognized by pediatric 
intensivists themselves; in a survey of 415 pediatric intensivists, over 95% found ran-
domized controlled trials (RCTs) on potentially life-saving therapies ethically acceptable, 
but at the same time almost all were in ethical conflict with these studies.30 The specific 
challenges faced by researchers in the PICU are, first, the extraordinary physical environ-
ment of the PICU that presents challenges to the design and conduct of research and its 
ability to generate useful results. Second, the children themselves may be too young to 
consent or incapable of it due to acute illness and sedation. Then, parents or surrogates 
are responsible for the decision to involve their child in research, with consequences for 
the informed consent process, notably under the stressful conditions of the admission. 
Last, patients in the PICU already undergo many painful and invasive procedures as part 
of clinical care. Therefore, additional burden and risk of research procedures must be 
minimized. 
Improving care of the critically ill child implies generating reliable knowledge with 
research widely endorsed by caregivers and families. This chapter addresses the main 
ethical issues specific to drug research in the PICU and proposes several solutions.
oPTimal sTuDy Design anD conDucT in The Picu
Research subjects included in research of poor quality are exposed to risk and burden 
without benefit, neither for themselves nor for others. Therefore, only methodologically 
sound research that can generate new results should be proposed to possible research 
subjects. This requirement was already laid down in the Nuremberg Code in 1949, 
and consequently in all other important ethical and legal documents concerned with 
research with humans.1-4 The specific study population, recruitment method, outcome 
measures, use of rescue medication and protocol adherence can influence the validity 
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of research in the critically ill child and consequently influence the usefulness of the 
generated results. Table 1 presents an overview of these issues.
Table 1: Challenges to quality of clinical drug studies in critically ill children
 Theme challenge impact on results of trial
study 
population
Heterogeneous, small patient populations and relative lack of 
multicenter research networks
Risk of inconclusive trials due 
to limited sample size




Selection of clinical relevant outcome measures may be jeopardized by 
small sample sizes




Allowing rescue medication with the study drug in placebo arm, as not 
doing so may be perceived as unethical




Protocol violations due to ethical conflicts e.g. when a child’s condition 
deteriorates and physician is biased towards the, potential life-saving, 
study intervention
May severely impact the 
validity of study results
study PoPuLation
Children in the PICU represent a wide age range and a broad case mix of underlying 
diseases and ICU diagnoses. Moreover, the critically ill child receives many drugs simul-
taneously and combinations differ between centers. Therefore, while studying a single 
drug, the interactions with co-medications and type of underlying diagnosis and care 
may interfere with outcomes. More than 80% of randomized controlled trials (RCT) are 
single-centred.31 This reduces generalizability of the results from these trials. Data shar-
ing and collaboration in larger international PICU research networks could overcome 
this limitation. Examples of pediatric critical care networks are the Canadian Critical 
Care Trials Group (Pediatric Interest Group) and the NICHD Collaborative Pediatric Criti-
cal Care Research Network. Europe and the other continents are lagging behind: to our 
knowledge international PICU networks are non-existent to date.
recruitment
An underestimated limitation to the generalizability of PICU trial outcomes could be 
the difficulty with recruitment. One third of RCTs in the PICU is terminated before the 
needed sample size is achieved, often due to recruitment problems.31 One of the reasons 
for recruitment problems could be reluctance to approach potential research subjects, 
also known as ‘gate-keeping’, which attitude may be due to the clinicians’ fear of exces-
sive patient burden.32 This usually means that the sickest patients are less likely to be 
included in research. To our knowledge, the study by Menon and colleagues is the only 
addressing barriers to the recruitment process in the PICU. This was an observational trial 
implying an ACTH stimulation test, blood sampling on an existing line and recruitment 
within 26 hours of admission. Almost 50% of 1707 eligible research subjects were not 
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approached due to unavailability of legal guardians, language issues, lack of agreement 
of treating physician or prior enrolment in another study.33 Thus, we need to be aware 
of possible selection bias and its effects on generalizability of research results in the 
PICU. One solution to recruitment issues could be co-enrolment of patients in multiple 
studies.34 Research shows that participation rates do not decline when parents are 
asked to have their child participate in two studies simultaneously. This is only possible, 
however, if it does neither effect study outcome (e.g. simultaneous inclusion in two RCTs 
with potential influence on outcome of the studies) nor increases patient burden and 
risk to unacceptable levels (e.g. additive blood sampling volume increases above safety 
margins). 
outcome measures
Appropriate outcome measures in PICU research are another challenge. It is difficult to 
identify good outcome measures due to the combination of low prevalence of major 
adverse events (e.g. severe morbidity, mortality) and small sample size of many studies 
(median of 49 patients).31 While the majority of trials report laboratory or physiological 
primary outcomes, mortality was the primary outcome measure in 2% of trials.31 Data 
from a recent feasibility trial of clonidine for sedation suggest that at least 190 patients 
are needed to show a 1.5 day difference in days of ventilation and many more to show 
relevant differences for other outcomes such as length of PICU and hospital stay.35 Labo-
ratory or physiological outcomes should be clinically relevant, otherwise the research 
cannot result in improvement of patient outcome.36 Relevant outcome measures and 
validated assessment tools are therefore essential. The latter is not always the case. For 
example, Vet and colleagues showed that two thirds of the many different sedation 
scores used in studies on ventilated children receiving a continuous infusion of sedatives 
were not validated for PICU patients.37 Regarding the effect of a medication, it must be 
kept in mind that adverse effects may not become apparent until years after PICU stay. A 
major concern in this regard is the possible effect of sedative and analgesic medication 
on longer-term neurological outcome.38 Enrolling former PICU patients in follow-up pro-
grams can broaden our knowledge on long-term outcomes. This should be encouraged, 
as currently very few units provide care and research beyond the ICU stay. 
rescue medication
The use of rescue medication in a randomized trial for a potential life-saving interven-
tion with a placebo group presents additional ethical and scientific challenges.39 Full 
equipoise regarding the efficacy of the study drug contrasts with the clinician’s per-
ceived need to administer the study drug as a rescue therapy despite the inclusion of 
the patient in the placebo group. When rescue therapy is allowed, only ‘early’ versus 
‘late’ effects can be determined when analyzing data on an intention to treat basis. More 
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children are needed to show a beneficial effect of the drug. As a consequence, overall 
more children will receive placebo and be at risk for a negative outcome, including 
death, provided the study drug is really effective. Holubkov and colleagues present an 
interesting hypothetical study, i.e. steroids for pediatric septic shock, and use sample 
size simulations to illustrate this challenge.39 A solution to avoid misuse of rescue medi-
cation is to educate physicians, nurses and other staff involved in the care of research 
participants on the rationale and clinical equipoise in research. 
ProtocoL adherence
Protocol adherence may be jeopardized if the treating physician is biased towards the 
study drug and may decide to violate the study protocol when a patient’s situation is 
deteriorating. In the survey of Morris and colleagues, discussed above, a large majority 
of physicians admitted that they may be biased toward the study arm on the basis of 
published data from uncontrolled studies.30 Moreover, two thirds indicated that they 
do not fully adhere to the study protocol when the patient’s condition deteriorates and 
parents ask for the study drug. There was a strong correlation between the occurrence 
of an ethical conflict and the likelihood of protocol violations, compassionate use of the 
study drug or alterations to the protocol. These violations are an important risk factor 
for bias in these studies and consequently may affect the validity of the findings. A way 
of avoiding protocol violation is to inform everyone involved in the care of the research 
subjects about the rationale for the study, the existing equipoise motivating its conduct 
and the potential benefits of the study. 
informeD consenT Process in The Picu
Informed consent is one of the ethical cornerstones of performing research with hu-
man subjects. It represents the implementation of the ethical principle of respect for 
persons. Respect for persons means that persons are treated as autonomous agents, and 
that persons with diminished autonomy have a right to protection.3 Informed consent 
has been incorporated in many ethical and legal guidelines concerned with research 
with humans.1-4 40 41 Five elements are distinguished, which are all essential for a valid 
consent: transmission of information; understanding of this information; no coercion 
by others; competence; and actual consent.42 These requirements cannot always be met 
in research with children in the PICU, due to the vulnerability of the population and 
extraordinary surroundings. Besides that, children in the PICU generally are not able to 
participate in the decision as they may be too young, too ill or too heavily sedated. In 
these cases their parents (or legal guardians) need to consent for them, a process that is 
known as proxy consent.43
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factors infLuencing informed (Proxy) consent in the Picu
A qualitatively good consent process prepares future research subjects for the trial, is 
free and informed. In the PICU, quality of consent is threatened by several factors.
ANxIETy
The stressful PICU environment has great impact on parents and children. Many parents 
of acutely ill children suffer from acute and post-traumatic stress disorder and this often 
lasts for months after discharge.44 45 Practitioners asking consent for trials in emergency 
situations reported that some parents are unable to focus on anything else than the 
health of their child and will not be able to take any decision about research, whereas 
others will still be receptive.46 The most important reason for refusal to consent as 
spontaneously provided by parents in the PICU is anxiety or being overwhelmed.33 47 In 
contrast, in a study by Thomas and colleagues parents mentioned being anxious, but 
said that this did not influence their decision regarding research participation.48 These 
parents provided useful suggestions. For example, tell parents about ongoing trials prior 
to PICU admission if possible (e.g. in the case of planned surgery) and do not approach 
parents when their child is in the operating room, but before or after surgery.48 
BURDEN OF RESEARCH
In a large study by Hulst and colleagues, 421 parents who declined informed consent to 
a nutritional assessment study implying additional procedures were asked for their rea-
sons. Two-thirds wanted to avoid additional burden to their child.49 In two multicenter 
studies, Menon and colleagues analyzed parents’ reasons to decline informed consent. 
One study was an observational study involving blood sampling, the other concerned 
different kinds of PICU research. In both studies, the burden of blood sampling was a 
major reason for declining participation.33 47 A small qualitative interview study was con-
ducted by Thomas and colleagues among parents who accepted or declined consent in 
an undefined PICU trial. The interviews identified added pain, discomfort and additional 
diagnostic testing as factors discouraging participation.48 Overall, it would seem that 
limiting the burden of research procedures is essential to increase participation. This is 
further elaborated on in the next paragraph about burden and risk in pediatric research.
ILLNESS SEvERITy
Interestingly, severity of illness does not seem to influence consent rates in the PICU. Two 
studies done in the PICU could not identify a difference in severity of illness between 
children of consenting and non-consenting parents.33 49 Still it should be borne in mind 
that the life-threatening nature of illness in the PICU can make parents more susceptible 
to the idea that the trial might convey a therapeutic benefit, when this is very unlikely.50
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UNDERSTANDING
Parents reach a good understanding of their child’s health condition within 24 hours 
after admission in PICU,51 but this need not be true for research participation. Studies in 
the neonatal intensive care unit (NICU) suggest that the conditions for a valid consent 
are often unmet.52 53 Understanding and recalling of information is difficult for parents in 
a research context and they also overestimate their understanding.54 55 Written informa-
tion and posters are identified by parents in the PICU as useful information tools in the 
informed consent process.48 56 
aLternative forms of informed consent 
The life-threatening and acute nature of illness in the PICU puts great pressure on the 
validity and process of informed consent. It is not always possible to achieve written 
informed (proxy) consent before start of the study in emergency settings. Alternative 
consent processes should balance the respect for the decision of future research par-
ticipants and the benefit trial participation might bring them. Two different alternative 
consent processes are available to deal with these time constraints: a waiver of consent 
or deferred consent.
WAIvER OF CONSENT
A waiver of consent, also known as exemption from informed consent, means that no 
consent is required for inclusion of research participants in research. It is sometimes 
allowed for studies in life-threatening conditions for which available treatments are 
unproven or unsatisfactory and the study intervention needs to be applied urgently to 
be effective. The conditions under which a waiver (or) is acceptable vary between coun-
tries. For example in the US, additional requirements are community consultation and 
public disclosure.57 They favor dialogue with the community, which is informed about 
the project beforehand and its results afterwards.58 Raymond and colleagues describe 
an efficient way of in-hospital community consultation for a trial of vasopressin added 
to adrenaline in cardiac arrest in the PICU. All parents were informed about the trial 
through posters, written information, a website and the research team, and were offered 
the possibility to opt-out of the study. 80% of parents were aware of the trial and knew 
how to opt out. The authors suggested this approach could increase recruitment while 
preserving freedom of choice.56
DEFERRED CONSENT 
Another way of dealing with the acute nature of decisions in emergency research, but 
still taking into consideration parental decision, is the use of deferred consent. This form 
of consent implies that patients are recruited without consent and that after enrolment 
consent is asked for use of already collected information and ongoing participation. 
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Just like a waiver of consent, deferred consent is an alternative in emergency situations 
where obtaining prior informed consent is not possible and postponing the interven-
tion would potentially harm the child. The conditions under which deferred consent is 
acceptable vary between countries, too. An example of conditions can be found in the 
upcoming new EU regulation on clinical trials.40
Research suggests that parents favor deferred consent over waived consent and consider 
it an acceptable alternative to informed consent for emergency situations.59 60 In a study 
by Woolfall and colleagues parents suggested it would be advisable for the researchers 
to seek advice from the bedside nurse to establish the moment when the child’s condi-
tion was stable and then ask consent.60 Practitioners with experience in asking deferred 
consent were generally positive about parental acceptance of this method of consent. 
They highlighted the importance of explaining the purpose of its use.46 A systematic 
review on waiver of informed consent in pediatric resuscitation trials concluded there 
is a general endorsement of research in life-threatening situations, but that parental 
preferences for waiving of consent or deferred consent vary depending on the approach 
and population.61 Opinions of children about being enrolled in studies with a waiver of 
consent or deferred consent have not yet been addressed in research. 
Interpretation of approval of alternative forms of consent by researchers and research 
ethics committee (REC) members may differ. It has been shown that REC members may 
be less prone to accept alternative forms of consent than are researchers.62 This may 
be a barrier to conduct trials with alternative forms of consent. Documenting parental 
acceptance of deferred consent process could provide insight into its acceptability.
Questions still remain on how to handle consent when a child dies before deferred 
consent from parents or proxies is asked. Problems arise with use and storage of the 
collected data. Excluding data from deceased patients (for whom no deferred consent 
was obtained) may impair validity of the results.63 64 Still, although seeking deferred 
proxy consent for a deceased child can burden parents, the majority of parents wish 
to be informed.59 Bereaved parents said it was important to adapt to their needs on a 
case-by-case basis and to allow time after the child’s death.60
COMBINED FORMS OF CONSENT
The waiver of consent and deferred consent methods are justified only in life-threatening 
situations where postponing trial inclusion would harm to the research subject.
If the required conditions should not be met, full informed (proxy) consent needs to be 
given prior to inclusion. Practitioners have suggested that an approach taking the reality 
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of parents into account would be ideal.46 Combining different forms of consent could be 
a useful way of adapting to the unpredictability of acute care environment. The FEAST 
trial, which studied the effect of fluid resuscitation on mortality, is an example of such a 
combination.65 Informed consent was asked only if the child was stable enough and the 
parents not too distressed. Otherwise, verbal assent was sought prior to inclusion and 
full written consent after child’s stabilization. 
imProvements to the informed consent Process
It would be worthwhile to study alternative consent approaches in pediatric intensive 
care, taking into account that approaches in different situations cannot be uniform. Al-
though we should be wary about adding burden to parents (which an informed consent 
conversation and decision can be), parents must be given the opportunity to make a 
decision. The approaches to obtaining informed consent in different situations cannot 
be uniform. The solutions to practical problems may never be a permit for exploitation 
and harm of the vulnerable population at the PICU. 
Getting informed consent is not a one time achievement: informed consent is a continu-
ous process, especially in the PICU. After improvements in health or decrease of seda-
tion, children can regain the capacity to consent or assent; and they are entitled to do so 
after reaching legal age of consent. They should then be informed about the study they 
were involved in and their assent or consent should be sought when feasible – usually 
when the acute phase of the disease is over or after transfer to the ward. It is advisable 
to consider this re-consent process in the design of the study because the research team 
needs to plan for the resources needed to allow this important follow-up. There are no 
studies on this re-consent process in critically ill children.
To our knowledge the amount of empirical research on preferences and motivations of 
parents and children to participate in drug research in the PICU is small. These prefer-
ences have been assessed more extensively in other pediatric populations, but data 
from the PICU are lacking. It would be relevant to study factors that shape the decision 
to consent or dissent to drug research in the PICU– for example with a focus on altruism, 
hope and loyalty. Having this information would enable us to better tailor the process of 
recruitment and informed consent to the needs of the parents (or legal guardians) and 
children.
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BurDen anD risK of Drug research in The Picu
According to the principle of proportionality, risk and burden of research participation 
should be balanced against the possible benefit of the trial. The principle of subsidiarity 
entails that research can only take place if there are no other less burdensome and less 
risky methods of generating the same results. In other words: burden and risk for the 
research participant need to be minimized, irrespective of the possible benefits of the 
trial for the individual or society. These principles of proportionality and subsidiarity 
underlie important ethical guidelines concerning research with humans.1-4 Children 
are vulnerable and therefore need additional protection against the risk and burden of 
research participation. Recent progress in drug research can decrease burden and risk 
for children participating in research in the PICU. Some of these new techniques are 
illustrated in the next paragraphs.
methods to decrease burden and risk by use of new techniques
PK studies traditionally implied collecting many 1-2 mL blood samples from a patient at 
scheduled intervals up to 12 times in 24 hours, which means a considerable burden to re-
search subjects. Recent progress in sampling methods, data analysis and outcome mea-
surement tools can decrease this burden while rational evidence-based drug regimens 
can still be derived. As an example, a solution to oversedation with morphine, which is 
often observed in neonates, was found using a three-step approach. First, PK data were 
collected during two RCTs.66 67 Second, the data were analyzed with population PK, and 
it was found that same dosing guidelines of morphine resulted in much higher plasma 
concentrations in neonates than older infants.68 Third, a new dosing guideline was cre-
ated on the basis of this finding, and validated.69 The following paragraphs detail how 
limited blood sampling schedules, novel drug concentration assays and data analysis 
methods can decrease burden and risk. 
OPPORTUNISTIC OR SPARSE BLOOD SAMPLING METHODS
PICU patients usually have an arterial or venous central line from which blood can 
be drawn. To avoid accessing lines just for research purposes, sampling for research 
purposes can be combined with regular blood work. In the absence of a line, samples 
can be collected during routine heel pricks.70 Opportunistic studies determine levels 
of the drug received as part of the patient’s treatment and no study drug is given.71 
Another strategy is to measure drug concentration in blood left over from routine 
analysis.70 71 Population pharmacokinetics make use of randomly collected and limited 
blood samples per patient. Maximum allowed amounts of blood for research purposes 
vary between hospitals and countries, but generally the maximum is set at 3-5% of total 
blood volume within 24 hours and 5-10% of total blood volume over 8 weeks.72 
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LOW vOLUME DRUG ASSAyS
High performance liquid (LC-MS) or gas (GC-MS) chromatography allows simultaneous 
analyses of many low concentration substances in small plasma volumes (10-100 µL) 
or left-overs.70 73 This is of particular interest for studies in neonates and small children, 
whose total blood volume is small.71 New emerging technologies such as digital micro-
fluidics will further decrease the sample volume needed and may represent the future 
of PK studies.74-76 If combined with sampling using micro needles sharp enough to 
minimize nerve contact,77 these technologies will further decrease the burden and risk 
of clinical drug trials in children.
DRIED MATRIx SPOTS 
Dried matrix spot analysis requires no more than a minimal volume (5-30 µL) of biologi-
cal fluids (urine, plasma, blood) on blotting paper, allowing for easy and cost-effective 
sample processing, storage and shipping.71 78 These samples can be used in PK studies 
and pharmacogenetic tests.78-82 Dried blood spots obtained during routine new-born 
screening can be used for genetic (DNA) and epigenetic (DNA methylation) analysis 
until 30 years later if stored at -20°C, as is routinely done in some countries.82 83
PK-PD MODELLING TOOLS
Population PK-PD analysis using non-linear mixed effect models allows using samples 
derived from different dosing regimens with random timing and only few samples per 
patient to estimate PK parameters and the PK-PD relationship and to optimize dos-
ing recommendations.84 Sparse sampling is a strategy by which just 2-3 samples per 
individual allow deriving PK parameters from a group of 25-100 infants.85 This enables 
studies in which the patient already receives the drug for clinical reasons and even the 
use of left-over material from regular blood work. Population PK calculates both the in-
ter- and intra-individual variability. The effects of different covariates like age and weight 
are tested by delineating their effects on inter-individual variability. Particularly relevant 
to PICU patients, the effect of disease and its treatment can be taken into account (e.g. 
renal function, inflammation, ECMO).86 PK-PD parameters in particular populations, such 
as patients on ECMO, can be estimated.87 A next step is to validate the obtained PK data 
and the dosing guidelines derived from these data in a prospective trial performing the 
same sample analysis. In an efficient new dosing regimen, inter-individual variability 
should be greatly reduced and dose-effect relationships should remain unchanged or 
improve. Regrettably, this validation is rarely performed.71 85 
MICRODOSING STUDIES
Microdosing is an elegant new method to minimize burden and risk in PK-studies in 
children.88 It uses a sub therapeutic, extremely low dose of drug, known as a microdose 
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(e.g. 1/100th of the therapeutic dose).89 90 Microdosing is ideal for non-therapeutic phar-
macokinetic studies in critically ill children because therapeutic or adverse effects will 
not occur. Microdosing also enables knowledge gain on drug metabolism or excretion, 
using probe drugs for these specific pathways. Radioactive labelling allows detection of 
the extremely low dose and carries very minimal risk, because the level of radioactivity 
is well below international cut-offs for radiation safety.91 It cannot be excluded, however, 
that parents and health care providers perceive this differently, and it is recommended 
therefore to underline in the informed consent process the minimal risk of microdosing. 
Table 2: Examples of ethical challenges of clinical drug trials in critically ill children
example of drug trial* ethical challenge**
RCT with daily sedation interruption92 Risk of ‘gate-keeping’ during recruitment and non-adherence to protocol during 
study for fear of accidental extubation or line removal.
RCT with corticosteroids for pediatric 
septic shock39
Potential life-saving medication: rescue medication in placebo arm may reduce 
validity of trial.
RCT with vasopressin add-on for 
cardiopulmonary resuscitation93
Emergency treatment leaves no time for informed consent: acceptability of 
deferred consent or waiver of consent.
Pharmacokinetic study with drug 
already prescribed to patient70
No potential benefit to patient. Multiple catheter accesses may increase risk of 
infection. Blood sample volume may compromise health, especially in small 
children.
Dose-finding study for new drug, 
e.g. Imatinib for pulmonary arterial 
hypertension
Risk of off-label prescription without any trial, ethical barriers may be perceived 
too high to perform a ‘non-therapeutic trial’.
Microdosing pharmacokinetic study 
with radio-active labelled drug94
No potential benefit to patient despite safe radiation dose: ‘gate-keeping’ by 
physicians and/or nursing staff out of fear for radiation-related negative outcomes. 
And possible misunderstanding of minimal risk by parents.
*Examples are illustrative and based on trials and experiences of researchers in the PICU. **Ethical challenges are 
examples that researchers could face when performing these kinds of studies but are of course not limited to 
these examples.
conclusion 
Drug research in the PICU is essential because there is a great need of evidence-based 
dosing guidelines. Conducting drug research in critically ill children is a precarious 
enterprise because of the vulnerability of the research population and the specific 
circumstances in the PICU – which present specific ethical challenges. Examples of these 
challenges are presented in table 2.
Characteristics of the specific study population, recruitment issues, challenging out-
come measures, use of rescue medication and sub-optimal protocol adherence, stand in 
the way of obtaining useful results. Gatekeeping does not only limit recruitment but is 
also an underestimated source of bias especially with acutely ill children. Collaboration 
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of intensive care units is bound to improve quality of research and to increase the likeli-
hood of producing generalizable data. 
Informed consent for research in the PICU implies almost invariably proxy consent by the 
parents or legal guardians. Documenting informed consent does not imply, however, 
that parents know what they signed for. Indirect evidence shows that informed consent 
may not be achieved in the stressful situation of the PICU due to parental anxiety and 
misunderstanding. The informed consent process does not stop when the consent is 
signed but is rather a continuous process. Continuous dialogue between researchers, 
parents, and children when possible, is the only way to do justice to the unpredictable 
and changing reality of the PICU. ‘One size fits all’ is not always possible for structuring 
informed consent in the PICU therefore alternative approaches to consent need to be 
developed and evaluated. 
Drug research carries burden and risk for the subjects and it is only logical that we 
should prevent or minimize these, especially in the vulnerable population in the PICU. 
New techniques allow us to generate evidence with decreased burden and risk to the 
research subject and deserve to be widely used and systematically evaluated. The dif-
ferent types of studies (e.g. dose-finding studies, PK studies, RCTs) each present specific 
challenges. Dealing effectively with these challenges is an essential step towards evi-
dence for dosing and drug choice in pediatric intensive care practice.
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aBsTracT
Information on motivations for research participation may enable professionals to bet-
ter tailor the process of recruitment and informed consent to the perspective of parents 
and children. Therefore, this systematic review assesses motivating and discouraging 
factors for children and their parents to decide to participate in clinical drug research. 
Studies were identified from searches in six databases. Two independent reviewers 
screened and selected relevant articles. Results were aggregated and presented by use 
of qualitative meta-summary. 
38 studies fulfilled the selection criteria and were of sufficient quality for inclusion in the 
qualitative meta-summary. Most mentioned motivating factors for parents were: health 
benefit for child, altruism, trust in research, and relation to researcher. Most mentioned 
motivating factors for children were: personal health benefit, altruism and increasing 
comfort. Fear of risks, distrust in research, logistical aspects and disruption of daily life 
were mentioned most by parents as discouraging factors. Burden and disruption of daily 
life, feeling like a ‘guinea pig’ and fear of risks were most mentioned as discouraging 
factors by children. 
Paying attention to these motivating and discouraging factors of children and their par-
ents during the recruitment and informed consent process in drug research increases 
the moral and instrumental value of informed consent.
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inTroDucTion
Clinical drug research with children balances between the advancement of knowledge 
- and consequently possible improvement in clinical care - and the protection of a 
vulnerable population. On the one hand children are relatively incapable of protecting 
their own interest and therefore need to be protected from harm and exploitation in 
research.1 On the other hand, clinical drug research is essential to generate sufficient evi-
dence for improvements in pediatric care and drug dosing. Current estimates of off-label 
or unlicensed use of drugs range between 10% and 60% in the pediatric population.2 
Precisely because clinical drug research with children is a precarious enterprise, special 
attention needs to be given to the informed consent process.
Informed consent is one of the ethical cornerstones of human research. It represents the 
ethical principle of respect for persons: persons are treated as autonomous agents and 
persons with diminished autonomy are protected.3 In the case of research with children, 
this means that their parents (or legal guardians) have to consent for them. This does 
not mean that children should be excluded from or ignored in the informed consent 
process. The United Nations Convention on the Rights of the Child states that children 
who are capable of forming their views have a right to express those views in any pro-
ceedings affecting the child directly.4 Since they are the ones undergoing the research 
burden and risk, constructions of co-consent and assent are introduced in ethical and 
legal legislation to do justice to the opinion of children.5-7
The process of informed consent and assent in clinical research with children might be 
clear in theory, in practice it is not. The question remains how to design this process 
of information and consent/assent as to include the perspective of children and their 
parents. Their perspective is vital, since they have the key role in decision-making on 
research participation. One way of taking their perspective into account is to look at the 
motivations children and their parents have to endorse or decline participation in pe-
diatric clinical research. When professionals know to which aspects of research children 
and their parents attach importance, they know what information is relevant for their 
decision. And this knowledge may enable professionals involved in research to better 
tailor the process of recruitment and informed consent/assent to the perspective and 
needs of parents (or legal guardians) and children.
To our knowledge no comprehensive systematic review exists on these motivating and 
discouraging factors for children and their parents to decide to participate in clinical drug 
research. Two narrative reviews exist on why parents enroll their child in research.8 9 Both 
reviews show personal benefit and altruism as most important motivations of parents 
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to enroll their child in research. However, these narrative reviews are not comprehensive 
nor systematically handled. Also, these reviews do not consider children’s motivations 
and are not focused on pharmacological research.
Therefore, we aimed to pool the existing empirical literature on motivations of children 
and their parents to consent or dissent to participation in clinical drug research. This 
systematic review attempts to answer the following research question: What are moti-
vating and discouraging factors for children and their parents to decide to participate in 
clinical drug research? 
meThoDs
This systematic review is reported in accordance with the Preferred Reporting Items for 
Systematic Review and Meta-analyses (PRISMA) statement.10
data sources and search strategy
We searched for peer-reviewed English-language articles using Embase, Medline, Web 
of Science, Pubmed, PsycINFO and the Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) for empirical studies investigating the motivations (motivating and 
discouraging factors) of children and their parents to consent or dissent to participa-
tion in clinical drug trials. The search strategy was developed in collaboration with an 
information specialist of the Medical Library. 
The search strategy was based on 3 concepts: 1) motivation for participation; 2) clinical 
drug research; 3) children and parents. The search strategy in Embase was as follows: 
(‘refusal to participate’/de OR ‘patient participation’/de OR ‘parental consent’/de OR 
(((refus* OR decision* OR decid* OR allow* OR reason* OR motivat* OR willing* OR as-
sent* OR consen* OR dissent* OR attitude* OR view* OR perspective* OR choos* OR 
choice*) NEAR/6 (participat* OR nonparticipat* OR enrol*))):ab,ti OR ((conflict/de OR 
‘motivation’/de OR drive/de OR ‘informed consent’/de) AND (participat* OR nonpartici-
pat* OR enrol*):ab,ti)) AND (‘clinical trial (topic)’/exp OR ‘pharmacological science’/exp 
OR ‘clinical research’/de OR ((RCT* OR trial* OR scien* OR research*) NEAR/11 (participat* 
OR enrol*)):ab,ti OR ((‘science in general’/de OR research/de OR ‘medical research’/de OR 
‘human experiment’/de) AND (pharmacology/exp OR ‘drug therapy’/exp OR (drug* OR 
pharmaco* OR medication* OR psychopharmacolog*):ab,ti))) AND (child/exp OR new-
born/exp OR adolescent/exp OR adolescence/exp OR ‘child behavior’/de OR ‘child par-
ent relation’/de OR (adolescen* OR infan* OR newborn* OR (new NEXT/1 born*) OR baby 
OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR girl* 
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OR minors OR underag* OR (under NEXT/1 ag*) OR juvenil* OR youth* OR kindergar* 
OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* 
OR school* OR preschool* OR highschool*):ab,ti). Searches in the other databases were 
based on the Embase search terms. 
Appendix 1 provides the exact search strategies in each database. We performed the 
initial search on March 20th 2013 and updated it on August 22th 2014. 
incLusion and excLusion criteria
Studies were included when they addressed empirical data of: 1) children and/or parents 
on; 2) motivations for dissent or consent; 3) to participation in clinical drug research. 
We excluded articles with: 1) No empirical data; 2) Participation in only other clinical 
research than drug research; 3) Participation in vaccination studies (this religiously 
debated subject might confound results); 4) Narrative reviews.
study seLection
After identification of records from the search strategy, duplicates were removed from 
the retrieved records. In the screening phase, two reviewers (KT and WB) independently 
screened titles and abstracts of identified records for relevance to the research question. 
In case of discrepancy between the primary reviewers, a third reviewer (SV) decided 
upon inclusion for further eligibility assessment. In the eligibility phase, two reviewers 
(KT and WB) independently assessed full-text articles for eligibility. Again, in case of dis-
crepancy between the primary reviewers, a third reviewer (SV) decided upon inclusion 
for systematic review. The PRISMA flow diagram presented in Figure 1 shows the process 
of study selection: identification, screening, eligibility assessment and inclusion. 
data extraction and study quaLity assessment
We extracted relevant data from the articles eligible for systematic review with the 
use of a data extraction form. A template of this form can be found in appendix 2. The 
main outcome measures extracted were motivating factors and discouraging factors 
mentioned by children and/or their parents (or legal guardians). Study population, 
in- and exclusion criteria, patient characteristics, study design, and other outcome fac-
tors besides motivating and discouraging factors were also extracted. We graded the 
level of evidence of individual studies according to levels set by the Dutch Institute 
for Healthcare Improvement (CBO) (as indicated in table 1 and table 2) and critically 
appraised the eligible articles to determine study quality and risk of bias (according to 
the Critical Appraisal Skills Program (CASP) checklists).11 Studies with a very low level of 
evidence (level ‘D’ for quantitative studies or level ‘-‘ for qualitative studies) or high risk 
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of bias (based on CASP checklists) were excluded from data synthesis of motivating and 
discouraging factors. 
Table 1: Level of evidence of quantitative studies
level of evidence* characteristics 
a1 Systematic reviews involving at least two studies at A2 level, of which the results of 
separate studies are consistent
a2 Randomized comparative clinical studies of good quality (randomized, double-blind 
controlled trails) of sufficient size and consistency




* Levels according to those set by the Dutch Institute for Healthcare Improvement (CBO)
Table 2: Level of evidence of qualitative studies
level of evidence* characteristics 
++ Credible meta-synthesis of qualitative studies
+ Credible study
+/- Study of which credibility is dubious
- Study of which credibility is minimal
* Levels according to those set by the Dutch Institute for Healthcare Improvement (CBO)
data synthesis
We performed a qualitative meta-summary to give an overview of the motivating and 
discouraging factors mentioned by children and their parents. A qualitative meta-
summary is a quantitatively oriented aggregation approach to research synthesis of 
descriptive findings from both quantitative and qualitative studies.12 This approach of 
data synthesis entails treating research reports as indexes of the studies conducted, and 
the research findings in these reports as indexes of the experiences of the persons who 
participated in those studies. Therefore this approach functions well for our research 
question concerning motivations for participation, answered by qualitative and quanti-
tative research. First, we extracted motivations mentioned by children or their parents 
from the result sections of the eligible studies regardless of how many participants 
endorsed the reason. Second, we created draft lists of all mentioned motivations in all 
studies for motivating factors and discouraging factors. Third, we grouped these motiva-
tions per theme and presented them as aggregated data. These themes of motivating 
and discouraging factors were not predefined, but defined by the total of extracted data.
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42 studies were included for systematic review  
Total of 7760 records in selection 
 
Embase:   2460  records 
Medline:  1930  records 
Web-of-Science:  1306  records 
PubMed:   233  records 
PsycINFO:   1295  records 
CINAHL:   536  records 
 
4950 records after duplicates removed 
 
Embase:   2392  records  
Medline:  620  records  
Web-of-Science:  571  records  
PubMed:   323  records 
PsycINFO:   915  records 
CINAHL:   129  records 
 
4842 articles excluded based on review of title and/or abstract  
 
Irrelevant:    4762  records 
No clinical drug trial:    53  records 
Vaccination trial:    27  records 
2810 duplicates removed 
 
26 records were excluded for eligibility assessment 
 
Article in French:    3  records 
Conference abstract:   20  records 
No full-text available:   3  records 
82 full-text articles were assessed for eligibility  
40 articles were excluded for systematic review 
 
Irrelevant:    17  articles 
No clinical drug trial:   17  articles 
Vaccination trial:   1  article 
Article with already published data: 1  article 
No empirical data:    2  articles 
Narrative review:   2  articles 
 
4 articles were excluded from synthesis due to high risk of bias 
or low level of evidence 
 
38 studies included in qualitative metasummary 
of motivational and discouraging factors 
figure 1: PRISMA flow diagram of study identification, screening, selection and inclusion
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resulTs
study seLection
Our initial search produced 4950 titles after removing duplicates. After title and abstract 
screening, 108 records remained for full-text eligibility assessment. After full-text review, 
42 articles could be included for data-extraction and systematic review.13-54 Figure 1 
shows in a PRISMA flow diagram the results of study identification, screening, eligibility 
assessment and inclusion. Extracted data from these 42 studies, including study char-
acteristics, motivating and discouraging factors, level of evidence and critical appraisal, 
can be found in the evidence tables in appendix 3. 
characteristics of incLuded studies for systematic review
Of the 42 articles that were included for systematic review, 26 were quantitative studies 
(including 15 written questionnaires, 7 verbally administered questionnaires and 4 stud-
ies analyzing registries of consent/dissent) and 16 were qualitative studies (including 
10 interview studies, 2 focus group studies, 1 interview and focus group study and 3 
studies with secondary analysis of interviews (of which one is a case study)). The number 
of research subjects involved per study ranged from 1 to 81 in the qualitative studies, 
and from 20 to 448 in the quantitative studies. In 37 studies parents (or caregivers/or 
legal guardians) were questioned about their motivations compared to 16 studies in 
which children themselves were questioned. The age of the children questioned ranged 
between 6 and 21 years. The majority of these studies included children up to 18 years of 
age. Three studies included children up to 21 years of age.19 35 42 Although, in Europe, we 
do not consider these respondents children, these studies were included because the 
majority of the respondents in these 3 studies were below 18 years of age. Two studies 
did not define the age of their respondents 16 39. The included studies were very diverse 
with regard to research population and setting (e.g. PICU/NICU setting, patients with 
airway diseases, with diabetes mellitus). Studies concerning oncology patients were 
most prevalent. Parents and children who consented to research were questioned in 
39 studies, while 24 studies questioned respondents who dissented to research partici-
pation. Some studies questioned respondents about drug research in general or on a 
hypothetical drug study protocol (vignettes). But the majority questioned respondents 
in daily practice about participation in a specific drug study protocol. Most studies 
entailed participation in drug protocols with a prospect of direct benefit for the partici-
pant, only 5 drug protocols were considered to have no prospect of direct benefit for the 
participants. Table 3 shows an overview of study characteristics. The extra supplemental 
material provides evidence tables including these 41 studies with extracted data (online 
resource 4).
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Table 3: Study characteristics of 42 included studies for systematic review









Quantitative study 26 See categories below
Written questionnaires 15 Barakat, 2013; Berg, 2010; Buscariollo, 2012; Cain, 2005; Cherill, 2010; 
Hoberman, 2013; Read, 2009; Sammons, 2007; Tait, 1998; Tait, 2003; 




7 Baren, 1999; Brody, 2005; Brody, 2012; Harth, 1990; Miller, 2013; 
Rothmier, 2003; Wendler, 2012
secondary analysis of data 4 Menon, 2012; Norris, 2010; Peden, 2000; Wynn, 2010
Qualitative study 16 See categories below
interviews 10 Barrera, 2005; Broome, 2003; Cartwright, 2011; Koelch, 2009; 
Liaschenko, 2001; MacNeill, 2013; Masiye, 2008; Patterson, 2014; 
Pletsch, 2001; Pletsch, 2001(2); Woodgate, 2010
focus groups* 3 Caldwell, 2003; Lebensburger, 2013 









only parents/caregivers 26 Baren, 1999; Buscariollo, 2012; Cartwright, 2011; Caldwell, 2003; 
Deatrick, 2002; Harth, 1990; Hoehn, 2005; Lebensburger, 2013; 
Liaschenko, 2001; MacNeill, 2013; Masiye, 2008; Menon, 2012; 
Oppenheim, 2005; Pletsch, 2001(2); Pletsch, 2001; Rothmier, 2003; 
Sammons, 2007; Tait, 1998; Truong, 2011; Tait, 2003; Van Stuijvenberg, 
1998; Vanhelst, 2013; Woodgate, 2010; Zupancic, 1997; Wynn, 2010; 
Hoberman, 2013
only children 5 Broome, 2003; Cain, 2005; Cherill, 2010; Koelch, 2009; Miller, 2013
Both 11 Barakat, 2013; Barrera, 2005; Berg, 2010; Brody, 2005; Brody, 2012; 






oncology 11 Barrera, 2005; Berg, 2010; Broome, 2003; Deatrick, 2002; Liaschenko, 
2001; Miller, 2013; Oppenheim, 2005; Pletsch, 2001; Read, 2009; 
Truong, 2011; Woodgate, 2010
Diabetes mellitus 5 Broome, 2003; Buscariollo, 2012; Cain, 2005; Pletsch, 2001(2); Pletsch, 
2001
airway diseases 7 Barakat, 2013; Brody, 2005; Brody, 2012; Harth, 1990; MacNeill, 2013; 
Rothmier, 2003; Sammons, 2007
sickle cell disease 4 Barakat, 2013; Lebensburger, 2013; Patterson, 2014; Wynn, 2010
Picu / nicu 4 Cartwright, 2011; Hoehn, 2005; Menon, 2012; Zupancic, 1997
sick and healthy children (not 
specified)
4 Caldwell, 2003; Cherill, 2010; Vanhelst, 2013; Wendler, 2012
anesthetics 3 Peden, 2000; Tait, 1998; Tait, 2003 
emergency department 2 Baren, 1999; Van Stuijvenberg, 1998; 
Psychopharmacology 2 Koelch, 2009; Wagner, 2006
other*** 3 Masiye, 2008; Norris, 2010; Hoberman, 2013; 
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Table 3: Study characteristics of 42 included studies for systematic review (continued)













real life drug study protocol 33 Barrera, 2005; Berg, 2010; Broome, 2003; Cain, 2005; Cartwright, 2011; 
Deatrick, 2002; MacNeill, 2013; Harth, 1990; Hoberman, 2013; Hoehn, 
2005; Koelch, 2009; Liaschenko, 2001; Masiye, 2008; Menon, 2012; 
Miller, 2013; Norris, 2010; Oppenheim, 2005; Peden, 2000; Pletsch, 
2001; Pletsch, 2001(2); Read, 2009; Rothmier, 2003; Sammons, 2007; 
Tait, 1998; Tait, 2003; Truong, 2011; Van Stuijvenberg, 1998; Vanhelst, 
2013; Wagner, 2006; Wendler, 2012; Woodgate, 2010; Wynn, 2010; 
Zupancic, 1997
Drug research in general 4 Sammons, 2007; Tait, 1998; Tait, 2003; Van Stuijvenberg, 1998
hypothetical drug study 
protocol














only studies with prospect of 
direct benefit
22 Baren, 1999; Brody, 2012; Cain, 2005; Cartwright, 2011; Harth, 
1990; Hoberman, 2013; Hoehn, 2005; Koelch, 2009; MacNeill, 2013; 
Masiye, 2008; Norris, 2010; Patterson, 2014; Peden, 2000; Pletsch, 
2001(2); Rothmier, 2003; Sammons, 2007; Tait, 1998; Tait, 2003; Van 
Stuijvenberg, 1998; Wagner, 2006; Wynn, 2010; Zupancic, 1997
only studies with no prospect of 
direct benefit
5 Barrera, 2005; Berg, 2010; Deatrick, 2002; Miller, 2013; Oppenheim, 
2005
Both 7 Broome, 2003; Liaschenko, 2001; Menon, 2012; Pletsch, 2001; Truong, 
2011; Vanhelst, 2013; Wendler, 2012
not specified 8 Barakat, 2013; Brody, 2005; Buscariollo, 2012; Caldwell, 2003; Cherill, 















only non-consenters 3 Peden, 2000; Norris, 2010; Menon, 2012
only consenters 18 Broome, 2003; Cain, 2005; Cartwright, 2011; Deatrick, 2002; 
Liaschenko, 2001; Masiye, 2008; Miller, 2013; Oppenheim, 2005; 
Pletsch, 2001; Pletsch, 2001(2); Rothmier, 2003; MacNeill, 2013; 
Truong, 2011; Van Stuijvenberg, 1998; Vanhelst, 2013; Wagner, 2006; 
Wendler, 2012; Woodgate, 2010;
Both 21 Barakat, 2013; Baren, 1999; Barrera, 2005; Berg, 2010; Brody, 2005; 
Brody, 2012; Buscariollo, 2012; Caldwell, 2003; Cherill, 2010; Harth, 
1990; Hoberman, 2013; Hoehn, 2005; Koelch, 2009; Lebensburger, 
2013; Read, 2009; Sammons, 2007; Tait, 1998; Tait, 2003; Patterson, 
2014; Wynn, 2010; Zupancic, 1997
Picu Pediatric Intensive Care Unit; nicu Neonatal Intensive Care Unit
* Study of Caldwell included also personal interviews; ** Study of Oppenheim is a case study; *** anorexia nervosa, 
malaria, vesico-ureteral reflux
study quaLity and risk of bias
The evidence tables in the extra supplemental material show level of evidence (based on 
classification in tables 1 and 2) and critical appraisal (including risk of bias) for individual 
studies. Four studies were of insufficient quality and were excluded from the qualitative 
meta-summary due to very low level of evidence (level ‘D’ or ‘-’) and high risk of bias. We 
excluded one qualitative study because the credibility was minimal (level of evidence 
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‘-’): the presented data did not answer their research question and essential parts of 
the data were not presented (population consisted of patients with diabetes mellitus 
and cancer, but data from cancer patients were missing in the article). 19 We excluded 
three quantitative studies due to high risk of bias: no separate analysis of adult research 
subjects and children 16; represented data did not support article conclusions 14; and 
inclusion of a very specific study population (patients with Anorexia Nervosa) in which 
treatment and research motivations cannot be looked at separately 36. After these four 
exclusions due to insufficient quality, 38 studies remained for data synthesis (qualitative 
meta-summary) of motivating and discouraging factors.13 15 17 18 20-35 37-54
quaLitative meta-summary of motivating factors
Of the 38 articles eligible for qualitative meta-summary 33 studies included motivating 
factors mentioned by parents to endorse research participation of their child. Ten studies 
included motivating factors mentioned by children themselves. The extracted motivat-
ing factors mentioned by parents and children in the individual studies can be found 
in the evidence table in the supplemental information. Table 4 and 5 give an overview 
of the motivating factors for parents and children. Individual health benefit, altruism 
(including helping others and contributing to science), a general trust in research and 
the relation to researchers are mentioned by parents in the highest number of studies. 
Other common motivating factors mentioned by parents to endorse research partici-
pation of their child include: more contact with the medical team, benefit for parents 
themselves, a sense of minimal burden for their child, the opportunity of financial reim-
bursement, feelings of having no other option, and influence of family and friends. For 
children themselves the most frequently mentioned factor favoring research participa-
tion include personal health benefit, altruism and increasing comfort by participation. 
Other motivating factors mentioned in multiple studies by children are the relation to 
the researcher, influence of family and friends, a financial reimbursement, increasing 
their knowledge about their disease and a sense of curiosity. In one study children also 
mentioned the feeling of having no other option available.
74 Chapter 4 
Table 4: Meta-summary of motivating factors mentioned by parents for participation of their child in clinical 
drug research 
motivating factor no. of studies
( total = 33)
individual studies
Personal health benefit for child* 31 Barakat, 2013; Baren, 1999; Barrera, 2005; Brody, 2005; Brody, 
2012; Buscariollo, 2012; Caldwell, 2003; Cartwright, 2011; Deatrick, 
2002; Harth, 1990; Hoberman, 2013; Hoehn, 2005; Lebensburger, 
2013; Liaschenko, 2001; MacNeill, 2013; Masiye, 2008; Oppenheim, 
2005; Patterson, 2014; Pletsch, 2001; Pletsch, 2001(2); Read, 
2009; Sammons, 2007; Tait, 1998; Tait, 2003; Truong, 2011; Van 
Stuijvenberg, 1998; Vanhelst, 2013; Wagner, 2006; Woodgate, 2010; 
Wynn, 2010; Zupancic, 1997
altruism** 26 Baren, 1999; Barrera, 2005; Buscariollo, 2012; Caldwell, 2003; 
Cartwright, 2011; Deatrick, 2002; Harth, 1990; Hoberman, 2013; 
Hoehn, 2005; Liaschenko, 2001; MacNeill, 2013; Patterson, 
2014; Pletsch, 2001; Pletsch, 2001(2); Read, 2009; Rothmier, 
2003; Sammons, 2007; Tait, 1998; Tait, 2003; Truong, 2011; Van 
Stuijvenberg, 1998; Vanhelst, 2013; Wendler, 2012; Woodgate, 
2010; Wynn, 2010; Zupancic, 1997 
Trust in safety of research 12 Barakat, 2013; Buscariollo, 2012; Cartwright, 2011; Harth, 1990; 
Hoberman, 2013; Hoehn, 2005; MacNeill, 2013; Patterson, 2014; 
Tait, 1998; Truong, 2011; Vanhelst, 2013; Zupancic, 1997 
relation to researcher 12 Buscariollo, 2012; Caldwell, 2003; Harth, 1990; Hoberman, 2013; 
Masiye, 2008; Read, 2009; Sammons, 2007; Tait, 1998; Tait, 2003; 
Truong, 2011; Woodgate, 2010; Van Stuijvenberg, 1998
more contact with medical team 8 Buscariollo, 2012; Caldwell, 2003; Harth, 1990; Lebensburger, 2013; 
MacNeill, 2013; Masiye, 2008; Wynn, 2010; Woodgate, 2010
Benefit for parents themselves 5 Harth, 1990; Oppenheim, 2005; Rothmier, 2003; Wagner, 2006; Van 
Stuijvenberg, 1998; 
minimal burden for child 4 Patterson, 2014; Pletsch, 2001(2); Read, 2009; Woodgate, 2010
financial reimbursement 5 Brody, 2012; Buscariollo, 2012; Harth, 1990; Masiye, 2008; Wagner, 
2006
felt as only option*** 4 Cartwright, 2011; Deatrick, 2002; Liaschenko, 2001; Oppenheim, 
2005
influence of family and friends 3 Buscariollo, 2012; Harth, 1990; Read, 2009
* Factor mentioned in studies with and without prospect of direct benefit; ** In 3 studies specifically defined as 
no motivating factor; *** All studies were in oncology setting
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Table 5: Meta-summary of motivating factors mentioned by children for participation in clinical drug research 
motivating factor no. of studies
(total = 10)
individual studies 
Personal health benefit* 8 Barrera, 2005; Brody, 2005; Brody, 2012; Cain, 2005; Miller, 2013; 
Patterson, 2014; Read, 2009; Wagner, 2006
altruism 6 Cain, 2005; Miller, 2013; Patterson, 2014; Read, 2009; Wagner, 2006; 
Wendler, 2012
increasing comfort 4 Cain, 2005; Koelch, 2009; Miller, 2013; Read, 2009
relation to researcher 3 Miller, 2013; Read, 2009; Wagner, 2006
influence of family and friends 3 Cain, 2005; Read, 2009; Wagner, 2006
financial reimbursement 3 Brody, 2005; Brody, 2012; Wagner, 2006
increasing knowledge 2 Cain, 2005; Wagner, 2006
curiosity 2 Cain, 2005; Koelch, 2009
felt as only option 1 Miller, 2013
* Factor mentioned in studies with and without prospect of direct benefit
quaLitative meta-summary of discouraging factors
Of the 38 articles eligible for qualitative meta-summary 24 studies included discourag-
ing factors mentioned by parents for research participation of their child. Six studies 
included discouraging factors mentioned by children themselves. These include moti-
vations mentioned by respondents who dissented to research participation, but also 
discouraging factors mentioned by respondents who did participate but considered 
these factors as negatively influencing their decision. The extracted discouraging fac-
tors mentioned by parents and children in the individual studies can be found in the 
evidence table in the extra supplemental material. Table 6 and 7 give an overview of the 
discouraging factors for parents and children. Fear of potential risks, a general distrust in 
research, logistical aspects and disruption of daily life and fear of burden for their child 
are mentioned by parents in the highest number of studies. Other common discourag-
ing factors mentioned in multiple studies by parents for research participation of their 
child include: decision considered to be too stressful, a fear of randomization, no pros-
pect of direct benefit for their child, financial constraints and a discomfort with being a 
proxy. Discouraging factors incidentally mentioned by parents are for example a discord 
between guardians, religious constraints or privacy issues. For children themselves the 
most frequently mentioned factors discouraging research participation include fear of 
burden for themselves and disruption of their daily life, feeling like a ‘guinea pig’ and 
a fear of risks. Other discouraging factors incidentally mentioned by children are the 
prospect of no direct benefit, no understanding of the study, preference for one arm and 
the decision considered to be too stressful.
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Table 6: Meta-summary of discouraging factors mentioned by parents for participation of their child in clinical 
drug research 
Discouraging factor no. of studies
(total = 24)
individual studies
fear of risks 14 Baren, 1999; Brody, 2005; Brody, 2012; Buscariollo, 2012; Caldwell, 
2003; Harth, 1990; Hoehn, 2005; Lebensburger, 2013; MacNeill, 
2013; Patterson, 2014; Pletsch, 2001(2); Read, 2009; Tait, 1998; Tait, 
2003; 
Distrust in research (‘guinea pig’) 11 Baren, 1999; Caldwell, 2003; Harth, 1990; Hoehn, 2005; 
Lebensburger, 2013; Menon, 2012; Peden, 2000; Read, 2009; 
Sammons, 2007; Tait, 1998; Wynn, 2010
logistics / disruption of daily life* 11 Baren, 1999; Brody, 2005; Caldwell, 2003; Patterson, 2014; Harth, 
1990; Lebensburger, 2013; Peden, 2000; Pletsch, 2001; Read, 2009; 
Tait, 1998; Wynn, 2010
Burden for child 9 Barrera, 2005; Brody, 2005; Buscariollo, 2012; Menon, 2012; 
Oppenheim, 2005; Peden, 2000; Pletsch, 2001(2); Read, 2009; 
Woodgate, 2010
Decision too stressful 7 Hoberman, 2013; Lebensburger, 2013; Menon, 2012; Pletsch, 2001; 
Read, 2009; Sammons, 2007; Tait, 1998
fear of randomization 6 Caldwell, 2003; Lebensburger, 2013; MacNeill, 2013; Sammons, 
2007; Tait, 1998; Wynn, 2010
no direct benefit for child** 5 Baren, 1999; Barrera, 2005; MacNeill, 2013; Read, 2009; Wynn, 2010
financial constraints 5 Baren, 1999; Buscariollo, 2012; Harth, 1990; Tait, 1998; Wynn, 2010
Discomfort with proxy consent 2 Buscariollo, 2012; Caldwell, 2003
* For child and rest of family; ** Of which 3 are defined as studies with no prospect of direct benefit
Table 7: Meta-summary of discouraging factors mentioned by children for participation in clinical drug research 
Discouraging factor no. of studies
( total = 6)
individual studies
Burden / disruption of daily life 4 Brody, 2005; Koelch, 2009; Read, 2009; Patterson, 2014
feeling like a ‘guinea pig’ 3 Koelch, 2009; Peden, 2000; Read, 2009
fear of risks 3 Brody, 2005; Brody, 2012; Patterson, 2014
Decision too stressful 1 Read, 2009
no understanding 1 Read, 2009
no direct benefit 1 Read, 2009
Preference for one arm 1 Peden, 2000 
Discussion
This systematic review shows that the most frequently mentioned motivating factors for 
parents to endorse their child’s participation in clinical drug research are: health benefit 
for their child, altruism, a trust in research, and their relation to the researcher. Most 
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frequently mentioned motivating factors for children to participate are: personal health 
benefit, altruism and increasing comfort. Fear of risks, distrust in research, logistical as-
pects and disruption of daily life are mentioned most frequently as discouraging factors 
to endorse participation of their child by parents. Burden and disruption of daily life, 
feeling like a ‘guinea pig’ and fear of risks were most frequently mentioned as discourag-
ing factors by children.
One of the most important ethical criteria on which a research ethics committee (REC) 
should evaluate a research protocol, is whether the objective outweighs the risk and 
burden to the research subjects: called a consideration of proportionality. In other words: 
a REC assesses the predictable risk and burden to the research subjects in comparison 
to the foreseeable benefit to them and to other individuals or groups affected by the 
investigated condition.6 Our review shows that this proportionality is also considered 
by parents and children in their own individual decision about research participation; 
personal health benefit and altruism are the most frequently mentioned motivating fac-
tors and risk and burden are frequently mentioned as discouraging factors. In 7 studies 
the weighing of these factors (proportionality) is even specifically mentioned by par-
ents.13 31 38 40 41 46 55 In 2 studies children mention explicit this proportionate weighing.29 38 
burden of ParticiPation
The results also show that it is not only burden for the participating child that influences 
the decision, but also burden for parents themselves and the rest of their family. Profes-
sionals involved in pediatric research need to be aware that when a child participates 
in research, a lot of the burden falls on the shoulders of parents: e.g. they need to be 
present at the hospital; they are often the ones filling in the diaries. This burden may 
negatively affect the decision of parents to let their child participate in research. That is 
also true for logistical aspects and disruption of the lives of the whole family. Parents are 
the ones absent from work and they need to make sure that other family members are 
looked after when their child participates in research. Parents mention for example ‘the 
inconveniences of trial participation’55 or ‘too many visits’53 as reasons for dissent. 
generaL trust and mistrust in research
Issues of general trust in research or general mistrust (often explained with wordings 
as ‘guinea pig’) influence the decision of parents and children greatly. These issues of 
trust and mistrust might indicate that their decision is not a weighing of factors but an 
a priori decision. This idea of an a priori decision was also suggested a few years ago by 
Pinxten in his thesis.56 The general trust of children and their parents in research needs 
to be protected by careful evaluation of study protocols by a REC beforehand. A proper 
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evaluation system beforehand ensures that the studies offered to parents and children 
are of such quality that their trust in research is well-founded.
PersonaL heaLth benefit
Personal health benefit is one of the most important motivators for parents and children 
themselves to participate in clinical drug research. This is of course not problematic 
when the study has therapeutic objectives, but is problematic when no prospect of 
direct benefit exists. 
In all 3 studies with no prospect of direct benefit (all oncology phase 1 studies) where 
parents were questioned, possible health benefit for their child was a motivating fac-
tor.15 25 37 In the study of Deatrick et al. most parents saw their child’s participation in the 
trial as ‘a means of providing treatment to prolong life, though an uncertain treatment’.25 In 
the study of Barrera et al. families main motivator for enrolling in phase 1 trials was ‘hope 
for a cure or prolongation of the child’s life and their belief that participating would ensure 
continuity of care’.15 Since the objective of these phase 1 studies is safety assessment 
and not effectiveness, and because of the fading boundary between research and care, 
therapeutic misconception is a clear danger in these studies.57 Adequate information 
on the rationale of the study is therefore essential. Professionals involved in clinical 
research need to be aware that the line between hope and reality is thin. As illustrated 
by an interviewed mother from the study from Oppenheim: ‘…the study was proposed 
as an alternative, and we accepted it to avoid the operation and to gain more time, even a 
week, but not really believing that it could cure F’.37 
Children are also vulnerable to therapeutic misconception, as shown in two studies with 
no prospect of direct benefit in which children themselves mention therapeutic benefit 
as an important motivating factor.15 35 
aLtruism
Helping others or contributing to science is an important motivation for parents to en-
dorse participation in clinical drug research. However, 3 studies concluded that altruism 
was explicitly not a factor in the decision of parents.13 37 50 Altruistic motivations might be 
overestimated in this review. These could be socially desirable answers. Remarkable is 
the finding of Truong et al., that parents with a child in a phase 3 study mention altruistic 
motivations more often than parents with a child in phase 1 studies.47 
Helping others and contributing to science were also mentioned frequently by children 
as a motivation for participation in research. For example, more than 80% of the ques-
tioned children in the study of Wendler et al. indicated that finding better treatments 
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for others was important to their decision to enroll.51 Two studies that showed altruistic 
motivations in children questioned children starting at an age of 6 years old. This might 
indicate that children can be altruistic at a much younger age than currently suggested.58 
Unfortunately, the studies addressing altruism had very wide age ranges (6-18 years) 
and no stratified analyses for age groups. It would be interesting to look deeper into the 
role of altruistic motivations of children in pediatric research. 
reLation to researcher
Parents and children mention their relation to the researcher quite often as a factor 
influencing their decision to participate. This should not be a problem if they ask him/
her for advice or feel safe with him/her. But it is problematic when parents and children 
use words as ‘I felt pressure’42 or even ‘They told me to’50. This means that parents and 
children may feel less free when asked to participate. The effect of this relationship on 
their decision needs to be considered even more carefully when the roles of researcher 
and treating physician converge in one, which is often the case in pediatrics.59
more contact with medicaL team
Parents mentioned quite often more contact with the medical team as a favoring 
factor for endorsing research participation. For example, in the study by Masiye et al., 
some participants felt that if they would refuse to participate in the study, their child 
might not receive attention from the healthcare workers whenever they would visit the 
hospital again.33 And some parents in Caldwell’s stated that their child would be better 
monitored when he/she would be in the trial.55This suggests that parents think their 
child is better looked after or treated when in research. Parents need to be aware that 
(non-)participation in research does not affect their regular treatment. In our opinion, a 
patient should not be dependent on research to get the attention he/she wishes for in 
a treatment setting. 
feLt as onLy oPtion
Striking is the observation that parents sometimes endorse participation because it 
feels for them as if they do not have an option.23 25 31 35 42 This can be a problematic factor, 
when there are other options available of which parents are not sufficiently aware of. But 
in certain hospital settings (for example oncology setting) participation in research is in-
deed the only option parents and children have opposed to palliative care. Furthermore, 
some children and parents can only accept the child’s upcoming death when they have 
tried all available options. One parent illustrated this clearly in a study by Deatrick et al.: 
‘There wasn’t really a choice in my mind because if I choose to not do anything then I would 
have been choosing to let her go and I’m not ready for that.’25
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no direct benefit for chiLd
Surprisingly, this review shows parents can refuse participation because they do not 
expect benefit for their child. It is striking that this is mentioned in three randomized 
phase 3 studies (where a prospect of benefit exists).14 32 53 A possible explanation could 
be that parents have a preference for the experimental intervention arm (compared to 
standard or placebo arm) and are suspicious of the randomization since it does not guar-
antee them access to the experimental intervention arm. This is illustrated in the study 
by Baren et al. in which parents mention fear of receiving less than optimal treatment in 
the study as a discouraging factor for participation.14
Limitations and strengths of this review
This systematic review gives a comprehensive overview of motivating and discourag-
ing factors for children and their parents to consent to clinical drug research. Since we 
aimed to give an overview of all the available empirical literature on this topic, there is a 
large variety in drug trials, settings and populations of the studies. This heterogeneity in 
studies might complicate the interpretation of the pooled data, but we feel it is essential 
to pool these heterogeneous results, since it reflects the diverse practice of pediatric 
drug trials.
Because of challenges in the search strings, we limited our research question to partici-
pation in pharmacological research. Therefore it is uncertain whether we can extrapo-
late these results to other medical research (including observational research and other 
interventional research). 
We reported in the qualitative meta-summary the number of studies citing a specific 
factor. The number of articles reporting a specific factor may not represent the impor-
tance of this factor to the research participants. Besides that, given the wide range in 
the number of research participants per study, an increasing number of studies citing 
a factor does not necessarily reflect more parents or children mentioning this factor. 
However, qualitative meta-summary is still the best way to pool this kind of data from 
qualitative and quantitative empirical studies. To get more insight in the motivations 
of parents and children qualitative research is of essential value and a large portion of 
the data in this review comes from qualitative data. Therefore, this way of pooling the 
data does justice to the diversity in qualitative and quantitative research available for 
answering our research question. By including qualitative and quantitative research the 
strengths of both types of research are combined; in depth results and possibility of 
unanticipated motivations from qualitative research, and large sample sizes and stan-
dardization from quantitative research.
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conclusion
It is essential that professionals during the recruitment and informed consent/assent 
process pay attention to the motivating and discouraging factors children and their 
parents have for participation in clinical drug research When professionals know more 
about the motivations of parents and children to endorse or decline participation in 
clinical drug research, professionals know which aspects of research parents and chil-
dren attach importance to and what information is of relevance for their decision. This 
information can then be used by professionals in the informed consent materials and 
conversations. When children and their parents are being informed about the aspects 
of research to which they attach importance, they may reach a decision more consistent 
with their own values. Therefore, the attention to these motivating and discouraging 
factors makes the informed consent/assent of parents and children more informed, which 
thus increases the moral value of informed consent/assent.
Besides leading to an increase in the moral value of informed consent, paying attention 
to the motivations of children and their parents for participation in clinical drug research 
can also be of instrumental value. By adapting the study protocol, the recruitment and 
the informed consent process to the needs and wishes of children and their parents, par-
ticipation rates will probably increase (and dropout rates can decrease). For example, by 
diminishing logistical barriers (which this review shows, are mentioned often by parents 
as negatively influencing their decision) at the setup of the study, parents and children 
will probably be more inclined to participate. Therefore, adapting the research protocol, 
recruitment and informed consent process to the needs of children and their parents 
may lead to more informed consents.
This systematic review gives a comprehensive overview of the available empirical data 
on motivating and discouraging factors for parents and children to consent/assent to 
clinical drug research. But it also shows us that specific populations are underrepre-
sented in this field of research. Further research is needed in diverse populations and 
research fields (for example healthy children, children with chronic disease such as 
cystic fibrosis, and critically ill children). This future research should specifically focus on 
the factors that shape the decision of children themselves, since research with children 
on this topic is scarce. Although children cannot consent by themselves, they can assent 
and we shouldn’t forget to listen to them. They are the ones bearing the burden and risk 
during participation in clinical drug research, and possible beneficiaries of the research.
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Knowing why parents and children want to participate in pediatric clinical research, 
teaches us what they attach importance to, what information they base their decision 
on and which information they need to receive in the recruitment and informed consent 
process to be able to make a proper decision. In this qualitative semi-structured inter-
view study, we explored minors’ and their parents’ motivations, views and expectations 
during the process of recruitment and informed consent for pediatric clinical research.
We interviewed children and their parents who had been asked to participate in clinical 
research and had had an informed consent conversation (N=34). Interviews were ana-
lyzed using thematic analysis.
Children and their parents attach more importance to burden than to risk when they 
need to decide about participation in clinical research. The anticipated burden of par-
ticipating is most frequently mentioned as motivating or discouraging for their decision 
to participate. However they have a very broad notion of burden, with an emphasis on 
logistical burden. They outsource their concerns about risk by trusting the research staff 
and their physicians. Their altruistic motivations are mostly reciprocity-based.
The design of pediatric clinical research and especially the recruitment and informed 
consent process can be ameliorated by the findings of our research regarding the moti-
vating and discouraging factors. This way, research will be better in line with the prefer-
ence of children and parents, and children and their parents will be better equipped to 
make a decision about participation. 
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inTroDucTion
On the one hand, we need children to participate in clinical research to advance scien-
tific knowledge and develop new - much needed - treatment options for children. On 
the other hand we want to protect children against the harms from research, because 
they are a vulnerable and dependent population.1
For decades scientists, ethicists, philosophers, physicians, members of research ethics 
committees and other healthcare professionals write about and discuss this precarious 
balance between protection and advancement of knowledge.2-5 But how do children 
and their parents, as key decision-makers in pediatric clinical research, experience this 
balance themselves? Is it a trade-off for them? Do they also weigh the harms against the 
benefits when they need to decide about participation in clinical research? Or are other 
factors just as important to them in their decision?
Why would you expose your child to the burden and risk of clinical research without the 
least expectation of a direct health benefit? Why would you as a child want to go to the 
hospital solely for research procedures, it being a place where you might already have 
negative experiences? Why would you undergo a bunch of procedures without knowing it 
will be of any help to you? Thinking about these questions makes us wonder why someone 
would let his/her child participate at all. Still, we do know research with children is needed, 
so we do offer it to them and they do participate. There are probably other factors at hand 
in their decisions to participate than just striking a balance between protection against 
harm and advancing knowledge. For example Hoberman and colleagues and Vanhelst 
and colleagues showed that the child’s health status also is an important factor in research 
decision-making by parents.6 7 The study by Hoberman also showed that parents with posi-
tive perceptions of the research team are more inclined to participate.7 And other studies 
showed that for many parents not participating didn’t even present itself as an option.8 
Results from a systematic review on motivations of parents and children to consent or 
dissent to clinical research showed that most research on this topic is done in the oncol-
ogy setting, and that other fields of clinical research are underrepresented.9 This review 
also revealed that the majority of the empirical research done in this field is of a quantita-
tive nature, while qualitative research can generate much more important and essential 
information to further this debate.10 Qualitative empirical research gives better insights 
into research subjects’ motives and attitudes, an indispensable element of normative 
work in medical ethics.11 Knowing why parents and children want to participate in pe-
diatric clinical research, teaches us what they attach importance to, what information 
they base their decision on and which information they need to receive in the recruit-
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ment and informed consent process for pediatric research to be able to make a proper 
decision. It helps us with the ethically sound inclusion of children in research and can 
improve both the instrumental and moral value of informed consent/assent in pediatric 
research. It gives us the chance to: a) communicate more decision-oriented information 
during the recruitment and informed consent process, creating more informed consents/
assents; and b) adapt the research design, recruitment and informed consent process to 
their needs and wishes, creating probably more informed consents/assents.
Therefore, the main objective of this qualitative interview study was to explore minors’ 
and their parents’ motivations, views and expectations during the process of recruitment 
and informed consent for pediatric clinical research. Secondary objectives were: 1) To as-
sess motivating and discouraging factors that shape the decision to consent or dissent 
to participation in pediatric clinical research; 2) To assess their views on the recruitment 
and informed consent process; 3) To assess their attitude in the decision-making process; 
4) To assess their expectations of participation in pediatric clinical research.
meThoDs
This study is reported in accordance with the consolidated criteria for reporting qualita-
tive research (COREQ).12
study setting and PoPuLation
The study population consisted of children and their parents who had been asked to 
participate in clinical research and had had an informed consent conversation with a 
health-care professional. Between March 2014 and July 2016 participants were recruited 
from three departments of Erasmus MC – Sophia Children’s Hospital: the department of Pe-
diatric Intensive Care, Pediatric Oncology, Pediatric Pulmonology (division: Cystic Fibrosis). 
Due to the qualitative nature of the study no sample size calculation was performed. 
Enrolment of participants ended when theoretical saturation was reached for answering 
the main research question and no new concepts emerged.13
To do justice to the variety of clinical research and to ensure a wide range of perspec-
tives, purposive sampling was used for the selection of the study population.14 Sampling 
consisted of children of diverse ages and mothers and fathers, who had been asked to 
participate in clinical drug trials (including phase I, II, III and IV; and pharmacokinetic/
pharmacodynamic studies), intervention studies other than drugs (including medical 
devices) and observational studies.
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Drawing comparisons between participants, diseases, and research types was not a 
central study aim nor is it possible with this type of qualitative data.15 16
interviews
KT conducted semi-structured interviews with all parents and children face-to-face in 
the hospital, at home or by telephone, according to the family’s preference. Six themes 
were addressed in the interviews: Why did you decide (not) to participate?; motivating 
and discouraging factors for this decision; views about the recruitment and informed 
consent process (including provision and content of the information); attitudes in the 
decision-making process; and expectations of participation.
coding and anaLysis
The interviews were audio taped and transcribed verbatim. Interviews were analyzed 
using thematic analysis. Through systematic objective coding, we identified and la-
belled themes, in order to elucidate relevant concepts and thus to interpret motivations, 
views and expectations of children and parents during the process of recruitment and 
informed consent in pediatric clinical research. We coded and analyzed the data using 
QSR International’s NVivo 11 qualitative data analysis Software.
KT initially coded all interviews. SvdV coded all interviews as a second researcher. Dis-
agreements were settled by consensus. Initial coding tree was based on the interview 
guide and included: 1) Main reason for participating in specific clinical research study; 
2) Motivating factors; 3) Discouraging factors; 4) Views about recruitment and informed 
consent process (including information material); 5) Attitudes in the decision-making 
process; 6) Expectations for participation in the research. Initial coding for motivating 
and discouraging factors was based on results from a previously executed systematic 
review on motivations for parents and children to participate in clinical research.9 Dur-
ing the process of coding and analysis this initial tree was adapted and elaborated based 
on the data from the interviews. Interview coding and analysis continued until no new 
codes, concepts, or patterns emerged.
resulTs
study PoPuLation
Between March 2014 and July 2016 34 participants of 21 families participated in this 
interview study. We interviewed 4 children about their own decision and 30 parents 
(11 fathers, 18 mothers, one adult sister) about the proxy decision for participation of 
their child. Participants were equally distributed amongst the three departments and 
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educational level of the parents was diverse. Some families had consented and some 
had declined to participate in the proposed pediatric clinical study. Table 1 presents an 
overview of the participant characteristics.
Table 1: Participant characteristics
characteristic no. of participants




Disease of child Cancer ** 11 
Cystic Fibrosis 10
Craniosynostosis  6 
Esophageal reflux 3
Rare genetic condition 2
Necrotizing enterocolitis 2
education level parents Secondary school 2
Intermediate vocational education 11
Higher vocational education 7
University 6
Unknown 4
age parents Median age [range] 34 [18-70] years of age
age of their children Median age [range] 3 [0-17] years of age
age interviewed children*** Median age [range] 15 [11-17] years of age
* 1 adult sister joined the interview, she is regarded a parent in the analyses; ** including acute lymphocytic leu-
kemia (ALL), acute myeloid leukemia (AML), lymphoma; *** not all children were interviewed, because they were 
too young or did not want to be interviewed
main motivator to consent or dissent
All parents and children were asked why they decided to consent or dissent to the 
proposed clinical study. 
One mother decided not to let her child participate in the proposed clinical research 
study. And another mother agreed with her child (boy, 17 year of age) not to consent 
to participation in the proposed clinical research study. Both children did participate in 
research in the past. Their main reason for not participating in the proposed study was 
concern with the expected burden of the study (table 2).




If it doesn’t work, it doesn’t work, that’s what they said…I am not a pill swallower. I’ve tried, but it really did not 
work. Twice it was successful and then they said: “you have to wait another day.” And then I thought: “I’m not 
going to take pills for another day” ... Then I said: “No.” Then it stopped.
What motivates children and their parents to participate in pediatric clinical research? An interview study 93
Children and parents who had consented to participation in the proposed clinical study, 
were asked what their main reason for participation was. Table 3 gives an overview of 
these main reasons for consent. The expected minimal or no burden of participation for 
the child was the most frequently mentioned main motivator. Altruistic motivations (not 
defined, helping science or helping other/future patients) and a personal benefit for 
the child were also mentioned frequently. Other main reasons included among others: 
a general trust in research and researchers and trust in the safety of research. Some 
participants mentioned a combination of two or more reasons for participation.
Table 3: Why did you decide to participate? Examples of main reasons for participating
main reason for participating* Quote
minimal or no burden for 
child
... understood from everything that she is not bothered by it herself and I think that is the 
most important thing. If she were bothered by it, I would not have done it. (mother 122)
altruism
-  helping future or other 
patients
- helping science 
yes, that was to see what helps best for later, for the future. And that’s why I participated, it 
can help people later. For me it does not really matter that much, they said, but I think yes if 
I can help people, try. ... yes, when I was one years old, I also had cancer, I also helped a lot of 
people. That’s what I’m gonna try again now. (child 201, age 17)
health benefit for child We think it is important that a solution is sought of course for his illness. That medication 
comes that improves his quality of life and of course stretches his life. (father 053)
no risks associated with 
participating
yes the same applies to me. If it is risk-free for him, I think it’s okay. (father 243)
general trust in research
- Trust in researchers
-  safe otherwise wouldn’t be 
offered 
I have all the confidence in this study. I had ... I think it’s one and a half, two years ago, that 
[physician x] started talking about it. And I also viewed his explanation on youTube a couple 
of times and I just really had all confidence. And I asked him, because at that moment we 
could not start because the study did not start yet, I said what would you do? And then he 
said to start immediately, he said. And I just had every confidence in it. (mother 042)
Possibility to stop 
participation
But then it turned out, yes I do not know about studies and stuff, I thought yes when you join 
then you are obliged [to continue (red)], but then it turned out that you could stop at any 
moment, if you did not like it anymore. So that is actually the reason that I thought I’ll do it. 
(mother 062)
curiosity Curiosity, well what will come from it. yes how it develops further. (father 123)
combination of reasons Because I think it is important that research can be done so that other people in the future 
can benefit from it. And also, they said at least, if in adults, the drug also tackles a broader 
spectrum of fungi t, so this medication also seems better to me.... yes that that medication 
works better than the standard medication. (child 131, age 16)
* Answer to the open question: “Why did you decide to participate in this clinical study?” or “Why did you let your 
child participate in this clinical study?”
motivating and discouraging factors
When asked to elucidate their decision, interviewees revealed that most of the times 
their decision was a result of weighing several motivating and discouraging factors 
(table 4). An illustrative overview of these motivating and discouraging factors is shown 
in figure 1.
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figure 1: Overview of motivating and discouraging factors
Diamond shapes show the factors influencing participation (reason); size of the diamond shape illustrates im-
portance of mentioned factors. Red squared boxes indicate discouraging factors; Green rounded boxes indicate 
motivating factors.
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Burden was mentioned by almost all participants as having an influence on their deci-
sion (table 4). This included minimal and no burden as a motivating factor and too much 
expected burden as discouraging factor. Fear of expected burden was not only limited 
to the burden of study procedures on the child, but included also the way in which their 
child’s participation would burden the parents (e.g. filling in questionnaires) and the 
logistical burden of being in clinical research (e.g. travel arrangements).
Table 4: Examples of motivating and discouraging factors
Participant Quote 
Weighing of factors
Mother 222 yes, we have already participated in several studies. And I often have something like, if it doesn’t burden them 
and cannot do any damage, then I think: “yes, you do not do this research for nothing, so it probably has positive 
effects for children who come after them or at least there is information that others can use.” And yes, then I do not 
mind.
Burden
Mother 112 yes of course it must be interesting, how often do we need to go to the hospital and that is to be planned with my 
husband’s job and that’s pretty much it. We do not live nearby… I mean to the hospital once more that does not 
matter. But if you are continuously…then it is not interesting for us: No.
Child 151 
(age 15)
I first thought about it, because they said what you would need to do and that you had to go to the hospital more 
often. I thought: “I really don’t want that, I do not want to go to the hospital more often and I do not want to do 
more than what I already do, with school and stuff.” So at first I said: “No, I do not want it.”
Personal benefit
Father 053 It was a promising study, what the doctors thought very promising. So we thought something like: “When we 




And yeah, if I can continue with it and it helps better than nebulizing, that would be easier of course. Because then 
I can go on with it in one go, it’s less work, I like that better. yeah, it is not every single time a device, charging the 
device, and all that kind of things.
altruism
Mother 242 For me it is a basic value, why I am also a blood donor and organ donor, things that I find important. If you can 
help someone with that, I actually think you should do that if it is possible.
Mother 072 yes, I think that is the ultimate goal, of course, to help your own child and other children. That is, what I think is the 
overarching ... not so much that it is not burdensome, but of course you do it for science and for the future.
Mother 132 I think the biggest reason is, yes you see from all sides that this study is necessary, that there is so much possible 
and it is of course beautiful that there is so much. yes a lot of study is needed for that. And yes, you yourself think if 
you can help a hand somewhere; if you see how much they do here for your child, what is mega important; and if 
you can help a little something with it. Then you do that. Then you want to do that.
Child 131 
(age 16)
Because I think it is important that research can be done, so that other people in the future can benefit ... yes ... 
without ... If no research could take place, in that way they would never evolve in healthcare. So then, like in the 
old days, it would have been, at least not that long ago ... now it’s a lot nicer to be here.
Trust and distrust
Mother 242 No actually not. Out of curiosity I would inquire about the usefulness, the necessity. But I assume that what they 
come up with and where budget is made available for, that that is necessary. So it does not matter to me.
Father 173 But if she would act as a guinea pig, yes, I would have my doubts about it.
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Expected personal benefit for the child encompassed not only direct personal health 
benefit (e.g. possible cure), but also an increase of comfort (e.g. less medication), buy-
ing time, the opportunity to get early access to new drugs, and more contact with the 
medical team (table 4).
Altruism was frequently mentioned as a reason for participation (table 4). Parents let 
their child participate, not only to help patients in the future or to further science, but 
also because they acknowledged that in the past children had participated in research 
of which their child might have benefitted now. Children themselves also mentioned 
altruistic reasons.
Parents and children also mentioned a general trust in research or the contrary, distrust 
in research, as a reason influencing their decision (table 4). Distrust included mentioning 
of words like “guinea pig’ or experimenting. Trust in research showed in terms like: I trust 
my doctor, it is safe otherwise it wouldn’t be offered and since it is an international and 
multicenter study, new medication is better.
Other reasons parents and children mentioned were related to the risks of participating, 
the decision itself, the voluntary nature of participating, and privacy issues. 
views on recruitment and informed consent conversation
Parents and children made explicit that they want to be asked for participation in clinical 
research, even in stressful situations with little time to decide (e.g. at the intensive care 
unit). They gave suggestions on how to approach them in those situations and advised 
to inform all personnel, research and healthcare personnel, about the study and include 
them in the organization (table 5).
attitude in the decision-making Process
Parents discuss the clinical study with each other when possible and this deliberation is 
considered relevant and important to them. They hardly mentioned discussing the study 
with other people except their child, partner or healthcare / research professionals.
Parents do discuss the study with their child and feel the child’s opinion is very impor-
tant. Most of them mentioned incorporating their child’s opinion in their decision or 
following the child’s wish, also when the child is not legally competent to consent. The 
older the child, the more importance they attach to their child’s opinion (table 5).
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Table 5: Examples views on recruitment and informed consent conversation, attitude in the decision-making 
process, and expectations
Participant Quote
views on recruitment and informed consent conversation
Mother 182 Just in two sentences: “I do research and this is what I need from [name child], but I understand the 
situation, that it is too much. But I want to ask if you want to think about it and then I leave some 
more information behind and then I’ll be back tomorrow.” But do not talk for minutes about your little 
research. No, because that really doesn’t interest you, when you are in the ICU. No, of course not, why 
would you care, it’s about your child getting better, not what kind of research is being done here... yes, I 
mean they are walking around here at the ICU, so you can come, but just ask the nurse of [name child]: 
“How is [name child] doing? Is it okay? And do you think I can approach the parents for research?”
Father 042 I think it works well, I think they are very professional. Our contact moments are very good. If we have 
questions we can ask them, we get good and comprehensive answers.
attitude in the decision-making process
Mother 182 yes, we do ask each other whether we are doing this or not? I’m not going to decide by myself.
Mother 062 I remember that I had [research nurse a or b] on the phone, at least one of those two. And I said: “Oh well 
I do not know.” Then she said: Well, then I just say that you will not participate.” Then I thought: ”Oh yeah, 
that’s a possibility too.” Then I was hesitating again, so that’s how it went.
Mother 022 And that is actually the age of [child, age 4] now. Then we would like to talk about it with [child]. About, 
yes they have to draw blood for research, do you want that? yes, for us his opinion means a lot, especially 
because he has a chronic illness.
Child 171 
(age 11)




yeah, yeah. Then, of course, your parents will push you a little bit: “Join in ... “.yeah, but that’s part of it, I 
guess. If I said no, they would have been fine with it too. yeah, in the end I have to do it myself, so they can 
say: “yes, do it.” But if I do not feel like it, I will definitely not do it every time.
expectations
Mother 174 I do not think so. We have signed a contract. yes, he cannot stop, we will not stop. yes, then I think it’s 
over.
Father 152 But there isn’t actually. There is no risk; at least it has all been tested in advance. So it has already been 
tested on adults. Well if you are not hypersensitive to that drug, then why would you not do that? I see no 
reason for that.
exPectations
Almost all parents and children were interviewed before their participation in the 
clinical research study had started or just at the beginning of the clinical research study. 
When deciding about participation they had certain expectations about their participa-
tion in the research, which were made explicit by them in the interview. Some of these 
expectations were surprising. Most parents and children consented on the assumption 
that participation in the clinical research study would not burden but benefit them in 
one-way or another. One parent expected her child to benefit from participation in 
an observational study. Several parents expected their child to be checked up more 
regularly in the study by the medical team. One family assumed being randomized to 
the standard treatment, meant not participating in the research at all. A frequently en-
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countered assumption was related to the expected safety of pediatric clinical research. 
Multiple parents assumed research participation to be without any risks, because the 
drug was already used safe and effective in adults. One family had assumptions about 
the (in)voluntary nature of the study; they talked about signing a contract and were not 
aware of the right to withdraw from research (table 5).
Discussion 
burden weighs more than risk in the decision
Our interview study shows that children and their parents attach more importance to 
burden than to risk when they need to decide about participation in pediatric clinical 
research. The anticipated burden of participating is most frequently mentioned as mo-
tivating or discouraging for their decision to participate (or let their child participate). 
This focus on burden is not only related to the burden of specific research procedures 
for the child, but entails also the logistical burden of participating in research for both 
child and parents. This includes time spent in the hospital for research purposes, missing 
school or workdays due to participation and missing out on leisure time. When a child is 
a research participant, it is easy to forget parents are not only proxy consenters but proxy 
participants as well: a child often depends on his/her parents to travel to the hospital, 
parents need to fill in questionnaires or help with diaries and parents need to collect 
samples for research purposes. These are efforts they are willing to make for care, but 
not always for research. 
In designing and reviewing pediatric clinical research, and in the recruitment and in-
formed consent process, this type of logistical burden for both child and parents should 
be given attention. Furthermore, since it is a main factor influencing their decision, 
minimizing this burden is crucial. A systematic review about discontinued clinical trials 
showed that burden for participants is one of the major reasons for recruitment failure.17 
Therefore paying more attention to these types of burden during the design of the study 
will also contribute to the success of clinical research.
trust in research
Although parents and children do not frequently mention risks as a factor influencing 
their decision, their focus on burden does not mean risk does not matter to them. On 
the basis of these interviews we conclude parents and children outsource their concerns 
about risk. They have a great deal of trust in research, research staff and physicians and 
do not expect high risk research or bad quality research to be offered to them. 
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This shows how important ethics governance systems and the prior-review role of re-
search ethics committees are. Despite the ongoing criticism on the ethical review system, 
including accounts of overprotection,18 19 our study shows potential participants expect 
research to be checked and reviewed beforehand and only safe and sound research to 
be offered to them, making ethical review an essential step in the process.
reciProcity is key in aLtruistic reasoning
Parents we interviewed quite often referred to helping other or future children and sci-
ence as important considerations in their decision. There is much debate in literature 
whether you can call this altruistic reasoning, given that parents are not research partici-
pants themselves.20 But taking in consideration our findings on burden, you can argue 
that parents also partly self-sacrifice when their child participates, an essential element 
of altruism. Therefore we characterize these considerations of children and parents as 
altruistic reasoning. 
Striking was that parents and children not only point to the future in their altruistic 
reasoning, but also reason backwards. Parents and children do not only focus on future 
patients, but also consider children who participated in the past. They now benefit, 
because in the past children participated in research. Luchtenberg and colleagues also 
recognized this backward reasoning in their interviews with children about research 
participation and introduced the term ‘reciprocity’ to characterize this type of altruism.21 
The results from our interviews accentuate this reciprocity-based altruistic reasoning in 
parents and children who are asked for clinical research.
Parents and chiLdren want to be asked, gatekeePing not desirabLe
Our interviews show that parents and children want to be asked for clinical research, 
even in difficult and stressful situations. However research professionals do not always 
approach all eligible patients for participation in a research study for various reasons 
(e.g. protection from burden, prejudiced anticipation on their dissent), a practice called 
‘gatekeeping’. An undesirable practice, as several other authors remarked in previous 
articles.22-24 Results from this interview study endorse this disapproval of individual 
gatekeeping by professionals, with respect for persons as the most important argu-
ment: parents and children want to be asked for research participation, and then decide 
themselves.
suggestions for imProvement in the informed consent and 
recruitment Process
The interviewed children and parents showed a large deal of trust in their treating 
physician. Previous research also showed that this trust is central to the willingness to 
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participate in research.25 26 But we need to be aware that this trust can become problem-
atic and jeopardize the voluntariness of research participation.26-28 Parents introduced 
a possible solution for this problem in our interviews and advised to let their treating 
physician introduce the study in just a couple of sentences and subsequently let the re-
search nurse or researcher explain the study in more detail and do the informed consent 
procedure. This process would strike the right balance of trust in your own physician and 
being able to make an independent free decision.
Another issue parents addressed in the interviews, and we observed ourselves, was the 
fact that not all personnel with whom parents were in contact with in the hospital knew 
about a study, resulting in insufficient or even incorrect information. Therefore, it is es-
sential that everyone at the work floor knows about the clinical trial. 
A third issue addressed by parents was their desire to receive information about the 
aggregate results at the end of the clinical research study. This is not yet, very common 
in research practice. We therefore advice research professionals to develop a policy at 
the start of the study for return of results, e.g. keep an update on a website, and ask all 
participants during the informed consent process if they want to be updated. 
misconcePtions bring a resPonsibiLity for the researcher
We were confronted with multiple misconceptions when asked about their expecta-
tions of research participation. These included difficulties with understanding the 
research-care distinction, the research design, the voluntary nature of participation, 
and risks associated with pediatric clinical research. These misconceptions can lead to 
participation in clinical research based on false assumptions. Therefore prevention of 
these misconceptions brings a responsibility to research professionals to inform parents 
and children correctly, be alert for these misconceptions and stay in contact during the 
study period. 
study strengths and Limitations
This qualitative interview study contributes to better acknowledgement of the 
importance of knowing the reasons why one might or might not want to participate 
in research.29 The recently revised Common Rule states mere comprehension and un-
derstanding of given information is not sufficient, the given information needs to be 
relevant for the decision.30 In order to design the informed consent process in a way 
that matches these needs of the participants, qualitative research into the motivations 
of people to participate in research is essential. Because we interviewed parents and 
children with cancer and other diseases, this study adds new perspectives and variety to 
the body of empirical research into the motivations for pediatric research participation. 
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Unfortunately, only a limited number of participants who dissented to research par-
ticipation was interviewed. Probably, people who dissent to a specific clinical study 
also dissent to participation in this interview study. Our study would have benefitted 
from inclusion of more dissenting families, to do justice to the variety of decisions. This 
type of qualitative research does not give insights in the distribution of motivations; 
therefore quantification of motivations is not possible with this data.
conclusion
Parents and children want to be approached for participation in clinical research, and 
burden is the most important factor in their decision. In general, the motivating and dis-
couraging factors influencing the decision of children and their parents are in line with 
discussions in research ethics committees. Our interviews revealed parents and children 
however have a much broader notion of burden, for example they attach importance to 
logistical burden, and that this is crucial in their decision on participation. 
The design of pediatric clinical studies and especially the recruitment and informed con-
sent in pediatric research can be ameliorated by the findings of our research regarding 
the motivating and discouraging factors. This way studies will be better in line with the 
preference of children and parents, and parents and children will be better equipped to 
make a decision about participation. 
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Knowing why parents decide to consent or dissent to participation of their child in 
pediatric clinical research is essential to further the ethical debate concerning pediatric 
research. We performed this qualitative focus group study with 16 parents from the 
Dutch general public to explore their perspectives on decisions to participate in pediat-
ric clinical research. 
Group discussion revealed: Parents conflate clinical research and clinical care; they do 
not grasp the trajectory of pediatric drug development; their protectiveness matches 
current research guidelines; and benefit for their child is the most important factor in 
their decision. 
Research professionals should be aware of the knowledge gap of parents, the pitfalls of 
jargon, and unintended false expectations. 
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inTroDucTion
‘Are you allowed to do that, test drugs on children?’ That’s the response we quite often 
received from friends and family at social gatherings when we tell them about our 
research on how to test new drugs on children in an ethically responsible way. Funnily, 
we hardly encountered such reactions during our research into the decision-making of 
parents and children concerning their participation in clinical research. Could it be that 
a lot of the children and parents questioned in previous studies were actually ‘proto-
professionalized’, leading to a skewed view, and that we do not have a good idea of how 
laypeople view the dilemmas concerning participation of children in clinical research?
The views from parents not recruited through hospitals, but from the general public 
are very much underrepresented in the literature. Most research in motivations and 
decision-making in pediatric research is done with (parents of ) hospitalized sick chil-
dren.1 The perspectives of parents from the general public might differ from parents 
of hospitalized sick children due to not being familiar with clinical research and not 
having to cope with a sick child. Our hypothesis is that this selection created a bias in 
the literature. 
Knowing why parents decide to consent or dissent to participation of their child in pedi-
atric clinical research is essential to further the ethical debate but especially the practices 
concerning pediatric research. The goal of informed consent for clinical research should 
be for potential research participants to make an informed decision, not simply for them 
to opt in to research participation.2 In practice the informed consent process often fails 
to achieve that objective, e.g. because people misunderstand information or receive ir-
relevant information.3-7 More insight in the decision-making of parents enables us to tai-
lor pediatric clinical research and the accompanying recruitment and informed-consent 
processes to their needs and perspectives. This includes the needs and perspectives of 
‘first timers’ in a hospital, who have little experience in research and hospitalization but 
can be confronted with offers for participation of their child in clinical research. It is 
therefore important to add their ‘laypeople’ perspectives to the body of evidence. 
Of course these perspectives cannot be taken at face value but should be used to inform 
normative deliberation on this topic.8 As a first step they should be incorporated in a 
reflective equilibrium.9 10 Reflected upon they may further the ethical debate concerning 
pediatric research. A valuable method to gain access to these perspectives is a focus-
group study. A focus group does not only create the opportunity to collect perspectives, 
but also to deepen them.11 Parents will not only interact with us as researchers, but also 
with each other. This makes them question others’ ánd their own intuitions, creating 
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a dynamic development of their perspectives. Surprisingly, even though these advan-
tages have been acknowledged in the literature, focus group research into parents’ 
perspectives on pediatric clinical research is scarce. A systematic review about motiva-
tions of minors and their children to participate in clinical research identified only two 
focus group studies 1. Lebensburger and colleagues identified with their focus groups 
common barriers and facilitators in pediatric Sickle Cell Disease trials.12 And Caldwell 
and colleagues showed with their focus groups that educating parents about trials, 
improving communication, increasing incentives while decreasing inconveniences, and 
providing decision aids for parents may increase parents’ willingness to let their child 
participate in trials.13 
We designed and performed this qualitative focus group study with parents from the 
Dutch general public to explore their perspectives on decisions to participate in pedi-
atric clinical research. We assessed their intuitions concerning pediatric research, their 
motivations to endorse or refuse their child’s participation in clinical research and which 
factors would influence their decision. 
meThoD
This study is reported in accordance with the consolidated criteria for reporting qualita-
tive research (COREQ).14 
This qualitative focus group study was deemed exempt from ethics approval by the re-
search ethics committee of Erasmus Medical Center (protocol number: MEC-2016-060). 
Written informed consent was obtained from all participants before start of the focus 
groups. All in accordance to Dutch legislation for medical research with humans.
PoPuLation
The study population consisted of 16 parents from the Dutch general public. Participants 
needed to have at least one child below the age of 12 years old and speak Dutch. To en-
sure a wide range of perspectives, purposive sampling was used by including a variety 
of parents concerning family composition, educational level and age of their children. 
Participants were recruited from the general public with assistance from ‘CG Selecties’ a 
bureau specialized in recruitment of participants for marketing research. This approach 
enabled us to recruit laypeople from the general public with minimal foreknowledge 
and experience in hospitals and medical research.
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focus grouPs
The two focus groups were held at Erasmus Medical Center in July 2016 and lasted up to 
120 minutes. One researcher (SvdV) moderated the discussions; One researcher (KT) took 
notes and aided in the discussions when required. Interaction and discussion between 
the participants was allowed and encouraged. But the researchers interfered when the 
debate strayed away from the purpose of the focus group or saturation was reached.
Informed consent was obtained from the participants before start of the focus group. 
This included permission to audio-record the focus groups to be transcribed later. To 
ensure confidentiality only participants and the two researchers were in the room, and 
confidentiality of the discussions was discussed and agreed upon by all participants.
The two focus groups were divided in three parts: 
PART 1: INTRODUCTORy ROUND
In part 1 participants were asked to introduce themselves by use of several key ques-
tions. 1) Who are you? Who are your children? Do you or your children have hospital 
experience? Do you or your children have experience with clinical research experience?. 
Answers to these questions were also collected at the end of the focus groups by use of 
a written questionnaire (supplementary file 1)
PART 2: INTUITIONS
Part 2 consisted of a facilitated group discussion to explore intuitions concerning 
medical research. Discussion centered around three key themes: 1) clinical research; 2) 
pediatric clinical research; 3) specific knowledge. Table 1 lists the key questions used in 
the discussion.
Table 1: key questions – part 2
Key questions – part 2
1. clinical research with humans:
 a. What do you think about then?
 b. What kind of research?
 c. Would you participate?
2. clinical research with children:
 a. What do you think about then?
 b. What kind of research?
 c. Would you let your child participate?
3. specific knowledge:
 a. Off label use of pediatric drugs
 b. Sick vs. healthy children
 c. Research vs. care 
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PART 3: vIGNETTE DISCUSSION
To identify relevant factors influencing parents’ decisions we used a vignette method in 
part 3. Two vignettes presented two hypothetical research protocols. Participants were 
asked which factors would influence their decision to participate in these two studies. 
With post-its they identified motivating and discouraging factors, followed by a group 
discussion about these factors. Table 2 and table 3 present the discussed vignettes. 
Table 2: Vignette A
clinical drug trial (phase 1/2)
The goal is to investigate the safety and efficacy of a cancer drug. The product has already been tested on animals, it was 
found safe in that study. Subsequently it was tested in adults, and for them it was found to be safe and working. Now the 
researchers want to investigate the drug in children.
- The study lasts a total of 8 weeks.
- Your child needs to take the medicine twice a day (by mouth) after a meal.
- Your child may not drink carbonated drinks during the study period.
- At 0, 4 and 8 weeks your child must come to the hospital for monitoring.
- During these visits, your child will have:
- a physical examination 
- a blood sample taken 
- At these moments, you and your child will also be asked to complete a questionnaire.
Table 3: Vignette B
observational cohort study
By collecting data in different ways, research is carried out into the development and growth of children, into the 
development of diseases and behavioral problems. The research thus makes an important contribution to health and care 
for all children in the Netherlands.
- The study lasts a total of 5 years.
- You and your child must visit the hospital every year for examination. This visit takes about 4 hours each time. 
- During these visits, the following examinations are carried out on your child:
- Physical examination (blood pressure, hearing, vision)
- Lung function test
- Electrocardiogram (ECG)
- X-rays of the teeth
- Urine sample
- Blood sample (1 tube of blood)
- Bike test (exercise test)
- Echo of the abdomen
- MRI scan to look at the brain and the heart
- IQ test
- Questionnaire (about health, feelings and school)
-  We also ask you as parents to fill in two questionnaires (health, lifestyle, important events). We also take your blood 
sample (1 tube of blood).
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coding and anaLysis
The focus groups were audio taped and consequently transcribed verbatim by an 
independent person. Focus groups were analyzed using thematic analysis. Through 
systematic objective coding, we identified and labelled themes, in order to elucidate 
relevant concepts. KT initially coded the focus groups. SvdV coded the focus groups as 
a second researcher. Disagreements were settled by consensus. Initial coding tree was 
based on the focus group guide and included: 1) Intuitions clinical research; 2) Intuitions 
clinical research with children; 3) Knowledge clinical research with children; 4) Motivat-
ing factors vignette A; 5) Discouraging factors vignette A; 6) Motivating factors vignette 
B; 7) Discouraging factors vignette B. During the process of coding and analysis this 
initial tree was adapted and elaborated based on the data generated from the focus 
groups. Interview coding and analysis continued until no new codes, concepts, or pat-
terns emerged. We coded and analyzed the qualitative data using QSR International’s 
NVivo 11 qualitative data analysis software.
resulTs
study PoPuLation
A total of 16 parents participated in in two focus groups. 9 participants in one focus 
group and 7 participants in the other. Age, gender, educational level, and number and 
age of their children were very diverse in the population. Some parents had experience 
as a research participant in clinical research themselves, but the majority had no expe-
rience with clinical research, neither personally nor with one of their children. Some 
parents had a chronically ill child (e.g. eczema, asthma) and some had experience with 
hospitalization of their children. Table 4 presents an overview of participant character-
istics.
Table 4: Participant characteristics
characteristic no. of participants
gender Father 9
Mother 7
educational level Secondary school 2
Intermediate vocational education 5
Higher vocational education 7
University 2
median age [range] Median age [range] 39.5 [32-53] years of age
number of children Median number [range] 2 [1-5] children
age of children Median age [range] 7 [0-18] years of age
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Table 4: Participant characteristics (continued)
characteristic no. of participants
approached for clinical research Yes 5
No 11
clinical research participant themselves Yes 5
No 11
child approached for clinical research Yes 3
No 13
child clinical research participant Yes 3
No 13
child hospitalized Yes 6
No 10
child with chronic illness Yes 3
No 13
intuitions: research in generaL
Parents’ intuitions about research with humans included reference to the importance of 
doing research:
“I think it’s really important that it happens, because you have to know the 
effect on people; you can keep testing on mice for a very long time, but in the 
end you can only know when you actually check things, check on people.”
“So yes, it never stops, healthcare, there will always have to be research.”
Feelings of distrust, associations with animal research and ‘guinea pigs’ and financial 
incentives for participation were also common first reactions:
“No, personally I think it does, a lot happens that we do not know of.”
“Do you know how far reaching the power of the pharmaceutical industry is? 
They buy entire countries; they cause the collapse of economies.”
“I see it right in front of me, these mice and those swollen heads, that’s a 
picture I get right in front of me, so I would be careful”
“At first I think of studies that you can earn a lot of money with, then I think: 
the more money, the more danger.”
Parents’ perspectives on pediatric clinical research: A focus group study with laypeople 113
Parents in the focus groups associated ‘research’ with a broad range of activities. They 
started talking not only about clinical drug trials, but also about clinical testing (e.g. an 
MRI scan, CT scan), new operating techniques, screening programs, IQ tests, behavioral 
tests and vaccinations: 
“yes, or cancer research, that can also be preventive, like the research on cervi-
cal cancer, that is also in your own interest to see if you have something.”
“A few years ago vaccination was announced, that everyone had to vaccinate 
against ...”
intuitions: research with chiLdren
Their first reactions concerning research specifically with children revealed that their 
knowledge about this topic was limited and that it was hard for them to grasp the trajec-
tory of clinical research and drug development. As some parents stated: 
“... I would not know how a company, a hospital or an agency, a medicine 
magnate will approach my daughters like ‘you want to participate in re-
search?’. Never heard about it too.”
“I think that no medication is given to children ... I think it will be tested on 
adults and if it is in an advanced stage ... I do not think that drugs will be 
tested on children just like that.”
Another parent grasped and expressed the dilemma of drug development and off-label 
drug use in children very well: 
“yes, I think it’s ambivalent, because on the one hand, if my child gets a medi-
cine that has never been tested, I think that’s bad. But on the other hand, I also 
find it very bad when my child ... that he will test that medicine.”
The consensus in the group was that parents are more protective of their child than of 
themselves. As one father explained: 
“That was also the reason why I just said: the children ... I would more easily 
participate myself than allow them to participate in research. I myself am 
responsible for my own situation; I can judge for myself what is happening. 
And I do not want to place that responsibility with my daughter who cannot 
defend herself. I think that’s really a point. Imagine that I make a wrong deci-
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sion and I destroy her life, then I am responsible for it. And I just do not want 
that on my conscience. So that would be an important reason for me to say 
no, I’m not going to do that fuss with my daughter, only when she wants to 
herself, then she is allowed to decide herself, but I will not start it.”
Parents were reluctant to let their child participate in clinical research, and expressed a 
lack of trust, and fear of risk and burden: 
“My first impression is that my children are not allowed to participate in medical 
research. It may be important, but I do not want to expose my children to it. But 
my first thought goes to a kind of drug research. But perhaps that can be broader, 
if it is only weighing and measuring, then I may judge differently. But the first 
impression is: No.”
“No, but I think with people it [red: research] is important, and in children as well, 
but to a certain level because children themselves cannot say what they want or 
not, because they cannot see and judge what the consequences are.”
“Look, if they take a little blood, I think it’s fine… if you are fully pumped with a 
new drug: yeah, that’s different.”
During the group discussion parents mentioned a variety of reasons for letting their 
child participate in clinical research. Expected benefit from participation for their child 
was mentioned by almost all parents as the main reason for having their child participate 
in clinical research. A lot of the discussion in the group about reasons for participation 
circled around the concepts of familiarity, knowing the disease first hand, and proximity, 
having a relative/neighbor with a disease. Both concepts played an important role in 
their future decisions:
“I can imagine if my niece gets seriously ill, that I would also like to let my 
children participate in a study.”
“yes, but also in general, you are a little bit more supportive of the research 
when there is something of a link with a child you know.”
vignette discussion
The vignette discussion centered around the questions: ‘Would you let your child 
participate?’ and ‘What factors would influence your decision?’. Table 5 and 6 present 
an overview of the mentioned motivating and discouraging factors for both vignettes, 
Parents’ perspectives on pediatric clinical research: A focus group study with laypeople 115
illustrated with quotes from the group discussion. In response to both vignettes the 
parents most frequently mentioned factors related to expected benefit and burden for 
their child. Their notion of benefit did not only entail direct health benefit (e.g. finding 
a cure), but also entailed getting a check-up for their child. In the context of vignette B 
parents in both focus groups referred to a periodic MOT-test for cars. Interestingly, the 
mentioning of a periodic check-up as an important reason for participating created a 
discussion in both focus groups about the return of individual research results. Most 
parents assumed that they would learn the results of all the tests during participation, 
while this was not mentioned in the vignette.
“... so only if you get results right away, otherwise I would never do it.”
The discussion also revealed factors that parents mentioned would be relevant for their 
decision but were unknown in the proposed vignettes. These included for vignette A: 
age of their child (referring to their ability to execute research procedures and to their 
decisional capacity), health status of their child and alternative treatment options, and 
for vignette B: consent of their child, financial compensation, logistical aspects, and 
privacy-guarantees. 
Table 5: Would you let your child participate and what factors would influence your decision? (Responses to 
vignettes: Motivating factors)
motivating factor Quote vignette a: clinical drug trial Quote vignette B: observational cohort 
study
altruism
Helping other children “I would like to participate because you can 
help other children, I wrote that down.”
“But when I look at my son again, he would 
really like to do this, so he can help other 
people. That is his responsibility.”
Helping science “yes, to actually mean something to science 
that is good.”
“Well, if science benefits from this, then that is 
always a reason.”
Benefit for child
Treatment / last resort “Then you come back to the point where we 
just were. Look if you hear that, I think you 
would seize everything to save your child.”
[not mentioned]
Checkup of child “I like that there is, for example, a periodic 
check-up, I think that’s a nice thing. And I like it 
that it is a factual check.”
“At first what [participant x] said, like a regular 
MOT test actually , that you can see closely how 
the development of your child goes ... Then you 
know right away if they are completely healthy, 
you have had everything.”
Educational / interesting 
for child
[not mentioned] “…my daughter would really like this…she 
would find that very interesting, I’m sure.”
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Table 5: Would you let your child participate and what factors would influence your decision? (Responses to 
vignettes: Motivating factors) (continued)
motivating factor Quote vignette a: clinical drug trial Quote vignette B: observational cohort 
study
minimal risks
Is safe (tested on animals/
adults
“Because it is a test and it is safe on adults and 
cancer is of course bad enough, so I almost 
think how bad can it be.”
[not mentioned]
No adverse events Not mentioned “And it does not affect [his] health. While with 
those other pills or whatever, medical research, 
or medication, then of course that could be 
the case.”
minimal burden
Burden is low [not mentioned] “Okay, they have to spend a few hours once 
a year. But yeah they are just a little bothered 
by it.”
Short study period “Well I found eight weeks a short period of 
time... Would it be you have to do something 
for six months, I would find that too much.”
[not mentioned]
curiosity
Self-interest of parents [not mentioned] “I like to participate because I find it interesting 
to follow the developments in this way.”
Table 6: Would you let your child participate and what factors would influence your decision? (Responses to 
vignettes: Discouraging factors)
Discouraging factor Quote vignette a: clinical drug trial Quote vignette B: observational cohort 
study
Burden
Burden for child too high “Swallowing by mouth is difficult for my child 
…I think a hospital admission is a bit much.”
“x-rays of the teeth, well we go to the dentist 
twice a year, that could just as easily be 
requested from the dentist. And blood sample 
and an ultrasound and that MRI scan... yes 
that’s a bit scary, that makes me think about 
it. If that is not the case. If, for example, it 
had been just one of those tests, only a blood 
sample, I would say well okay, that is still 
limited. But all those tests together I find it 
drastic.”
Too many restrictions “Well anyway, those drinks they aren’t allowed. 
And I miss the explanation why carbonated 
drinks aren’t allowed to be drunk, I would 
absolutely want to know.”
[not mentioned]
Study period too long [not mentioned] “I think it’s too much to state it like that. And I 
just think it takes a long time. It’s five years, the 
research lasts four hours.”
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Table 6: Would you let your child participate and what factors would influence your decision? (Responses to 
vignettes: Discouraging factors) (continued)
Discouraging factor Quote vignette a: clinical drug trial Quote vignette B: observational cohort 
study
risks
Fear of risks / adverse 
events
“I drop out with the word cancer, the fact that 
it’s drugs against cancer. For me, that means a 
heavy drug. And I do not want a heavy drug in 
my children... Or if there is too much risk, I think 
that’s more precise.”
“Those x-rays, they are equal to so much 
radiation. And if your child is healthy ... you just 
said it yourself: if you have a child that maybe is 
not healthy then you might do it, but now: No.”
Consequences unknown “It does not say anything about the 
consequences.”
[not mentioned]
Not enough check ups “In this case, I found that there were few control 
moments, because quite a lot can happen in 
four weeks. And especially when it comes to 
oral medication, I think I would feel safer if the 
child would drop by every week to see how 





“And last, answering a questionnaire with the 
child… I have my thoughts about that: I think 
what will that be?”
“What I had written as negative: The purpose of 
research. It only concerns research on disease 
causes and behavioral problems. But the link 
between behavioral problems and an MRI scan, 
I do not see that. …We live in a very prosperous 
country, and these diseases in children are 
they very common? Is that why you want to 
do research? Isn’t there a goal behind it, shall 
I say?”
Discussion 
Parents confLate cLinicaL research and cLinicaL care 
Our focus group study revealed that parents have various interpretations of the term 
‘research’ and not everyone understands the difference between research and care. 
This difference however does matter to them and influences their decision. Responsible 
research professionals should focus on this difference during the recruitment and in-
formed consent process for pediatric clinical research.
In medical practice the word ‘research’ is used in very different contexts. Especially in 
Dutch, the native language of the participants in the focus groups, ‘research’ (in Dutch: 
‘onderzoek’) has multiple homonyms. Dutch people do not only use this word to address 
clinical research, but also use the word for specific clinical tests (e.g. MRI/CT/blood tests) 
and for screening purposes. Therefore, it is not surprising that parents have very diverse 
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associations with the term ’research’ and that they conflate these different contexts. This 
conflation can create a therapeutic misconception.15 16 This becomes problematic when 
unjustified therapeutic optimism influences parents’ decisions to have their child partici-
pate in clinical research. A recent study by Janssen and colleagues showed that decliners of 
study participation had significantly fewer therapeutic misconceptions than consenters.17 
Discussion in our focus groups showed that the difference between research and care, 
when understood correctly, does matter to parents and that they make different decisions 
concerning research and clinical care. Although some authors argue we do not have to 
focus on the fundamental difference between research and care or even try to avoid the 
therapeutic misconception,18 our findings emphasize the importance of disentangling 
research and clinical care to potential research participants and their parents. Therefore, 
it is crucial that health care and research professionals explain this difference to parents 
(and their children) during the recruitment and informed consent process, and start this 
discussion with explaining what ‘research’ actually means and avoid the pitfalls of jargon.
Parents do not grasP the trajectory of Pediatric drug deveLoPment
The discussion in the focus groups revealed that most parents do not grasp the trajec-
tory of pediatric drug development. For parents to be able to make an informed decision 
about their child’s participation in clinical research, they must understand to what they 
consent or dissent. Our study indicates there is a knowledge gap between starting level 
of the information in informed consent documents and the basic knowledge of parents 
about what clinical research and drug development entails. 
Context is crucial; for detailed information on a specific trial (e.g. goal, burden, risk) to 
stick, knowledge about the whole research enterprise is essential. However, empirical 
research in this field of comprehension mainly been focused on the understanding of 
specific elements of informed consent documents and improvement of these docu-
ments.19 20 This could explain why single interventions to improve informed consent 
documents are not consistently effective.21 22 Initiatives to improve parents’ understand-
ing should therefore not only focus on interventions for the informed consent docu-
ments for specific trials but also on interventions to improve this knowledge gap. For 
example, before giving information about a specific trial, give short, but comprehensible 
information about clinical research and drug development in general. 
Parents Protectiveness matches current research guideLines
Parents in our focus group were more protective of their children than of themselves, and 
stated it is better to test drugs on adults than on children. They value their child’s opinion 
in the decision to participate. Current guidelines concerning informed consent/assent and 
burden and risk thresholds in pediatric research are in line with these parental intuitions. 
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In important legal and ethical guidelines (e.g. CIOMS guideline, Declaration of Helsinki, 
EU Clinical Trials Regulation) additional measures are taken for the protection of mi-
nors.23-25 For example, all three documents: 1) State that research with children cannot 
be carried out if it can be carried out with less vulnerable subjects. This matches par-
ents’ statements that it is better to test drugs on adults than on children; 2) Set limits 
to acceptable risk for pediatric research without a direct benefit, matching the greater 
protectiveness that parents have for their children than for themselves; and 3) Value 
the opinion of the child by requiring assent of the child for participation, matching the 
importance parents attach to their child’s choice.23-25
benefit for their chiLd is the most imPortant factor in their decision 
Discussion in the focus groups revealed benefit for their child to be the main motiva-
tor of parents to endorse participation of their child in clinical research. Interestingly, 
parents use a much broader definition of benefit than direct health benefit, e.g. being 
regularly checked up also constitutes a benefit for them. However this can only be a 
benefit when they are informed about the results of the check-up, so a proper return 
of results policy is necessary in these cases. The discussion in our focus groups showed 
that people expect the individual test results to be returned back to them and see no 
return of result as a good result (my child is healthy). Such a return of results policy is 
not always at hand. To the contrary, in practice, tests with a research objective are done 
and evaluated most of the time without a clinical look, and are sometimes not even 
evaluated during the trial but afterwards.
As expected benefit plays an important factor in the decision-making of parents to par-
ticipate in research, we should ask what counts as benefit. Research can only be accept-
able when the risk-benefit ratio is positive. A lot has been written and discussed about 
the risk and burden in that equation for pediatric research,26 27 but much less research 
focused on the other side of that equation, benefit.28 The parents in this focus group 
study, next to a direct health benefit for their child, also considered being checked up 
regularly and, for example, an educational benefit for their child, as benefits for their 
children. Staphorst and colleagues found similar results concerning benefit in their in-
terview study with children.29 These children also had a much broader notion of benefit 
than direct health benefit. Staphorst and colleagues argued, based on these results, 
that next to direct health benefit other specific forms of benefit (learning, altruism and 
fun) could also be justifiably qualified benefits of research participation. But they also 
argued that ‘getting extra attention from healthcare staff’ isn’t one of those justifiable 
benefits that could be used in the risk-benefit analysis.29 30 We completely agree. Patients 
(including parents and children) should not be dependent on research to get the atten-
tion they wish for in clinical practice.1 It can be considered an undue inducement for 
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research participation. That parents do state it as an important reason for participation 
is therefore problematic and deserves attention. 
study Limitations
This study has some limitations that deserve mentioning. Unfortunately, the study 
consisted of just 2 focus groups with a total of 16 participants. Ideally, more participants 
should have been included to make the results more robust. On the other hand, data 
saturation was reached within both focus groups. The focus group sample was diverse 
in many aspects (e.g. age, gender, educational level) and people with different ethnic 
backgrounds participated, but ethnicity of the participants was not registered. There-
fore, this aspect could not be taken into consideration, while it can be a relevant aspect 
in empirical research into research participation.31
conclusion
Despite its limitations this focus group study makes two important contributions to the 
tailoring of pediatric research to the perspective of parents. First, it makes clear that 
parents have various interpretations of the term ‘research’ and do not always understand 
the difference between research and care. But this difference does matter to them and 
does influence their decision. During recruitment and informed consent for pediatric 
clinical research this difference should therefore be explicitly discussed. Secondly, the 
main motivator for parents to endorse participation of their child in research is expected 
benefit for their child. Their definition of benefit however is much broader than direct 
health benefit as commonly discussed in research ethics committees. For parents being 
regularly checked up is a benefit as well. This implies research professionals need to 
present a proper return of results policy. 
On the whole, research professionals should be aware of the knowledge gap of parents 
concerning drug development and clinical research, the pitfalls of jargon, and unin-
tended false expectations.
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aBsTracT
Professionals should not be reluctant to ask young people to participate in clinical trials; 
overly doing so is known in the literature as gatekeeping (not approaching all eligible 
research participants). 
Our research into participation in pediatric clinical trials identified reasons why profes-
sionals engage in gatekeeping; these are e.g. protection of child and prejudice beliefs 
about the choice the child will make. 
Although gatekeeping might be understandable, we argue it is not desirable because 
of the negative implications this practice entails (e.g. denies children a choice, might 
introduce inclusion bias and introduces unfair distribution of risk and benefit). 
We call upon pediatric health care and research professionals to be aware of the many 
negative implications of their reluctance and in principle to refrain from the problematic 
practice of gatekeeping.
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PreamBle
The article, on which this chapter was based, was an open peer commentary on a target 
article by Luchtenberg and colleagues in The American Journal of Bioethics.1 Although 
this chapter is a commentary it can be read and understood without reading that spe-
cific target article. 
Luchtenberg and colleagues interviewed 25 young people aged 10 to 23 years of age 
who were invited to take part in clinical trials. They had a similar goal as we had for our 
interview study: to understand the experiences and motivations of people participating 
in pediatric clinical research. There is a difference also: we mainly interviewed parents, 
whereas they interviewed adolescents. They found that personal benefit and helping 
others were the main motivators for the adolescents, and that these factors were more 
complicated than they expected. Similar to our results, discussed in chapter 5, they also 
found the altruistic motives of participants to be reciprocity-based. 
Another important similar finding they showed was the fact that the interviewed 
adolescents wanted to be asked to participate in clinical research and they concluded 
their article with the statement that research professionals should not be reluctant to 
ask young people to participate in clinical trials. We agree with that statement. In this 
commentary, we elucidate our views about gatekeeping by professionals in pediatric 
clinical research.
inTroDucTion
Luchtenberg and colleagues bring their interesting article to a close with the concluding 
statement that professionals should not be reluctant to ask young people to participate 
in clinical trials. They substantiated this recommendation with results from their inter-
view study with young people about their experiences with and motivations for partici-
pation in clinical trials. The young people they interviewed welcomed the opportunity 
to contribute to medical research and wanted to learn from it. Unfortunately though, 
the interviewed young people also mentioned that they had wanted to take part in 
clinical trials before, but had not always been offered a chance to contribute.1
We recognize this reluctance of professionals to ask children, and consequently their 
parents, to participate in clinical trials. Being overly reluctant is a practice known as 
gatekeeping. Definitions of gatekeeping in a research context differ in the literature. For 
instance, Hudson and colleagues define gatekeeping as the process by which people’s 
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capacity to be invited into a research project, or to make an informed decision regarding 
research participation, is inhibited by others.2 The definition of Sharkey and colleagues 
focuses on the health care professional who prevents the researchers access to eligible 
patients for research recruitment.3 These definitions have in common that eligible sub-
jects are not approached to participate in research. Therefore, we define gatekeeping by 
professionals in a research context as follows: having implicit in- and exclusion criteria 
that lead to not approaching all eligible research participants. This gatekeeping by indi-
vidual professionals adds a third layer to the assessment of acceptability of pediatric 
research (the protective measures in legislation concerning research with children being 
the first layer and evaluation of the protocol by a research ethics committee (REC) the 
second).
During our own empirical research concerning participation of minors (and their 
parents) in clinical research this practice of gatekeeping kept cropping up. We have 
encountered it ourselves: we were dependent on other professionals to approach their 
patients (children and their parents) for participation in our interview study, and noticed 
eligible children and their parents were selectively approached. The issue also rose in 
discussions, focus groups and personal talks we had with other researchers, physicians 
and (research) nurses about participation of children in clinical research. 
In this commentary we want to share some of the reasons these professionals men-
tioned to justify their gatekeeping behavior. These reasons show why gatekeeping can 
be an understandable practice. Moreover, we want to point out that there are negative 
implications and argue that, however understandable, it is not a desirable practice. 
reasons for gaTeKeePing
So, why are professionals reluctant to approach children and their parents for participa-
tion in clinical trials? In all probability the core of their justification lies in the fact that 
children are a vulnerable population susceptible to harm and exploitation in research 
and need to be protected. For this reason precisely, ethical and legal documents con-
cerning research with humans, such as the Declaration of Helsinki, set specific protective 
measures for children in research.4 However individual professionals might feel they 
need to be more protective than the legislation and/or REC prescribe. 
The explicit intention to protect the child from burden and risk associated with trial 
participation is a reason we were frequently given by professionals for not approaching 
eligible children (and their parents). This reluctance to burden patients can result in not 
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approaching the sickest children, and lead to inclusion of a non-representative study 
population.
Furthermore, sometimes professionals think the informed consent procedure itself is 
too burdensome for certain eligible children and their parents. They decide not to ap-
proach children and their parents to protect them from the burden of being asked. 
A third reason we encountered is that professionals sometimes refrain from approach-
ing certain eligible children and their parents in order to protect the researcher. For 
example: a clinician does not approach an eligible child that has shown non-compliance 
with a prescribed drug before, in order to protect the researcher from the possibility of 
drop-out.
Prejudiced beliefs of professionals about the choice children and their parents will 
make regarding trial participation can be considered yet another reason for gatekeep-
ing behavior. This may happen, for example, if in the past parents did not consent to 
participation of their child in a similar study, and the research nurse therefore assumes 
they do not want to participate in this new study and refrains from approaching them. 
It can also be the case that the health care professional responsible for recruitment 
(e.g. the treating physician) does not support the rationale or methods of the study and 
therefore decides not to approach his/her patients eligible for the study.
Finally, practical concerns can influence reluctance of professionals to approach eligible 
research subjects. Especially when the professionals responsible for recruitment are not 
involved in the research project themselves (e.g. lack of time or resources to approach 
eligible children).
negaTive imPlicaTions of gaTeKeePing
Although gatekeeping is understandable in pediatric research, it is not desirable be-
cause of the negative implications this practice entails. Luchtenberg and colleagues 
already addressed an important one: it denies children the opportunity to contribute to 
medical research.1 However, gatekeeping has many more negative implications. 
First of all, gatekeeping by professionals involved in pediatric research denies par-
ents (and children who have the capacity to co-consent or assent) a choice. Thereby, 
gatekeeping in recruitment for research violates the principle of respect for persons.3 
130 Chapter 7
In pediatric clinical trials, respect for persons is operationalized by the informed proxy 
consent of parents for the participation of their child and when possible the co-consent 
or assent of the child itself.4 In general children’s right to express their views is arranged 
in the United Nations Convention on the Rights of the Child.5 It is therefore problematic 
that the young people interviewed in the target article stated they had not been of-
fered the chance to participate. Essentially, with gatekeeping, it is the professional who 
makes the choice (one of non-participation), not the child and his/her parents, which is 
a paternalistic practice.
Second, by not approaching eligible children and their parents with an offer for par-
ticipation in the trial, professionals could deny children a possible beneficial treatment. 
This argument is not applicable to so called non-therapeutic research (e.g. observational 
studies and phase 1-drug trials). However professionals need to be aware that there are 
studies from which children may directly benefit (e.g. randomization in intervention arm 
of phase III drug trial); and by withholding the opportunity to participate from children 
and their parents, they might withhold a beneficial intervention.
Third, gatekeeping practices of professionals decrease inclusion rates in trials. This can 
become problematic when this decrease means that the needed sample size is not 
achieved. This endangers the scientific and social value of the study. A large international 
review study showed that one third of randomized controlled trials in the Pediatric In-
tensive Care Unit (PICU) is terminated before the needed sample size is achieved, often 
due to recruitment problems.6 We suggested in a previous article that these recruitment 
problems in the PICU could be caused by gatekeeping of professionals.7
Fourth, gatekeeping does not only decrease inclusion, it can also cause selective inclusion. 
The selective approaching of eligible children introduces bias. This selective approach 
can create a non-representative study population, which endangers the generalizability 
of the results. A recent study by Crocker et al. showed that this threat is not hypothetical 
at all. They found evidence of gatekeeping behavior (they call it selective invitation prac-
tices) that can bias research findings in pediatric palliative care research.8 The effects of 
gatekeeping bias on the representativeness of the study population are more difficult to 
assess than other biases. For instance: non-response bias can be assessed by comparing 
responders with non-responders. But with bias due to gatekeeping this is generally not 
possible as the eligible patients who are not approached, are not known. 
Finally, gatekeeping by professionals involved in research could create an unfair distri-
bution of burden, risk and benefit among children and thereby violates the principle of 
justice.3
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gaTeKeePing is an unDesiraBle PracTice
Although gatekeeping might be understandable in the context of pediatric clinical re-
search, there are also negative implications. Gatekeeping should therefore be avoided. 
Luchtenberg and colleagues already concluded their target article with the statement 
that professionals should not be reluctant in approaching young people for participation 
in research.1 They base their recommendation on their finding that children welcome 
the opportunity to contribute to medical research. 
We presented some additional arguments to support their recommendation. To con-
trol gatekeeping practices in pediatric clinical research, it is of crucial importance that 
professionals involved in the recruitment process are aware of their behavior and the 
negative implications of their gatekeeping.
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aBsTracT
Trust plays a fundamental role in patients’ willingness to participate in research. 
Some authors have suggested that empirical findings related to trust challenge the cur-
rent model of research ethics, ‘because that model is primarily focused on supporting 
individual autonomy.’ We disagree. To the contrary, we argue that patients’ trust confirms 
the rationale and necessity for the current model of research ethics. We argue the cur-
rent model consists of more than informed consent, as the consent can only be asked for 
after a review process by a research ethics committee. 
We substantiate this statement with results from interviews we did with parents and 
children about their willingness to participate in research. 
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PreamBle
The article on which this chapter was based was an open peer commentary on a target 
article by Kraft and colleagues in The American Journal of Bioethics.1 Although this chap-
ter is a commentary it can be read and understood without reading the target article. 
Kraft and colleagues presented results from their focus group study about biobank 
research with ethnically diverse people. They focused specifically on how to build 
long-term trusting relationships with participants. They discussed four points of con-
sideration: 1) addressing the history and the role of trust; 2) tackling concerns about 
potential group harm; 3) addressing cultural values and communication barriers; and 
4) integrating patient values and expectations in oversight and governance structures.
In this commentary we corroborated their empirical findings on trust, as we found 
similar results in our interview study. However, we drew different conclusions from these 
results. They state that their findings concerning patients’ trust challenge the current 
model of research ethics; we think it rather underlines its importance.
inTroDucTion
Kraft and colleagues make a convincing plea for the importance of trustworthiness and 
trusting relationships between patient-participants and research professionals in medi-
cal research in their interesting article.1 We do however not agree with the authors that 
their findings concerning patients’ trust challenge the current model of research ethics, 
‘because that model is primarily focused on supporting individual autonomy’, to the 
contrary, we think it underbuilds the current research system. 
Although Kraft and colleagues specifically researched trust in biobank research among 
ethnically and culturally diverse groups, we also found trust to be of major importance 
in an average Dutch population who were asked for participation in a clinical trial. 
We interviewed parents and their children about their willingness to participate in 
clinical research, after observing informed consent conversations between them and 
research professionals. We wanted to know: what motivated them to participate, and 
what influenced their decision? Trust was one of the main issues that was put forward 
by them as an influencing factor. In this commentary we want to share our results and 
corroborate the results presented by Kraft and colleagues. But we also want to point out 
that we draw partially different conclusions from these results. 
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TyPes of TrusT influencing ParTiciPaTion
In our own empirical research we asked over 30 parents and children what motivated 
them to consent or dissent to the clinical trial proposed to them. Together with antici-
pated burden and altruistic reasons, trust was mentioned by them as one of the most 
important factors influencing their decision and willingness to participate. We therefore 
completely agree with Kraft and colleagues that trusting relationships are very impor-
tant in medical research.
Kraft and colleagues identified the trustworthiness of physicians, researchers, health 
care system, government and corporate institutions as important condition for ethni-
cally and culturally diverse participants’ willingness to participate in precision medicine 
research. Even though our own research was in a very different population and setting 
(Dutch parents and children asked for participation in a clinical trial), we identified iden-
tical types of personal trust and institutional trustworthiness influencing their decision. 
PersonaL trust
As the authors address, we also found a type of personal trust, directly linked to the 
researcher. For many (chronically ill) patients, a personal relation with the researcher 
influences their decision to participate (table 1). 
Table 1: Example personal trust
Participant Quote
mother (age 52) I just trusted his judgment. I asked him: ‘what would you do in my place?’ He then answered ‘start 
immediately’. I just completely trusted that answer.
For a potential participant to actually trust the researcher, it means that they believe 
that the researcher has designed and will conduct the research in their best interest. 
In a way they ‘surrender’ their health to the research professional.2 This sense of trust 
is closely linked to the doctor-patient relationship, and therefore not entirely without 
moral problems. Patient-participants do not always distinguish the separate roles of 
their treating physician and research professionals. Their treating physician should act 
in the best interest of the patient, but for research professionals other interests are also 
at stake. Although a research professional will always need to minimize burden and risk 
and avoid harm to the participants, that does not mean that participation is always in 
the best interest of the patient. This physician- and research-role can conflate in practice 
and then potential participants’ trust is not always based on correct assumptions. It is 
the responsibility of the researcher to make this distinction clear, so that the personal 
trust participants have in them is legitimate.
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institutionaL trust
Second, our potential participants’ willingness was also influenced by institutional 
trustworthiness. For example, for some respondents, the fact that a study was done with 
international collaboration or an academic hospital, enhanced their trust (table 2).
Table 2: Example institutional trust
Participant Quote
father (age 48) That the study was done internationally played a big role, so yes, then you already have faith in it. 
If it were a study of just the [x]-hospital, their own in-hospital research, that would be a different 
picture.
For this type of trust it is not so much the personality of the individual researcher that in-
fluences the decision of the potential participant, but the characteristics of the institute 
in itself (e.g. international collaboration is better, academic hospital is better).
trust in research in generaL
We also found that potential participants’ trust can be linked to a trust in research in 
general. We quite frequently encountered a positive stance towards research and an 
optimism regarding the possible benefits: ‘what is being investigated is new, and what 
is new, is better’ (table 3).
Table 3: Example trust in research in general
Participant Quote
Boy (age 16) They’re, of course, not going to do something they think does nothing. A lot of people believe that 
this is better
We consider this form of therapeutic optimism (or maybe even therapeutic misconcep-
tion, since research should be based on clinical equipoise), as an expression of trust in 
research. Potential participants can believe that research means progress and conclude 
from that, that new/experimental is always better. This type of therapeutic optimism 
and the link to trust is also identified and emphasized by other authors.3 It is crucial that 
research professionals are realistic about the rationale of the study and its anticipated 
benefits and do not to take advantage of this type of trust.
trust in overarching system
The last type of trust we identified, also in line with the authors’ results, is trust in the 
overarching system. Our respondents told us that they expect that immoral and unsafe 
research would not be allowed and offered to them, and that any research that is al-
lowed in an academic hospitals such as ours, must therefore be safe (table 4).
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Table 4: Example trust in overarching system
Participant Quote
father (age 48) Of course, there are some risks attached, but even so, once they’re testing on humans a lot of steps 
have been made towards this point, so it’ll be safe
You could say that by this type of trust they outsource their concerns about risks. They 
assume the research that is offered to them is adequate and safe, otherwise it wouldn’t 
be offered to them; and they expect that processes are in place that protect them.4 This 
trust in an overarching system, a type of institutional trust as Kraft and colleagues call 
it, shows the importance of the ethical review system and the ‘filtering’ role of research 
ethics committees (RECs). 
filTering role of The research eThics commiTTee
As presented above, we found in our own research results parallel to those by Kraft and 
colleagues. Our conclusions differ, however. They state that their results challenge the 
current model of research ethics, ‘because the current model of research ethics…focuses 
primarily on supporting individual autonomy’.1 We conclude the opposite: The trust that 
patient-participants have in the overarching system actually confirms the rationale and 
necessity for the current model of research ethics and the importance of RECs. 
Consensus exists about the primary role of RECs to protect participants, whilst not 
standing in the way of advancing science. However, according to some, there is a threat 
of RECs being overprotective and acting as a gatekeeper to filter research.5-7 Several 
authors have argued that this ‘filtering’ role gives RECs the inappropriate capacity to 
prevent research from being conducted, since participants, as long as they are compe-
tent, are best placed to decide on what are appropriate risks when deciding whether to 
take part in research.8 We argue, based on the results presented above, that this filtering 
is a legitimate and even fundamental task of a REC. 
In order to deserve the trust that patients have in the system (allowing only morally and 
medically acceptable research), the ‘filtering’ role of a REC is crucial. A REC needs to make 
a decision whether a specific research protocol is scientifically and ethically adequate 
before it can be proposed to potential participants. This filtering task is moreover laid 
down in important ethical and legal rules and legislation, like the Common Rule and the 
Declaration of Helsinki.9 10 Our research shows potential participants assume that this 
filtering has taken place; they rely on the filtering by the REC. In this way they outsource 
a part of their decision-making process to the REC. 
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conclusion
We therefore do not agree with the authors that autonomy seems to be the only impor-
tant element in research ethics, nor that it should be. Of course, respecting autonomy, by 
making sure every potential participant has given informed consent, is a cornerstone for 
research ethics, but it is not the whole building. Kraft and colleagues’ results, combined 
with the results we just presented, concerning patients’ trust emphasize this. 
Informed consent can only be given after a REC has evaluated the protocol and executed 
their legitimate filtering role. The large influence that patients’ trust has on the decision 
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This thesis aims to contribute to the optimal inclusion of children in pediatric clini-
cal research, in such a way that we can further clinical research to advance scientific 
knowledge and develop much-needed treatment options for children while protecting 
children against harms from research.
In this chapter, I combine the main findings of the preceding chapters into a normative 
framework to assist research professionals when including children in clinical research. 
This framework aims to tailor the process of recruitment and informed consent to the 
perspective and the needs of children and their parents, who have the key role in deci-
sions regarding research participation. I will conclude this chapter with some develop-
ments in clinical research that necessitate new research efforts, policy changes and new 
ethical guidance.
Before formulating this framework, I need to explain the steps in the research enterprise 
before children can participate in research. 
gaTes in The research enTerPrise
Before a research proposal reaches potential participants (and their parents), other ethi-
cal decisions related to the research have been made on which the potential research 
participants and their parents have no influence. Only then potential participants and 
their parents make a decision about participation. I call those decisions, ‘gates’ in the 
research enterprise. These decisions concern 1) protective measures in legislation; 2) 
research design; 3) medical-ethical review; 4) recruitment by the professional; and 5) 
informed consent by the potential research participant. Figure 1 shows an illustrative 
overview of these gates.
gate 1: Protective measures in LegisLation
Protective measures start with the fact that society has laid down specific requirements 
for clinical research, especially for research involving children, in law and legislation. 
The rationale behind these requirements is that there is a consensus about the fact that 
not all research with children is ethically acceptable. These requirements are related to, 
e.g., informed consent/assent, dissent and refusal during research and risk and burden 
thresholds. Related to these risk and burden thresholds, most countries, including the 
Netherlands, have restrictions on pediatric clinical research without a prospect of direct 
benefit.
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As discussed in chapter 2, restrictions on research without a prospect of direct benefit 
vary between legal frameworks. Chapter 2 compares these specific requirements for 
pediatric clinical research in the European Clinical Trials Directive and the European 
Convention for the Protection of Human Rights and Dignity of the Human Being with 
Regard to the Application of Biology and Medicine (further Oviedo Convention). In the 
addendum of chapter 2 I have added information regarding the upcoming European 
Clinical Trials Regulation that will replace the Directive. The common core of the upcom-
ing EU Clinical Trials Regulation, the Oviedo Convention and also the Dutch WMO, is that 
certain limits are set to pediatric clinical research without a direct benefit to the child 
participating.1-3 Some pediatric clinical research is not allowed at all or is required to 
adhere to specific risk and burden thresholds. This implies that even if researchers want 
to design these types of clinical research and even if children and their parents want to 
participate, legislation prohibits these studies. These studies are simply not allowed and 
may not be offered to potential participants. There is, of course, an ongoing discussion 
about these restrictive policies.4 5 Based on results presented in this thesis, there are ar-
guments either way. On the one hand, the empirical finding presented in chapter 5 that 
parents and children want to be asked for research participation even in difficult and 
stressful circumstances, could be used to argue that all research should be offered to 
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beforehand, making additional risk thresholds in legislation unnecessary. On the other 
hand, the empirical finding presented in chapter 5 that parents and children expect only 
safe-and-sound research to be offered to them, could emphasize the necessity of these 
additional risk thresholds in legislation. However, whether these specific restrictions 
concerning risk and burden thresholds are justified is beyond the scope of this thesis. I 
took these legal and ethical requirements as fixed points. Nonetheless, it is important to 
note that these legislated restrictions create a first gate before children and parents can 
say yes or no to research.
gate 2: research design
A ‘gate’ that is quite often forgotten as being an ethical gate and having influence on 
who participates in the research is the design of the research by the research profes-
sional. Decisions made by research professionals in the design of the research influence 
the participation of children and their parents. The selection of the study population 
prescribes whether a child can participate, while for example, the choice of research 
procedures influences whether a child wants to participate.
The selection of the population is made explicit by the inclusion and exclusion criteria in 
a research protocol. The criteria need to be specific enough so that the research will gen-
erate valid results and that people who should be protected against harm are excluded 
but wide enough so that results from the trial will be generalizable to clinical practice 
and that people who could benefit from participation gain the chance to be in the trial. 
It is important that research professionals find a balance between their inclusion and 
exclusion criteria so that the right children are included in the trial.
Furthermore, the study design chosen by research professionals also directly influ-
ences the willingness of children and parents to participate in research. As we showed 
in chapters 4 and 5, burden is one of the most important factors for children and their 
parents, influencing their decision to participate. Research professionals therefore need 
to look critically at the design of their study and assess from the start how they can 
minimize the burden on participants. In chapter 3, we made some concrete suggestions 
for lowering the burden of specific procedures in clinical drug research by using new 
techniques. Techniques such as low-volume drug assays, dried matrix spots and PK-PD 
modeling tools decrease the amount and intensity of blood sampling from children. 
The empirical research into the motivations of children and their parents described in 
chapters 4 and 5 also showed that the focus of children and their parents on burden is 
not exclusively related to the burden of specific research procedures for the child but 
entails much more. The logistical burden of participating in a trial for both children 
and parents greatly influences their decision. This includes time spent in the hospital 
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for trial purposes, missing school or workdays due to participation and missing out on 
leisure time. Additionally, when a child is asked to participate in research, it is easy to 
forget that parents are not only proxy consenters but also proxy participants. A child 
often depends on his/her parents to travel to the hospital, and parents regularly need 
to collect samples for research purposes. In designing pediatric clinical research, this 
type of logistical burden on both children and parents should be given attention and 
minimized. The design of the research is thus a second gate in the research enterprise 
before children and their parents are offered participation and can consent to research.
gate 3: medicaL-ethicaL review
After a specific research protocol is designed, in most cases (depending on local rules), 
it has to be reviewed by an independent research ethics committee (REC). An REC evalu-
ates the risk-benefit ratio of the protocol and assesses whether the proposed research is 
ethically acceptable. In other words, an REC needs to decide whether a specific research 
protocol is ethically acceptable before it can be proposed to potential participants. The 
rationale behind this role of RECs is that one cannot offer just any research to potential 
participants because they do not have the tools, experience and knowledge to assess 
the ethical quality of the research. Therefore, in practice, we need two approvals for 
clinical research: approval from the REC and from the potential participant. There is 
currently much criticism on the role of RECs, specifically, on their protective nature and 
their filtering role.6 7 Some authors such as Edwards and colleagues have argued that 
RECs are too paternalistic since participants are best positioned to decide themselves on 
what risks are appropriate when deciding whether to take part in research.8 In chapters 
5 and 8, we argued, on the contrary, that RECs and their filtering roles are legitimate and 
vital for an ethically acceptable research enterprise. Chapter 5 showed that children and 
their parents outsource their concerns about risk and that they expect research to be 
evaluated and reviewed beforehand so that only safe-and-sound studies be offered to 
them. The trust that potential participants have in research and in research professionals 
further emphasizes this filtering role of RECs (chapter 8).
In addition, the trust by parents and children is not served with a review process that only 
checks the compliance of a protocol to relevant regulations, as some authors propose 
to be the sole task of an REC.9 Such trust requires an REC that expertly and thoroughly 
assesses the ethical acceptability of protocols, including a judgment about the scientific 
justification, methodological approach and competency of the research team.10 The 
results in this thesis show that parents and children expect that only ethically acceptable 
research is offered to them. This finding shows the importance of an adequate review by 
an REC as an essential gate for research.
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gate 4: recruitment by the ProfessionaL
A research protocol that has been approved by an REC can start with the inclusion of 
participants. This inclusion is conducted by professionals. I call this process gate 4 in 
the research enterprise. Researchers decide (implicitly or explicitly) who they will ap-
proach for a specific research project. Explicit factors that play a role in this recruitment 
by the professional are the predefined in- and exclusion criteria in the research protocol. 
Children who do not fulfill these criteria will not be approached. As discussed in chapter 
7, these factors can also be implicit. Professionals may have implicit criteria for (not) ap-
proaching potential participants (e.g. wanting to protect children from risk and burden 
associated with trial participation or prejudiced beliefs about their choice). This can 
result in gatekeeping by professionals, meaning that they do not approach all eligible 
research participants. In that sense, this approach creates a fourth gate in the research 
enterprise before parents and children can make a decision about participation. I will 
elaborate on the desirability of this practice later in this chapter (Step 1: Who do you 
approach).
gate 5: informed consent by the PotentiaL ParticiPant
After the research plan has already passed four gates, the potential research participant 
has the choice to give informed consent (or not) for participation in that research study 
after a proper informed consent process.
gates: obstacLes or necessary safeguards?
The above-described gates are pivotal in the research enterprise. When we revisit the 
central dilemma of clinical research with children, people who are more on the protec-
tive side would see the presented gates as necessary and useful protective safeguards 
for children in clinical research. Others who lean more towards the other side might 
see the presented gates, especially gates 1 and 3 (protective measures in legislation 
and medical-ethical review), as unnecessary obstacles that impede improvement and 
innovation in medicine or as overprotective paternalistic hurdles that withhold parents 
and children from having a choice about participation.
frameWorK for recruiTmenT anD informeD consenT
This thesis is mainly focused on the last two gates: recruitment by the professional and 
informed consent by the potential participants or their parents. Therefore, the second 
part of this chapter will go more into detail regarding these two gates. How can we en-
sure that these last two gates serve their purpose in pediatric clinical research? How can 
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we incorporate views of children and their parents into the pediatric research enterprise 
and specifically into these last two gates of recruitment and informed consent? 
When we know why children and parents consent or dissent to research and what 
elements they use in their decision, we know what they attach importance to in their 
decision. From this data, we learn which information they want and need to make a valid 
informed decision. This information helps us to increase both the moral and instrumen-
tal value of informed consent in pediatric clinical research.
I propose a normative framework to support research professionals in the ethically sound 
inclusion of children in pediatric clinical research. This framework tailors the process of 
recruitment and informed consent to the perspectives and needs of children and their 
parents. Figure 2 shows an illustrative overview of this framework for recruitment and 
informed consent.
steP 1: who is asked
Gate 4 starts with the recruitment of potential research participants by the professional. Pro-
fessionals are in the lead for approaching parents and children for their research. However, 
who should they ask? To state it bluntly: Everyone who is eligible.
Unfortunately, as illustrated with some examples in chapter 7, this is not the case in 
practice. I learned during my empirical research that professionals do not always ap-
proach all eligible potential research participants: this selection is known as gatekeep-
ing. We argued that, although this practice is understandable, professionals should 
refrain from it since it is not ethically desirable. Arguments that undergird our point of 
view are both ethical and methodological and relate to respect for persons, individual 
beneficence, scientific and social value, introduction of bias and justice. An important 
empirical finding supporting this concept can be found in the fact that children and 
their parents actually want to be asked. The results from the interview study presented 
in chapter 5 show that children and their parents want to be given the chance to say yes 
(or no), even in stressful and difficult decisions. They explicitly stated that it was not up 
to the researcher to decide for them.
The general rule should be to ask everyone eligible, with specific attention to how and 
when. Clinical professionals can help find the right moment to approach children and 
their parents. This timing and coordinating can make a difference when children and 
their parents are approached for participation in clinical research. It is therefore impor-
tant that research professionals who recruit potential participants communicate with 
their clinical colleagues. Nurses, in particular, have frequent contact with patients during 
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the day. Parents and children ask them questions when research professionals are not 
around. These colleagues from clinical practice should therefore also be informed about 
(and endorse) the study. General discussion 
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figure 2: Overview of the framework for recruitment and informed consent
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steP 2: who asks
As discussed in step 1 (‘who should be asked’), a question emerges regarding who should do 
the asking. Who should approach the potential research participants and their parents? In 
short, the answer is the research professional, preferably (when possible) a research nurse.
Chapters 4, 5 and 8 showed that trust is an important motivational factor in the decision-
making process for parents and children. In chapter 8, we distinguished four types of 
trust: personal trust, institutional trust, trust in research in general and trust in the over-
arching system. In particular, personal trust, directly linked to the research professional, 
influences the decision to participate. Chapter 5 shows that parents and children believe 
that the research professional has designed and will conduct the research in their best 
interest. In that sense, their trust is closely linked to the doctor-patient relationship. The 
treating physician should act in the best interest of the patient, but for research profes-
sionals, other interests are also at stake. In practice, the physician role and researcher role 
can be conflated. Then, this trust is not always based on correct assumptions. Therefore, 
it is the responsibility of the research professional to make this distinction clear, so that 
the trust participants have in him/her is legitimate (chapter 8).
When possible, the roles of treating physicians and research professionals should be 
separate to avoid therapeutic misconception and to guarantee the voluntary nature of 
research participation. A recent study by Hoof and colleagues showed that physicians 
and research nurses in pediatrics differ in their opinion about this matter. The ques-
tioned physicians clearly indicated that informed consent is the sole responsibility of 
the treating physician. The research nurses, however, also saw a role for other research 
professionals such as themselves in the informed consent process.11 I agree with these 
research nurses. It is the research professional who is ethically and legally responsible 
for the informed consent for a research proposal. Informed consent legally defines the 
rights and duties of both the research professional and the participant, not of the treat-
ing physician and of the patient.
I suggest creating a two-step recruitment and informed consent process in which 
these roles are distinguished: 1) introduction of the research proposal by the treating 
physician and 2) an informed consent conversation with the research professional. The 
introduction of the research by the treating physician (e.g., in a couple of sentences) 
shows the parents and children that their treating physician endorses the aim of the 
proposed research. The informed consent conversation with the research professional 
will make it clear to the potential participants that research is fundamentally different 
from clinical care and emphasizes the voluntary nature of the decision. In practice, the 
treating physician is sometimes also one of the researchers. Especially in these situa-
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tions, it is important to use this two-step approach to clarify the distinction. Preferably, 
the responsibility for step 2 should lie with the research nurses. Due to their coordinat-
ing role, they have an overview of all research protocols currently being undertaken in 
a specific department that an individual researcher may not have. This gives research 
nurses the possibility to combine multiple research proposals within one informed con-
sent conversation (when applicable) and to address the collective additional burdens 
and risks for the potential research participants and their parents.
steP 3: focus on motivating and discouraging factors
Law and legislation prescribe what information a research professional needs to give to 
potential research participants and their parents. Then, the parents and children are able 
to make an informed decision. However, if the potential participants do not use the infor-
mational elements in their decision-making is the informed consent then not informed? 
A research professional needs to determine which factors parents and children attach 
importance to and which they would want to use in their decision and inform them about 
these aspects, thereby identifying the motivating and discouraging factors relevant to the 
decision.
It is essential that research professionals pay attention during the recruitment and 
informed consent process to the motivating and discouraging factors children and their 
parents have for their research participation. When professionals discover more about 
the motivations of parents and children to accept or decline participation in pediatric 
clinical research, the professionals will know which aspects of research the parents and 
children attach importance to and what information is relevant to their decision. This 
information can then be used in the informed consent materials and conversations.
IMPORTANT MOTIvATING AND DISCOURAGING FACTORS
RECs assess the expected risks and burdens for potential participants in comparison to 
the expected benefit to them and to other individuals or groups affected by the inves-
tigated condition, a process involving proportionality weighing. The empirical research 
presented in chapters 4, 5 and 6 shows that this proportionality is also considered by 
parents and children in their own individual decision about research participation. 
Benefit and altruism are important motivational factors, risk and burden are important 
discouraging factors, and potential participants often emphasize the weighing of these 
factors in their decision.
The systematic review presented in chapter 4 and the interview study presented in 
chapter 5 show that children and their parents attach more importance to burden than 
to risk when they need to decide about participation in pediatric clinical research. The 
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anticipated burden of participating is most frequently mentioned as motivating or 
discouraging for their decision to participate (or to let their child participate). As men-
tioned before, this focus on burden is not only related to the burden of specific research 
procedures imposed on the child but also entails the logistical burden of participating 
in research for both children and parents. Research professionals need to pay specific 
attention in the recruitment and informed consent process to this type of logistical bur-
den for both children and parents.
The systematic review presented in chapter 4 showed and the focus group and interview 
studies presented in chapters 5 and 6 confirmed benefits for the child to be a main mo-
tivator of parents to endorse the participation of their child in pediatric clinical research. 
Interestingly, parents in the focus groups used a much broader definition of benefit 
than direct health benefit, e.g., being regularly checked up also constituted a benefit for 
them. However, these check-ups can only provide a benefit when the participants are 
informed about the results. Research professionals need to be aware of this concern and 
develop a proper return-of-results policy.12 13
The systematic review in chapter 4 and the interview study in chapter 5 show that altru-
ism is an important reason for parents and children to participate in research. An inter-
estingly related result from the interviews, which was not found in the included articles 
in the systematic reviews, is that parents and children not only consider the future in 
their altruistic reasoning but also reason backwards. Parents and children not only focus 
on future patients but also consider children who participated in the past. They now 
benefit because, in the past, other children participated in research. Luchtenberg and 
colleagues recognized this concept in their interviews with children regarding research 
participation and introduced the term ‘reciprocity’ to characterize this type of altruism.14 
The results from our interviews accentuate this reciprocity-based altruistic reasoning 
in parents and children who are asked to participate in clinical research. In my view, 
research professionals may endorse this reasoning when parents or children bring it up. 
It is important, however, that they do not use this reasoning as leverage in the decision-
making process.
Finally, it can be very informative for research professionals to know why potential 
participants decide not to participate. This information can be used to perhaps adapt 
the current research and definitely to design future research protocols in such a way that 
they better fit the wishes of the research population. Therefore, I suggest registering the 
discouraging factors children and their parents mention when they explain why they 
decided not to participate. However, it should never become mandatory for parents and 
children to state their reasons, nor should they be pressured to state their reasons.
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steP 4: Prevent and correct misconcePtions
During the informed consent process, it is important to pay attention to misconceptions 
children and their parents may have about participation in the research. Their motivations 
to participate can be influenced by misconceptions, and their motivations can also expand 
the misconceptions they have. It is the responsibility of the research professional to prevent 
and correct these misconceptions.
There are no intrinsically wrong motivations for parents and children to participate in 
research unless they conflict with the parents’ duty to care for their children. The em-
pirical research presented in chapters 4, 5 and 6 did not uncover any such motivations 
conflicting with parents’ duty to care. We did, however, encounter motivations of chil-
dren and their parents based on incorrect information or misinterpretation of correct 
information. Preventing and correcting these misconceptions are the responsibility of 
the research professional. What can we do about these misconceptions and on which 
elements should a research professional focus?
Although the written informed consent material represents only one aspect of the 
informed consent process, it continues to serve as the primary vehicle for the disclosure 
of research information.15 Additionally, a signed informed consent document is not an 
end in itself; it represents only the conclusion of a participant’s decision-making. To 
achieve the goal of adequately informing a potential participant, informed consent 
materials, including the informed consent document itself, should be as simple and 
concise as possible.16 Tait and colleagues concluded from their research that an eighth-
grade reading level, improved formatting, and use of graphical elements improve the 
comprehensibility of informed consent materials.17 Particularly in research involving 
children, examining these factors when designing information materials can make a 
difference due to the children’s developing capacity. To address this issue in pediatric 
clinical research, Grootens-Wiegers and colleagues developed and tested new informa-
tion materials specific for children in the Netherlands, in the mode of a comic book.18 It 
is crucial that these initiatives are stimulated and implemented in practice.
I received feedback on informed consent documents multiple times from parents in my 
interview study: “I read the information material for children; it is more understandable 
than the one that is written for myself”. Does this feedback mean that the material for 
parents is written at a too-high level? It is likely that it is. Some years ago, in a different 
project, we evaluated the comprehensibility and language level of informed consent 
documents in the Netherlands. We concluded from a reading level test of 35 informed 
consent documents approved by RECs in the Netherlands that the majority (n=33) were 
too difficult for the general public to understand.19 It would be much better if research 
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professionals invested in understandable information material and pay attention to pre-
venting and correcting misconceptions of children and parents in the informed consent 
process.
IMPORTANT MISCONCEPTIONS
Chapters 5 and 6 discuss misconceptions of children and their parents that were en-
countered in the interviews and focus groups. In general, parents (and children) conflate 
research and care and have difficulties grasping the trajectory of clinical drug develop-
ment (chapters 5 and 6). It is therefore important for research professionals to start their 
informed consent conversations by explaining what research actually means.
This explanation of research is also vital to tackle misconceptions regarding the benefit 
someone can expect from research participation. The research presented in chapters 4, 5 
and 6 demonstrated that the expected health benefit is an important reason for children 
and their parents to participate but that the chances of this benefit arising are also often 
misinterpreted. Interviewed parents and children expected health benefits, even from 
observational research. This expectation is much related to the idea they have of being 
checked up regularly in clinical research and receiving extra attention from healthcare 
staff. As we already argued in chapter 6, patients (including parents and children) should 
not be dependent on research to receive the attention they wish for in clinical practice. 
Therefore, it is advisable for research professionals to avoid such terminology.
In phase 1 pediatric drug research especially, misconceptions related to expected ben-
efits should be prevented and corrected. Research professionals should try and temper 
the understandable hope for benefit that parents and children have by emphasizing 
the reality that most children do not benefit from participation in a phase 1 pediatric 
drug trial. Falsely reassuring communication may lead children and their parents to 
make decisions they might not have made otherwise.20 Miller and colleagues showed 
in their observation and interview study that physicians in phase 1 pediatric research 
failed to mention no treatment and/or palliative care as options in 68% of the informed 
consent conversations. Physicians also failed to mention in 85% of the informed consent 
conversations that the disease was incurable.21 Physicians should be honest and realistic 
and should state that most children do not respond to phase 1 pediatric trials. The 
reality is that phase 1 trials are not developed with the aim of benefiting the patients 
participating in the trial. Although some mention that this premise does not count for 
pediatric phase 1 research because it is built on adult data, two extensive reviews show 
that the opposite is true. All phase 1 pediatric oncology trials published in the periods 
1990-2004 and 2004-2015 showed an objective response rate of only approximately 
10% (including complete and partial responses), while the average grade 3/4 adverse 
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event rate was more than 1 per person.22 23 Both reviews concluded with the statement 
that these findings are similar (with respect to benefit and harm) to the results of phase 
1 trials in adults.
steP 5: informed consent as a continuous Process
Research professionals should consider and act upon informed consent as being a continu-
ous and dynamic process. Obtaining a signature on an informed consent form is not the goal 
and endpoint of an informed consent process. Research professionals should stay in contact 
with the participating parents and their children regarding their decisions during the course 
of the research.
Although the framework ends after this step 5, the informed consent process in clinical 
research does not stop. It is important to realize that informed consent is not a one-
time achievement but should be a continuous and dynamic process between research 
professionals and (potential) participants. In pediatric clinical research, the continuity of 
the informed consent process is even more important because of children’s developing 
capacity.
In a recent article, Kadam depicts informed consent as an information highway in clinical 
research to explain study procedures, risks, benefits and participant rights.24 I do not 
know if a highway is the analogy I would choose, but to continue the traffic terminology, 
I would rather use a round-about to illustrate the informed consent process, namely, a 
dynamic and continuous process before and during the research, in which (potential) 
participants can at any time make different choices based on new information. Informed 
consent in pediatric clinical research should therefore encompass a dynamic and con-
tinuing exchange of information between the research team and (potential) participants 
and their parents.
In practice, this means the following for research professionals: Stay in contact with 
your participants, including during the course of the research. Research professionals 
should provide participants and their parents with new information when relevant and 
be aware that their former decisions can change. Just as research professionals should 
not act upon implicit assumptions about the initial choice children and their parents 
will make regarding trial participation, professionals also should not act upon these 
assumptions during the trial. When an aspect might be relevant to the decision made 
by children and their parents, professionals should inform them about it. To optimally 
guide the process, it is important for research professionals to anticipate the continuity 
of the process of informed consent at the beginning of the research.
160 Chapter 9
neW DeveloPmenTs: neW eThical guiDance
New developments in medicine, clinical research, ethical oversight and technology bring 
new questions that request new ethical guidance. These developments are not specific 
to clinical research with children but present overarching themes that are also relevant 
for pediatric research practice. New developments also arose during the course of this 
research. The framework I presented and the conclusions I drew will be dependent upon 
and will need to be adapted to these (upcoming) developments. In this paragraph, I 
therefore discuss some of these developments and make suggestions regarding how 
guidance should proceed or what new ethical research would be needed to optimally 
incorporate these developments. These developments may have an effect on all five 
gates in the research enterprise because they necessitate changes in the protective 
measures in legislations, new choices in research design, adaptation of the medical-
ethical review process, and different recruitment strategies; these developments will 
also influence the informed consent by potential participants.
digitaL technoLogies in informed consent
New digital technologies are emerging, and they could also be useful tools to improve 
the informed consent process in pediatric clinical research.25-28 In particular, as informed 
consent is considered a continuous dynamic process, new digital technologies can 
support and emphasize this continuous and dynamic contact between participants and 
research professionals. For example, block chain technology has even been introduced 
by researchers to follow such types of informed consent flows in clinical research to 
improve the transparency and traceability of informed consent.29
Of course, the use of new digital decision support and informed consent tools should 
not completely replace the much-needed face-to-face contact between a researcher 
and potential participant. The use of new digital technologies in the informed consent 
process will probably raise the same concerns regarding the amount of information, 
readability and formatting as paper informed-consent documents did, but there are a 
couple of advantages. New digital decision support and informed consent tools: 1) can 
promote active participation instead of the passive participation mode of a paper con-
sent form; 2) can possibly provide a pictorial superiority effect (a picture says more than 
words), especially in people with poor literacy; 3) can incorporate corrective feedback 
that results in real-time understanding and learning; and 4) can tailor the information to 
the needs of the individual participant.15
A systematic review performed by Grootens-Wiegers and colleagues made apparent the 
large readability gap between the reading level of the information material for pediatric 
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clinical research and the reading ability of children.30 For example, an empirical study by 
Tait and colleagues showed that compared with the use of traditional modes of informa-
tion dissemination, the use of digital information resulted in a significant increase in 
understanding by children and parents.31 Their review also showed that interventions 
that were effective used a story format, multimedia or illustrations for probabilities in 
pediatric clinical research. These last three components lend themselves perfectly to be 
implemented in new digital technologies. To enhance understanding, research profes-
sionals and RECs should adopt innovative communication strategies and new digital 
technologies.
The implementation of these new digital technologies requires critical reflection on and 
perhaps even a revision of ethical and legal guidance concerning informed consent. 
For example, in the Netherlands, researchers are obliged to use an informed consent 
document template designed by the Dutch Clinical Trial Foundation (DCRF) working 
group commissioned by the Central Committee on Research Involving Human Subjects 
(CCMO). It would be worthwhile to investigate how to adapt the current templates into 
digital support tools so we can stimulate researchers to tailor the process of informed 
consent more closely to the needs of their study population.
Another way to implement new digital technologies in pediatric clinical research would 
be to explore the possibility and acceptability of digitally signing informed consent 
forms. Currently, an original autograph written on paper is needed. In the practice of 
clinical research, this signing of the papers can be logistically very difficult, while this 
prerequisite has no effect on the meaningfulness and validity of the informed consent. 
Especially in pediatric research, the collection of autographs of both parents and chil-
dren at the same time can be logistically demanding. Could digital signing of informed 
consent documents by the use of DigiD be an elegant way of tackling this issue?
aLternative forms of informed consent
In principle, we want informed consent of potential participants before we commence 
research procedures. This order of consent and then participation can become compro-
mised during research in an emergency setting. For instance, in the research practice of 
the PICU, it is not always possible to achieve written informed (proxy) consent before 
the start of the study. The following alternative consent models are being introduced 
to balance respect for the decision of potential participants and the benefit research 
participation might bring them: a waiver of consent and a deferred consent approach. 
These alternatives are discussed in chapter 3. As a waiver of consent means not asking 
for consent at all, I do not consider this a justified alternative. It does not balance any 
other aspects and completely eliminates the choice of potential participants and their 
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proxy decision-makers. However, a process of deferred consent may be an elegant solu-
tion in specific difficult circumstances.
Currently, the WMO gives minimal ethical guidance about the acceptability of deferred 
consent (art 6:4 WMO 1998). The WMO considers deferred consent acceptable only 
when it is practically impossible to obtain consent before the start of the trial and 
when the trial may benefit a participant in urgent need of medical treatment. Some 
researchers suggest using deferred consent when they consider the decision to be too 
stressful for parents and potential participants, even without an emergency situation. 
In my view, difficult circumstances, stress for parents or an expected high dissent rate 
are not acceptable arguments to justify the implementation of such a procedure. On 
the contrary, the results in chapter 5 show that parents and children want to be asked 
about participation, even in stressful situations. International legislation and guidance 
documents concerning this topic also propose other conditions that need to be met 
for deferred consent to be acceptable,32 namely: limits to the acceptability of burden 
and risk in the trial (upcoming EU Clinical Trials Regulation); mandatory public consulta-
tion beforehand about the desirability of deferred consent (US guidance for IRBs); and 
mandatory public information in the department where the research is carried out, for 
example, through poster announcements (US guidance for IRBs).1 33
It may be worthwhile to assess the desirability and necessity of implementing these ad-
ditional requirements in Dutch research practice. Developing a framework for deferred 
consent in the Netherlands should be done considering the additional measures that 
are used in other countries. This framework will help research professionals implement 
deferred consent in an ethical manner and provide RECs with much-needed tools to 
review these adapted informed consent models.
combining research ProtocoLs
A new approach in clinical drug development is the creation of overarching research 
protocols that combine different phases of drug research, especially in pediatric re-
search, for example, creating a study in which phase 1, 2 and 3 studies are combined in a 
single protocol. Researchers aim to accelerate drug development through this approach, 
which creates more coherence and effectiveness and reduces time and cost compared 
to stacking individual trials. However, it also creates an ethical concern relating to the 
risk-benefit ratio in such combined research.
Drug development is traditionally split in separate phases of research, with each phase 
having its own distinct goal, outcome measures and population. These distinctions lead 
to different expected benefits and risks for the different stages of research and result 
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in differing risk-benefit ratios for the consecutive phases of research.34 When these dif-
ferent phases are combined in one protocol, it begs the question of how the overall 
risk-benefit assessment is created by researchers, evaluated by RECs and perceived by 
potential research participants in their decision-making.
The creation of one risk-benefit ratio for such a combined protocol by researchers is 
flawed for the following reasons. First, different subjects participate in the different 
phases of the specific research, and there is no overarching risk-benefit ratio for an 
individual participant. Second, how are researchers even able to estimate the benefit 
and risk in the subsequent phases before the start of the initial phases of the research? 
It is not possible to make those estimates when the early phase research has not been 
carried out and has not yet generated results that inform the expected benefit and risk. 
Therefore, researchers should separate the risk-benefit ratios for the different phases, 
even if they combine the different phases into one protocol.
RECs evaluate the ethical acceptability of research protocols and assess the risk-benefit 
ratio. To evaluate such a combined research protocol, it is necessary to assess the differ-
ent phases of the research with their distinct risk-benefit ratios. Therefore, RECs need 
to have explicitly available in the protocol the risks and benefits of the separate phases 
and which participants participate in which phase. Only then can they evaluate the risk-
benefit ratio. In practice, RECs will hopefully give provisional approval of the protocol, 
which includes only the first phase of the research. The expected safety and risks for 
participation in the consequent phases cannot be evaluated by an REC until the mo-
ment the first phase has generated results.
As already stressed before, burden and expected benefit are important factors for the 
decision-making process of potential research participants, which implies that their de-
cisions will differ for the different phases. Participants will participate in a specific phase 
of the research and should therefore be informed about the expected benefit and risks 
associated with participating in that specific phase. To present the potential participants 
with the overall risk and benefits of the entire research would be misleading. It is neces-
sary to create different information materials and informed consent documents for the 
separate phases.
The above discussion makes it clear that this new trend of combining research proto-
cols is ethically problematic and that RECs need to be vigilant regarding the proposed 
combined risk-benefit assessments and informed consent documents in such protocols. 
Although combining protocols can accelerate the research process, separate risk-benefit 
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assessments and informed consent documents for the subsequent phases of a research 
protocol are needed, both for the REC and for the potential research participant.
creating readiness cohorts
Novel approaches are being developed to improve screening for eligibility and facilitate 
the recruitment of research participants. One of those developments is the creation of 
‘readiness cohorts’ for clinical research. This approach has been mainly developed and 
published in research on the prevention of Alzheimer’s dementia.35 36 It is, however, not 
unthinkable that the development of readiness cohorts will also reach other fields of 
medicine, including research involving children. Because of the small population avail-
able for pediatric clinical research in orphan diseases, these readiness cohorts can be 
expected to become more common.
These ‘readiness cohorts’ link existing research cohorts, studies or patient registries 
with new research. The primary goal of these cohorts is to provide a well-characterized 
population of potential research participants for recruitment into trials, for example, 
to reduce recruitment time and costs. From these established ‘readiness cohorts’, indi-
viduals are recruited into new clinical trials. Although this development may improve 
research recruitment, setting up such research infrastructures obliges us to evaluate our 
current ethical guidance, which is currently focused on distinct individual trials. Specific 
attention should be given to the requirements for recontacting participants in existing 
research studies and for obtaining informed consent as participants move through the 
research process.37
We need to be aware that people participating in a readiness cohort might drop out at 
increased rates from the existing studies because this process adds a burden. Next, we 
need to think of guarantees to ensure access to an actual trial for people who are not 
part of the readiness cohort. In addition, the other way around, people participating 
in a readiness cohort should not be excluded from other research offers merely on the 
grounds that they were placed in this cohort. Both constraints would create a monopoly 
of these patients and influence the voluntary nature of research participation.
The longitudinal and transitional character of readiness cohorts makes it difficult to 
ensure that potential participants are fully informed about the scope of the research 
before they consent to take part. Participants in a readiness cohort do not know at the 
start whether they will eventually be asked to participate in a clinical trial and what that 
trial will entail because this information is not known beforehand. This situation creates 
the danger of a fish trap. One is drawn into the research project, in which it becomes 
increasingly difficult to return or leave the research project. This fish trap can be pre-
General discussion 165
vented by introducing a staged consent model.37 38 This consent model feeds relevant 
information, bit by bit, along a research participant’s journey and asks for informed con-
sent at every moment in which important decisions need to be made by participants. 
Although informed consent is always given for a specific stage of the research project, 
information about the ‘totality of the project’ also needs to be always and explicitly part 
of the informed consent process. It is important that researchers and RECs are aware of 
the distinct ethical challenges that are related to this new development of ‘readiness 
cohorts’.iv
Learning heaLthcare system
We are moving gradually into a new era of clinical research and the research ethics related 
to it. In 2007, Emanuel and Grady elaborated on four paradigms in clinical research and 
oversight. They defined four different paradigms in research: 1) research paternalism; 2) 
regulatory protectionism; 3) participant access; and 4) collaborative partnership.39 These 
paradigms follow each other, with several elements of previous paradigms still being 
present. I believe we are slowly stepping into a new, fifth paradigm with the implemen-
tation of ‘Learning Healthcare Systems’.40 A learning healthcare system combines care 
and research and originates from high-scale reuse of health data and the inclusion of 
patient perspectives into care models.41 In the field of pediatrics, the learning healthcare 
system is also being explored. Pediatric oncology, where research and care are highly 
intertwined, is mentioned as an example of a learning healthcare system.42
Advocates of learning healthcare systems want to achieve additional and direct effects 
of research on clinical care and more clinical perspectives in research. Although I sup-
port this goal, I wonder whether a learning healthcare system can achieve this goal in 
a morally acceptable way. A learning healthcare system is characterized by the inter-
twinement of clinical care and research. This intertwinement imposes the need to find 
a new collaboration between traditional research ethics and clinical ethics.43 44 Brody 
and Miller state that it is crucial that we retain the distinction between research and 
clinical care, and I agree.45 The following important elements differ between clinical care 
and research: 1) patient - research participants; 2) individual - population; 3) request 
for help - hypothesis testing; 4) treatment - generalizable knowledge. The results from 
this thesis show how important the distinction between research and clinical care is for 
potential research participants and how difficult it is for them to grasp the concept of 
research. The danger of this new paradigm is that we lose the ethical guidance and the 
iv  This paragraph is partly based on an article I wrote with colleagues from the European Prevention of Al-
zheimer’s Disease (EPAD) consortium (Milne R, Bunnik E, Tromp K, Bemelmans S, Badger S, et al. Ethical issues 
in the development of readiness cohorts in alzheimer’s disease research. J Prev Alzheimers Dis 2017;4(2):125-
13).
166 Chapter 9
sensitivity that were developed for clinical research and its oversight and that we return 
to a situation of less transparency and more reliance on individual trust. This new para-
digm requires new ethical thinking based on empirical research, specifically focused on 
the research-care intertwinement before we can introduce it in a way that we advance 
science but still provide adequate protection.
conclusion
With this thesis, I aimed to contribute to the optimal inclusion of children in pediatric 
clinical research in such a way that we can further clinical research to advance scientific 
knowledge and develop much-needed treatment options for children while protecting 
children against harm from research. I combined the main findings of my research into a 
normative framework for research professionals to include children in pediatric clinical 
research. This framework tailors the process of recruitment and informed consent to 
the perspective and the needs of children and their parents, who have the key role in 
decisions regarding research participation. I focused mainly on the motivations children 
and their parents have to participate in clinical research. With this approach, research 
professionals can increase the moral and instrumental value of informed consent in 
pediatric clinical research: more informed consent and probably more informed consent.
In this way, we can support children and their parents, such as the mother I quoted at 
the beginning of this thesis, in finding a balance in that difficult ethical dilemma regard-
ing pediatric clinical research and in making an informed, meaningful and valid decision 
about participation in pediatric clinical research.
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summary
With this thesis, I aim to contribute to the optimal inclusion of children in pediatric 
clinical research in such a way that we can further clinical research to advance scientific 
knowledge and develop much-needed treatment options for children while protecting 
children against harm from research.
Ethicists, researchers and physicians have extensively discussed this precarious balance 
between advancement and protection in pediatric research. However, how do children 
and their parents view this balance? Do they also weigh the possible harms against the 
benefits when they are approached for participation in clinical research? Or do they 
have other reasons and put other factors into the equation? Because children and their 
parents are the key decision-makers and children are ultimately the ones participating 
and undergoing the risk and burden of the research, it seems obvious that their views 
about this balance are crucial.
Why do children and parents want to participate (or not)? What are their motivations 
and what is important to them in their decision? What expectations do they have of 
participation? Answers to these questions are indispensable in order to incorporate 
their views into the pediatric research enterprise and tailor the process of recruitment 
and informed consent to their needs and perspectives. When we know why children and 
parents consent or dissent to research and what elements they use in their decision, we 
know what they attach importance to in their decision. From this data, we learn which 
information they want and need to make a valid informed decision. This information 
helps us to increase both the moral and instrumental value of informed consent in pe-
diatric clinical research; we obtain more informed consent and probably more informed 
consent.
Therefore, the main research aims of this thesis are as follows:
1. To explore children’s and their parents’ motivations, views and expectations during 
recruitment and informed consent processes in pediatric clinical research.
	 •  What are their motivations to consent/assent to participation in pediatric clinical 
research? What factors influence their decisions?
	 • What are their views on recruitment and informed consent?
	 • What are their expectations of research?
2. To analyze these motivations, views and expectations and the factors that shape 
them from an ethical and legal perspective.
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3. To develop a normative framework to support research professionals in the ethically 
sound inclusion of children in pediatric clinical research. This framework tailors the 
process of recruitment and informed consent to the perspective and the needs of 
children and their parents, who have the key role in decisions on research participa-
tion.
chapter 2 sketches the European regulatory landscape for pediatric clinical research 
and shows how specific ethical issues regarding clinical research with children, such 
as informed consent/assent and risk-benefit thresholds, are incorporated into relevant 
legislation.
This chapter focusses on three documents: the European Convention on Human Rights 
and Biomedicine (also called the Oviedo Convention); Directive 2001/20/EC (also called 
the Clinical Trials Directive); and Regulation (EC) No. 1901/2006 (also called the Pediat-
ric Regulation). In addition, this chapter discusses major ethical concerns in pediatric 
clinical research, with a focus on the acceptability of research risks and the informed 
consent process. In a short addendum I explain the new upcoming European Clinical 
Trials Regulation.
chapter 3 gives an overview of the ethical challenges that arise when planning and 
conducting clinical research with a specifically vulnerable group of children, namely, 
critically ill children in the Pediatric intensive care unit (PICU). This chapter discusses 
ethical challenges concerning study design, informed consent and risk and burden and 
proposes several solutions to these ethical challenges.
The informed consent process at a PICU is a challenge due to the stressful environment 
for parent and child and the frequently occurring need to act acutely. Alternative forms 
of informed consent have been developed taking into account the unpredictable reality 
of the acute critical care environment and are discussed in this chapter. Furthermore, 
as with any research in children, burden and risk should be minimized also in the PICU. 
This chapter demonstrates recent developments in sample collection and analysis 
that should be considered in the design of studies in the PICU. Despite the difficulties 
inherent to clinical research in critically ill children, ethically sound research resulting in 
relevant and generalizable data is possible. This chapter states how. 
chapter 4 reviews the empirical literature concerning the motivations of children 
and their parents to consent or dissent to pediatric clinical drug research. This chapter 
provides a comprehensive overview of the motivating and discouraging factors that 
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influence children’s and their parents’ decisions to participate in pediatric clinical drug 
research reported in the empirical literature.
Relevant empirical studies were identified from searches in 6 databases and subse-
quently screened and selected for analysis. Results were aggregated and presented 
by use of qualitative meta-summary. 38 studies fulfilled the selection criteria and were 
of sufficient quality for inclusion in the qualitative meta-summary. Most frequently 
mentioned motivating factors for parents were: health benefit for child, altruism, trust 
in research, and relation to researcher. Most mentioned motivating factors for children 
were: personal health benefit, altruism and increasing comfort. Fear of risks, distrust in 
research, logistical aspects and disruption of daily life were mentioned most by parents 
as discouraging factors. Burden and disruption of daily life, feeling like a ‘guinea pig’ and 
fear of risks were most mentioned as discouraging factors by children. 
chapter 5 reports on a qualitative interview study aimed at gaining insight into chil-
dren’s and their parents’ motivations, views and expectations during the process of 
recruitment and informed consent for pediatric clinical research. This interview study 
presents perspectives from three different hospital settings: children and their parents 
in pediatric oncology, pediatric pulmonology (subdivision: cystic fibrosis) and the PICU.
I interviewed children and their parents who had been asked to participate in clinical 
research and had had an informed consent conversation (N=34). Children and their 
parents attach more importance to burden than to risk when they need to decide 
about participation in clinical research. The anticipated burden of participating is most 
frequently mentioned as motivating or discouraging for their decision to participate. 
However they have a very broad notion of burden. This burden also includes traveling 
to the hospital and needing time off from work or school (an emphasis on logistical 
burden). The interviews revealed also that they outsource their concerns about risk 
and have a great deal of trust in their treating physicians and research professionals. 
They expect only safe and sound research to be offered to them. Additionally, parents 
and children often refer to helping other or future children and science as important 
considerations in their decisions. The design of pediatric clinical research and especially 
the recruitment and informed consent process can be ameliorated by the findings pre-
sented in this chapter. This way, research will be better in line with the preference of 
children and parents, and children and their parents will be better equipped to make a 
decision about participation. 
chapter 6 reports on a qualitative focus group study aimed to explore parents’ perspec-
tives on decisions to participate in pediatric clinical research. This focus group study was 
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performed with 16 parents recruited from the general public to add the intuitions and 
motivations of non-professionalized (non-hospitalized) parents to the body of empirical 
evidence.
We explored their perspectives on the (hypothetical) decisions to participate in pediatric 
clinical research. Group discussion revealed that: parents conflate clinical research and 
clinical care; they do not grasp the trajectory of pediatric drug development; current 
ethical guidelines are in line with their protective intuitions; and benefit for their child is 
the most important factor in their decision. The results presented in this chapter teach 
us that research professionals should be aware of the knowledge gap of parents, the 
pitfalls of jargon, and unintended false expectations. 
chapter 7 discusses the phenomenon of gatekeeping in the recruitment for pediatric 
clinical research. Gatekeeping is a practice in which research professionals have implicit 
inclusion and exclusion criteria that lead to not approaching all eligible research partici-
pants. 
Our research into participation in pediatric clinical trials identified reasons why profes-
sionals engage in gatekeeping; these are e.g. protection of the child and prejudiced 
beliefs about the choice the child or parent will make. Although gatekeeping might 
be understandable, we argue it is not desirable because of the negative implications 
this practice entails (e.g. it denies children a choice, might introduce inclusion bias 
and introduces unfair distribution of risk and benefit). This chapter calls upon pediatric 
professionals to be aware of the many negative implications of their reluctance and in 
principle to refrain from the problematic practice of gatekeeping.
chapter 8 discusses the different types of trust that children and their parents have in the 
research enterprise illustrated with empirical results from the interview study presented 
in chapter 5. This chapter also sketches how this trust influences their decision-making 
and how it emphasizes the necessity of prior review of a research ethics committee and 
its filtering task.
We argue in this chapter that patients’ trust confirms the rationale and necessity for 
the current model of research ethics that consists of more than informed consent, as 
consent can only be asked for after a review process by a research ethics committee. We 
substantiate this statement with results from the interviews with parents and children 
about their willingness to participate in research presented in chapter 5.
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chapter 9 concludes this thesis with a general discussion in which I combine the main 
findings of the preceding chapters into a normative framework for research profession-
als to include children in an ethically sound manner in pediatric clinical research. 
This chapter starts with an overview of the steps in the research enterprise before children 
can participate in research. Before a research proposal reaches potential participants 
(and their parents), other ethical decisions related to the research have been made on 
which the potential research participants and their parents have no influence. Only then 
potential participants and their parents make a decision about participation. I call those 
decisions, ‘gates’ in the research enterprise. Consecutively, I propose a framework that 
tailors the process of recruitment and informed consent to the perspectives and needs 
of children and their parents. This framework addresses five elements: 1) who is asked; 
2) who asks; 3) focus on motivating and discouraging factors; 4) prevent and correct 
misconceptions; 5) informed consent as a continuous process. I conclude this chapter 
with some developments in clinical research that necessitate new research efforts, 
policy changes and new ethical guidance. I discuss: digital technologies in informed 
consent, alternative forms of informed consent, combining research protocols, creation 
of readiness cohorts and the implementation of learning health care systems.
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samenvaTTing
Met dit proefschrift beoog ik bij te dragen aan de optimale inclusie van kinderen in 
medisch-wetenschappelijk onderzoek; op een zodanige manier dat we adequate 
wetenschappelijke kennis genereren en de hoognodige behandelingsopties voor 
kinderen ontwikkelen, terwijl we tegelijkertijd ook kinderen beschermen tegen schade 
door hun deelname aan onderzoek.
Ethici, onderzoekers en artsen hebben al uitgebreid gediscussieerd over dit precaire 
evenwicht tussen vooruitgang en bescherming bij medisch-wetenschappelijk onder-
zoek met kinderen. Maar hoe zien kinderen en hun ouders dit evenwicht? Wegen zij 
ook de mogelijke nadelen af  tegen de voordelen wanneer ze worden benaderd voor 
deelname aan onderzoek? Of hebben ze andere redenen en spelen andere factoren 
een rol in hun afweging? Aangezien kinderen en hun ouders een sleutelrol hebben in 
de beslissing en kinderen uiteindelijk degenen zijn die deelnemen aan onderzoek en 
het risico en de belasting van het onderzoek ondergaan, zijn hun opvattingen over dit 
evenwicht cruciaal.
Waarom willen kinderen en ouders meedoen (of niet)? Wat zijn hun motivaties en wat 
is voor hen belangrijk in de beslissing? Welke verwachtingen hebben ze van deelname? 
Antwoorden op deze vragen zijn onmisbaar om hun opvattingen mee te nemen in de 
ontwikkeling van medisch-wetenschappelijk onderzoek met kinderen. Hiermee kun-
nen we het proces van werving en informed consent aanpassen aan hun behoeften en 
perspectieven. Als we weten waarom kinderen en hun ouders toestemmen geven voor 
deelname aan onderzoek en welke elementen zij in hun beslissing gebruiken, weten we 
wat zij belangrijk vinden en wat zij nodig hebben voor een valide geïnformeerde besliss-
ing. Deze informatie helpt ons om zowel de morele als de instrumentele waarde van in-
formed consent in medisch-wetenschappelijk onderzoek met kinderen te vergroten. Zo 
komen we tot meer geïnforméérde toestemming en waarschijnlijk méér geïnformeerde 
toestemmingen.
De belangrijkste doelstellingen voor dit proefschrift zijn dan ook:
1. Het verkennen van de motivaties, opvattingen en verwachtingen van kinderen en 
hun ouders tijdens de werving en het informed consent proces in medisch-weten-
schappelijk onderzoek met kinderen.
	 •  Wat zijn hun motivaties om toestemming te geven voor deelname? Welke facto-
ren beïnvloeden hun beslissing?
	 • Wat zijn hun opvattingen over de werving en het informed consent proces?
	 • Wat zijn hun verwachtingen van deelname aan het onderzoek?
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2. Het analyseren van deze motivaties, opvattingen en verwachtingen en de factoren 
die daar invloed op uitoefenen vanuit een ethisch en juridisch perspectief.
3. Een normatief kader ontwikkelen om onderzoeksprofessionals te ondersteunen 
bij het ethisch verantwoord includeren van kinderen in medisch-wetenschappelijk 
onderzoek. Dit kader laat zien hoe we het proces van werving en informed consent 
zo goed mogelijk kunnen laten aansluiten bij het perspectief en de behoeften van 
kinderen en hun ouders.
hoofdstuk 2 schetst het Europese landschap van regelgeving voor medisch-weten-
schappelijk onderzoek met kinderen en laat zien hoe specifieke ethische kwesties voor 
onderzoek met kinderen zijn opgenomen in deze regelgeving (zoals informed consent 
en de aanvaardbaarheid van risico en belasting bij onderzoeksdeelname).
Dit hoofdstuk richt zich op drie documenten: het Europees Verdrag inzake de rechten 
van de mens en de biogeneeskunde (ook wel het Verdrag van Oviedo genoemd); Rich-
tlijn 2001/20/EC (ook wel de Europese Richtlijn Geneesmiddelenonderzoek genoemd); 
en Verordening (EG) Nr. 1901/2006 (ook wel de Pediatrische Verordening genoemd). 
Daarnaast behandelt dit hoofdstuk de belangrijkste ethische aspecten van medisch-
wetenschappelijk onderzoek met kinderen, met een focus op de aanvaardbaarheid 
van onderzoeksrisico’s en het informed consent proces. In een kort addendum bij dit 
hoofdstuk bespreek ik de nieuwe Europese Verordening Geneesmiddelenonderzoek.
hoofdstuk 3 geeft een overzicht van de ethische uitdagingen die zich voordoen bij 
het opzetten en uitvoeren van medisch-wetenschappelijk onderzoek met een specifiek 
kwetsbare groep kinderen, namelijk kritisch zieke kinderen op een pediatrische Inten-
sive Care (kinder-IC). Dit hoofdstuk behandelt ethische uitdagingen met betrekking tot 
onderzoeksdesign, informed consent en belasting en risico van deelname en suggereert 
verschillende oplossingen voor deze ethische uitdagingen.
Het informed consent proces op een kinder-IC is een uitdaging door de stressvolle 
omgeving voor ouder en kind en de vaak voorkomende noodzaak om acuut te han-
delen. Alternatieve vormen van informed consent zijn mogelijk waarbij rekening wordt 
gehouden met de onvoorspelbare realiteit van de acute zorgomgeving (bijv. deferred 
consent). Deze komen in dit hoofdstuk aan de orde. Bovendien moeten, net als bij al 
het medisch-wetenschappelijk onderzoek, belasting en risico ook bij onderzoek op 
de kinder-IC geminimaliseerd worden. Dit hoofdstuk beschrijft enkele innovatieve 
onderzoeksmethoden om dit te doen. Ondanks de moeilijkheden die inherent zijn aan 
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medisch-wetenschappelijk onderzoek met kritisch zieke kinderen, is ethisch verant-
woord onderzoek op de kinder-IC mogelijk. Dit hoofdstuk stelt voor hoe.
hoofdstuk 4 betreft een systematisch literatuuronderzoek over de motivaties van kin-
deren en hun ouders om toestemming te geven voor deelname aan pediatrisch genees-
middelenonderzoek. Dit hoofdstuk biedt een uitgebreid overzicht van de motiverende 
en ontmoedigende factoren die van invloed zijn op de beslissingen van kinderen en 
hun ouders.
Relevante artikelen zijn verzameld uit zes databases en vervolgens gescreend en gese-
lecteerd voor beantwoording van de onderzoeksvraag. De resultaten zijn verzameld en 
gepresenteerd aan de hand van een kwalitatieve metasamenvatting. 38 studies voldeden 
aan de selectiecriteria en waren van voldoende kwaliteit om te worden opgenomen 
in de kwalitatieve metasamenvatting. De meest genoemde motiverende factoren voor 
ouders waren: gezondheidsvoordeel voor het kind, altruïsme, vertrouwen in onderzoek 
en relatie tot de onderzoeker. De meest genoemde motiverende factoren voor kinderen 
waren: persoonlijk gezondheidsvoordeel, altruïsme en verbetering van comfort. Angst 
voor risico’s, wantrouwen jegens onderzoek, logistieke aspecten en verstoring van het 
dagelijks leven werden door ouders het meest genoemd als ontmoedigende factoren. 
Belasting en verstoring van het dagelijks leven, het gevoel een ‘proefkonijn’ te zijn en 
angst voor risico’s werden het meest genoemd als ontmoedigende factoren bij kinderen.
hoofdstuk 5 presenteert de resultaten van een kwalitatieve interviewstudie opgezet 
om inzicht te krijgen in de motivaties, opvattingen en verwachtingen van kinderen en 
hun ouders tijdens het proces van werving en informed consent voor medisch-weten-
schappelijk onderzoek met kinderen. Deze interviewstudie beschrijft perspectieven 
vanuit drie verschillende ziekenhuisafdelingen: kinderoncologie, kinderlongziekten 
(divisie: cystische fibrose) en de kinder-IC.
Ik interviewde kinderen en hun ouders die waren gevraagd om deel te nemen aan 
medisch-wetenschappelijk met kinderen en een informed consent gesprek hadden ge-
had (N = 34). De resultaten lieten zien dat kinderen en hun ouders de belasting van het 
onderzoek meer laten meewegen in hun beslissing over onderzoeksdeelname dan het 
risico. De verwachte belasting bij deelname wordt het meest genoemd als motiverend 
of ontmoedigend voor hun beslissing om deel te nemen. Ze hebben echter een zeer 
breed begrip van belasting. Kinderen en ouders verstaan veel zaken onder belasting, 
zoals ook het reizen naar het ziekenhuis of vrij moeten nemen van school of werk (veelal 
de nadruk op logistieke belasting). Uit de interviews bleek ook dat zij hun bezorgdheid 
over risico’s ‘uitbesteden’ en veel vertrouwen hebben in hun hun behandelend artsen 
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en onderzoeksprofessionals. Zij gaan ervanuit dat ze alleen onderzoeksprotocollen 
voorgelegd krijgen die adequaat en veilig zijn. Tenslotte verwijzen ouders en kinderen 
vaak naar het helpen van andere en/of toekomstige kinderen en een bijdrage aan de 
wetenschap als belangrijke overwegingen bij hun beslissingen. De opzet van medisch-
wetenschappelijk onderzoek met kinderen en in het bijzonder het proces van werving en 
informed consent is te verbeteren met behulp van de bevindingen in dit hoofdstuk. Op 
deze manier zullen studies meer in overeenstemming zijn met de wensen van kinderen 
en ouders, en zullen kinderen en hun ouders beter toegerust zijn om een  beslissing te 
nemen over mogelijke deelname.
hoofdstuk 6 rapporteert de resultaten van een kwalitatieve studie met focusgroepen, 
opgezet om de perspectieven van ouders te verkennen, als zij moeten beslissen om hun 
kind deel te laten nemen aan medisch-wetenschappelijk onderzoek. Deze focusgroep 
studie werd uitgevoerd met 16 ouders geworven uit de algemene bevolking om de 
intuïties en motivaties van niet-geprofessionaliseerde ouders toe te voegen aan de 
empirische literatuur.
We onderzochten hun perspectieven op (hypothetische) beslissingen om hun kind deel 
te laten nemen aan medisch-wetenschappelijk onderzoek. Uit de focusgroepen bleek 
dat: ouders onderzoek en zorg door elkaar halen; ze het traject van geneesmiddelenon-
twikkeling niet begrijpen; de huidige ethische richtlijnen in overeenstemming zijn met 
hun beschermende intuïties; en voordeel voor hun kind de belangrijkste factor in hun 
beslissing is. De resultaten die in dit hoofdstuk worden gepresenteerd, laten zien dat 
onderzoeksprofessionals zich bewust moeten zijn van de kenniskloof van ouders, de 
valkuilen van jargon en onbedoelde valse verwachtingen.
hoofdstuk 7 bespreekt het verschijnsel gatekeeping bij het werven van deelnemers 
voor medisch wetenschappelijk onderzoek met kinderen. Gatekeeping is een praktijk 
waarbij onderzoeksprofessionals impliciete inclusie- en exclusiecriteria hanteren die 
leiden tot het niet benaderen van alle geschikte potentiele deelnemers.
Ons onderzoek naar deelname aan medisch-wetenschappelijk onderzoek met kin-
deren identificeerde redenen waarom professionals gatekeeping toepassen; deze zijn 
bijvoorbeeld bescherming van het kind en overtuigingen over de keuze die het kind 
of de ouder zal maken. Hoewel gatekeeping misschien begrijpelijk is, roept dit hoofd-
stuk onderzoeksprofessionals op zich bewust te zijn van de vele negatieve implicaties 
(bijvoorbeeld het ontnemen van een keuze, introductie van inclusiebias en oneerlijke 
verdeling van risico en voordeel van onderzoeksdeelname) en in principe af te zien van 
deze problematische praktijk.
Summary / samenvatting 183
hoofdstuk 8 bespreekt de verschillende soorten vertrouwen die kinderen en hun oud-
ers hebben in onderzoek, geïllustreerd met empirische resultaten van de interviewstudie 
gepresenteerd in hoofdstuk 6. Dit hoofdstuk schetst ook hoe dit vertrouwen van invloed 
is op hun besluitvorming en hoe essentieel de filtertaak en toetsing van protocollen 
door een medisch-ethische toetsingscommissie is.
We beargumenteren in dit hoofdstuk dat het vertrouwen van patiënten de rationale 
en de noodzaak bevestigt van het huidige model van onderzoeksethiek. Dat bestaat 
immers uit meer dan geïnformeerde toestemming: toestemming kan alleen kan worden 
gevraagd na een beoordelingsproces door een medisch-ethische toetsingscommissie. 
We onderbouwen deze verklaring met resultaten van de interviews met ouders en 
kinderen over hun bereidheid om deel te nemen aan onderzoek gepresenteerd in 
hoofdstuk 5.
hoofdstuk 9 sluit dit proefschrift af met een algemene discussie waarin ik de belan-
grijkste bevindingen van de voorgaande hoofdstukken combineer tot een normatief 
kader voor onderzoeksprofessionals om kinderen op een ethisch verantwoorde manier 
te includeren in medisch-wetenschappelijk onderzoek. Dit kader laat zien hoe we het 
proces van werving en informed consent zo goed mogelijk kunnen laten aansluiten bij 
het perspectief en de behoeften van kinderen en hun ouders.
Het hoofdstuk begint met een overzicht van de stappen in de opzet van onderzoek 
voordat kinderen aan onderzoek kunnen deelnemen. Voordat een onderzoeksvoorstel 
potentiële deelnemers (en hun ouders) bereikt, zijn er andere ethische beslissingen in 
relatie tot het onderzoek genomen waarop de potentiële onderzoeksdeelnemers en 
hun ouders geen invloed hebben. Daarnaast nemen zij uiteraard ook zelf een beslissing 
over deelname. Ik noem die beslissingen gates. Vervolgens stel ik een normatief kader 
voor dat de werving en het informed consent proces afstemt op de perspectieven en 
behoeften van kinderen en hun ouders. Dit kader behandelt vijf aspecten: 1) wie wordt 
gevraagd; 2) wie vraagt; 3) motiverende en ontmoedigende factoren; 4) misconcepties; 
5) informed consent als continu proces. Ik sluit dit hoofdstuk af met enkele ontwikkelin-
gen in medisch-wetenschappelijk onderzoek die vragen om nieuwe onderzoeksinspan-
ningen, beleidswijzigingen en nieuwe ethische richtlijnen. Ik bespreek: digitale technol-
ogie in informed consent, alternatieve vormen van informed consent, het combineren 
van onderzoeksprotocollen, het creëren van readiness cohorts en de implementatie van 













This thesis is a result of a research project funded by ZonMw: The Netherlands Organiza-
tion for Health Research and Development in the program Priority Medicine for Children 
(grant number: 113203203). Part of this program aimed to generate more knowledge on 
the ethical and legal aspects of clinical drug research with children. 
My research focused on the motivations of children and their parents to participate in 
clinical research. Five other research projects in the Netherlands were funded in this pro-
gram with different focus points in pediatric clinical research which resulted in several 
PhD-theses:
• Research by Wendy Bos focused on risk-benefit assessments of RECs and dissent/
resistance of children in pediatric clinical research.1
• Research by Sara Dekking focused on dependency and the research-care distinction 
in pediatric clinical research in oncology.2
• Research by Irma Hein focused on children’s competence to consent to pediatric 
clinical research.3
• Research by Ronella Grootens-Wiegers focused on development of information 
material for children in pediatric clinical research.4
• Research by Mira Staphorst focused on children’s experiences of burden in pediatric 
clinical research.5
imPLementation of resuLts
Relevant results from our distinct research projects were implemented in (upcoming) 
guidelines for clinical research with children. Results from systematic reviews we per-
formed in the research projects were implemented in the ‘Guideline Criteria Research 
with Children’ of the Dutch Association of Pediatrics. The results published in chapter 
5 of this thesis are implemented in this upcoming guideline. Results from the above 
mentioned research projects were also implemented in the revision of the ‘Ethical 
considerations for clinical trials on medicinal products conducted with minors’ of the 
European Commission. The main objective of this revision was to align the document 
with the upcoming Clinical Trials Regulation (EU) No 536/2014 and with the latest in-
sights on research with children. I was a member of the working group lead by the Dutch 
Ministry of Health, Welfare and Sports who drafted this revision. Specific results from my 
research project were implemented in that revision (e.g. results relating to motivations, 
burden and trust in research).
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aPPenDix 1
search strings Per database – chaPter 4
Database
embase
(‘refusal to participate’/de OR ‘patient participation’/de OR ‘parental consent’/de OR (((refus* OR decision* OR decid* OR 
allow* OR reason* OR motivat* OR willing* OR assent* OR consen* OR dissent* OR attitude* OR view* OR perspective* 
OR choos* OR choice*) NEAR/6 (participat* OR nonparticipat* OR enrol*))):ab,ti OR ((conflict/de OR ‘motivation’/de OR 
drive/de OR ‘informed consent’/de) AND (participat* OR nonparticipat* OR enrol*):ab,ti)) AND (‘clinical trial (topic)’/exp OR 
‘pharmacological science’/exp OR ‘clinical research’/de OR ((RCT* OR trial* OR scien* OR research*) NEAR/11 (participat* 
OR enrol*)):ab,ti OR ((‘science in general’/de OR research/de OR ‘medical research’/de OR ‘human experiment’/de) AND 
(pharmacology/exp OR ‘drug therapy’/exp OR (drug* OR pharmaco* OR medication* OR psychopharmacolog*):ab,ti))) AND 
(child/exp OR newborn/exp OR adolescent/exp OR adolescence/exp OR ‘child behavior’/de OR ‘child parent relation’/de OR 
(adolescen* OR infan* OR newborn* OR (new NEXT/1 born*) OR baby OR babies OR neonat* OR child* OR kid OR kids OR 
toddler* OR teen* OR boy* OR girl* OR minors OR underag* OR (under NEXT/1 ag*) OR juvenil* OR youth* OR kindergar* 
OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* OR preschool* OR 
highschool*):ab,ti)
medline
(“refusal to participate”/ OR “patient participation”/ OR “parental consent”/ OR (((refus* OR decision* OR decid* OR allow* 
OR reason* OR motivat* OR willing* OR assent* OR consen* OR dissent* OR attitude* OR view* OR perspective* OR 
choos* OR choice*) ADJ6 (participat* OR nonparticipat* OR enrol*))).ab,ti. OR ((“Conflict (Psychology)”/ OR “motivation”/ 
OR “drive”/ OR “Intention”/ OR exp “informed consent”/) AND (participat* OR nonparticipat* OR enrol*).ab,ti.)) AND (exp 
“clinical Trials as Topic “/ OR “Biomedical Research”/ OR ((RCT* OR trial* OR scien* OR research*) ADJ11 (participat* OR 
enrol*)).ab,ti. OR ((“Science”/ OR research/ OR exp “Human Experimentation”/) AND (exp pharmacology/ OR pharmacology.
xs. OR exp “drug therapy”/ OR drug therapy.xs. OR (drug* OR pharmaco* OR medication* OR psychopharmacolog*).ab,ti.))) 
AND (exp child/ OR exp infant/ OR adolescent/ OR exp “child behavior”/ OR exp “Parent-Child Relations”/ OR (adolescen* 
OR infan* OR newborn* OR (new ADJ born*) OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR 
teen* OR boy* OR girl* OR minors OR underag* OR (under ADJ ag*) OR juvenil* OR youth* OR kindergar* OR puber* OR 
pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* OR preschool* OR highschool*).ab,ti.)
Web-of-science
TS=(((((refus* OR decision* OR decid* OR allow* OR reason* OR motivat* OR willing* OR assent* OR consen* OR dissent* 
OR attitude* OR view* OR perspective* OR choos* OR choice*) NEAR/6 (participat* OR nonparticipat* OR enrol*)))) AND 
(((RCT* OR trial* OR scien* OR research*) NEAR/11 (participat* OR enrol*))) AND ((adolescen* OR infan* OR newborn* OR 
new born* OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR minors OR 
underag* OR under age* OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* 
OR pediatric* OR paediatric* OR school* OR preschool* OR highschool*)))
Pubmed
(refus*[tiab] OR decision*[tiab] OR decid*[tiab] OR allow*[tiab] OR reason*[tiab] OR motivat*[tiab] OR willing*[tiab] OR 
assent*[tiab] OR consen*[tiab] OR dissent*[tiab] OR attitude*[tiab] OR view*[tiab] OR perspective*[tiab] OR choos*[tiab] 
OR choice*[tiab]) AND (participat*[tiab] OR nonparticipat*[tiab] OR enrol*[tiab]) AND (scien*[tiab] OR research*[tiab]) AND 
(adolescen*[tiab] OR infan*[tiab] OR newborn*[tiab] OR new born*[tiab] OR baby[tiab] OR babies[tiab] OR neonat*[tiab] 
OR child*[tiab] OR kid[tiab] OR kids[tiab] OR toddler*[tiab] OR teen*[tiab] OR boy*[tiab] OR girl*[tiab] OR minors[tiab] 
OR underag*[tiab] OR under age*[tiab] OR juvenil*[tiab] OR youth*[tiab] OR kindergar*[tiab] OR puber*[tiab] OR 
pubescen*[tiab] OR prepubescen*[tiab] OR prepubert*[tiab] OR pediatric*[tiab] OR paediatric*[tiab] OR school*[tiab] OR 
preschool*[tiab] OR highschool*[tiab]) AND publisher[sb]
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Psycinfo
(“Participation”/ OR “client participation”/ OR (((refus* OR decision* OR decid* OR allow* OR reason* OR motivat* OR 
willing* OR assent* OR consen* OR dissent* OR attitude* OR view* OR perspective* OR choos* OR choice*) ADJ6 
(participat* OR nonparticipat* OR enrol*))).ab,ti. OR ((exp “Conflict”/ OR exp “motivation”/ OR “Intention”/ OR exp “informed 
consent”/) AND (participat* OR nonparticipat* OR enrol*).ab,ti.)) AND (“clinical Trials”/ OR ((RCT* OR trial* OR scien* OR 
research*) ADJ11 (participat* OR enrol*)).ab,ti. OR ((“Sciences”/ OR Experimentation/ OR) AND (exp pharmacology/ OR exp 
“drug therapy”/ OR (drug* OR pharmaco* OR medication* OR psychopharmacolog*).ab,ti.))) AND (100.ag. OR 200.ag. OR 
“Child Psychology”/ OR exp “Parent-Child Relations”/ OR (adolescen* OR infan* OR newborn* OR new ADJ born* OR baby 
OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR minors OR underag* OR under 
ADJ ag* OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR 
paediatric* OR school* OR preschool* OR highschool*).ab,ti.)
cinahl
(MH “refusal to participate”+ OR MH “Consumer Participation”+ OR (((refus* OR decision* OR decid* OR allow* OR reason* 
OR motivat* OR willing* OR assent* OR consen* OR dissent* OR attitude* OR view* OR perspective* OR choos* OR choice*) 
N6 (participat* OR nonparticipat* OR enrol*))) OR ((MH “Conflict (Psychology)”+ OR MH “motivation” OR MH “drive” OR MH 
“Intention” OR MH “consent”+) AND (participat* OR nonparticipat* OR enrol*))) AND (MH “clinical Trials”+ OR ((RCT* OR 
trial* OR scien* OR research*) N11 (participat* OR enrol*)) OR ((MH “Science” OR MH research) AND (MH “Pharmacy and 
Pharmacology”+ OR MH “drug therapy”+ OR (drug* OR pharmaco* OR medication* OR psychopharmacolog*)))) AND (MH 
child+ OR MH “child behavior”+ OR (adolescen* OR infan* OR newborn* OR (new N1 born) OR baby OR babies OR neonat* 
OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR minors OR underag* OR (under N1 age) OR juvenil* OR 
youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* 
OR preschool* OR highschool*))
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aPPenDix 2
data extraction form – chaPter 4
study number
author and year
Type of study □ Qualitative study: …
□ Quantitative study: …
setting (description)
-  Moment of questioning related to decision and 
participation
-  Real life / hypothetical research / research in 
general
- Therapeutic / non therapeutic
- Parents and /or children
- Separate analysis of parents and children?
- Consenters / non-consenters
study for which participation is asked
study population






motivating factors Parents:… Children:…
Discouraging factors Parents:… Children:…
other outcome measures 
Possible confounders
critical appraisal (including risk of bias)*








□ + / - 
□ -
* With use of the Critical Appraisal Skills Program (CASP) checklists; ** Levels according those set by the Dutch 
Institute for Healthcare Improvement (CBO)
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aPPenDix 3
evidence tabLes – chaPter 4
author, year
Barakat, 2013
Study population: 103 children and 76 AYA’s with 
Asthma or SCD and their 224 caregivers with and 
without prior research experience.
Inclusion criteria: ability to speak and read English.
Exclusion criteria: not mentioned.
Characteristics: consenting and non-consenting 
children (8-18 years) and parents.
Design: quantitative study; written questionnaires 
during regularly scheduled follow-up visits in 
clinic about research in general (including drug 
trials). Exploratory factor analysis to identify latent 
structures.
Motivating factors: patient benefit, trust in safety of research, the 
opportunity costs to engaging in research (parents).
Discouraging factors: mistrust of research and researchers 
(parents).
Other outcomes: proportionality, prior research exposure.
Confounding: not mentioned.
Level of evidence: B
Critical appraisal: large sample size, adapted questionnaire 
for children. No open ended questions, only opinion (yes/no) 
asked about statements. No descriptive results of questionnaire 
published, only the factors in the model. 
Barrera, 2005
Study population: 227 parents of children being seen 
for minor traumatic injuries in 3 pediatric emergency 
departments.
Inclusion criteria: not mentioned.
Exclusion criteria: parents whose children were 
aged 16 years or older, sustained injuries raising 
suspicion of abuse, required IC admission or operative 
intervention.
Characteristics: consenting and non-consenting 
parents (mean age: 34 years).
Design: quantitative study; verbal questionnaires 
about participation in hypothetical clinical drug trial 
(RCT with Phenytoin).
Motivating factors: benefit to child (85%); benefit to other children 
(72%); further medical knowledge (60%).
Discouraging factors: fear of adverse effects (54%); don’t want 
child to be a research subject (39%); need to discuss with family 
first (27%); can’t decide unless in actual situation (26%); fear of 
less than optimal treatment(10%); opposition to medical research 
(9%); do not understand study (9%); religious beliefs 3 (4%); 
do not have time to participate 2 (3%); financial concerns (3%); 
language barrier (3%); prior bad experience with research (1%); 
prior bad experience with medical profession (1%); other (21%).
Other outcomes: ethnicity and household income associated with 
consent decision.
Confounding: hypothetical protocols.
Level of evidence: B
Critical appraisal: large population size; good thing that 
questioning of reasons was not predefined. hypothetical study, 
and critical ill children were excluded, therefore maybe not 
applicable to real situation.
Berg, 2010
Study population: 53 subjects who participate in a 
phase 1 anticancer drug study. 
Inclusion criteria: consent or dissent to PK sampling.
Exclusion criteria: not mentioned.
Characteristics: 8 adult subjects, 4 adolescents 
and 38 parents/legally authorized representatives; 
consenting and non-consenting.
Design: quantitative study; written questionnaire 
administered within 4 weeks after consent to phase 
1 drug study about (non)consenting to extra PK 
sampling within study.
Motivating factors: 97% defined altruistic reasons as very or 
extremely important; 83% ranked “no extra pain or harm to child” 
as very or extremely important.
Discouraging factors: Large percentage defined time and need for 
an extra IV as important concern.
Other outcomes: additional comments by subjects.
Confounding: no attempt to control for demographic factors.
Level of evidence: C
Critical appraisal: bad quality; no distinction between children, 
parents and adult participants; content of questionnaire not clear.
192 Addendum
Brody, 2005
Study population: 36 adolescent-parent dyads 
(predominantly mothers) of which children had a 
prior diagnosis of asthma.
Inclusion criteria: child with prior diagnosis of asthma.
Exclusion criteria: not mentioned.
Characteristics: 2 guardians, 34 parents (30-60 years) 
and 36 adolescents (11-17 years); consenters and 
non-consenters.
Design: quantitative study; separate interviews about 
willingness to participate after presentation of 9 
hypothetical asthma research protocols.
Motivating factors: parents: perception of research benefit 
(45%), Children: perception of research benefit (40%), financial 
compensation (10%).
Discouraging factors: parents: concern over hassle (25%), risk 
(25%), discomfort (3%); children: concern over hassle (35%), risk 
(10%), discomfort (7%).
Other outcomes: 60% of the time parents and adolescents held 
concordant views on participation decisions.
Confounding: parents and children were interviewed separately, 
this differs from actual process; order of protocols was 
systematically varied but could have an influence on decision.
Level of evidence: C
Critical appraisal: positive and negative responses of willingness 
to participate are grouped together.
Brody, 2012
Study population: 111 adolescents with asthma and 
their 111 parents.
Inclusion criteria: prior diagnosis of asthma, English 
speaking, child between 11 and 17 years of age.
Exclusion criteria: not mentioned.
Characteristics: mean age adolescents 13.6 
(range:10-17); parents mean age 41.9 years, 93% 
at least high school diploma; consenters and non-
consenters.
Design: quantitative study; development of 
conceptual model of research participation decisions 
is developed. adolescents and parents are interviewed 
about hypothetical asthma research protocol 
(informed by video).
Motivating factors: benefit and financial compensation are factors 
in model for adolescents and parents.
Discouraging factors: perceived risks is factor in model for 
adolescents and parents.
Other outcomes: 67% of parents and adolescents agreed on the 
participation decision.
Confounding: demographic variables, level of comprehension.
Level of evidence: C
Critical appraisal: small sample size to build a model on with that 
many variables; single hypothetical protocol.
Broome, 2003
Study population: 34 children and adolescents 
with DM or hematological malignancies requiring 
treatment who are/were previous enrolled in research.
Inclusion criteria: consent from parent, > 7 years of 
age, diagnosed with a health condition requiring 
treatment, enrolled in a research study within the 
last 2 months, speaks English, at least one English-
speaking parent who is also willing to be interviewed.
Exclusion criteria: not mentioned.
Characteristics: age range: 8-22 years; 23 with 
hematologic malignancy, 10 with DM; only 
consenters.
Design: qualitative study; tape-recorded semi 
structured interviews at home or in hospital about 
various drug studies.
Motivating factors: the monetary incentive that was offered (DM 
patients).
Discouraging factors: time involved and number of needle sticks 
(DM patients).
Other outcomes: influence/relationship with parents.
Confounding: not mentioned.
Level of evidence: -
Critical appraisal: bad quality, only results from DM patients 
presented, limited information from interviews, article does not 
answer their research question.
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Buscariollo, 2012
Study population: 166 parents of children with DM1.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: 81% female, 90% Caucasian; 
consenters and non-consenters; 
Design: quantitative study; 48-item written 
questionnaire including open-ended, yes/no and 
5-point responses to assess parental attitudes towards 
DM1 clinical trials and willingness to participate 
(research in general and hypothetical trials).
Motivating factors: potential benefit for their own child 
(92%), potential benefit for other children in the future (87%), 
opportunity to contribute to science (43%), influences of family 
and friends (31%), financial compensation (32%), increased 
physician access at no additional cost (47%).
Discouraging factors: risk of side effects associated with trial 
participation (57%), discomfort with consent by proxy or making 
decisions about trial participation for their children (27%), fear 
of having to pay for research treatment (30%), lack or cost of 
transportation (30%), child’s fear of receiving injections (19%).
Other outcomes: prediction factors for WTP; comfort scores with 
different types of trials.
Confounding: possible non-response bias effects.
Level of evidence: B
Critical appraisal: extensive description of results, but very low 
response rate.
cain, 2005
Study population: 36 children who had participated in 
a trial comparing insulin detemir with NPH in a multi-
injection therapy for type 1 diabetes.
Inclusion criteria: from UK and Ireland; age between 
6-17 years.
Exclusion criteria: not mentioned.
Characteristics: consenting children; 6-11 years: 17%; 
12-14 years: 58%; 15-17 years: 25%.
Design: quantitative study; non-validated, 23-item 
postal questionnaire, child friendly written with 
graded scales, numerical scales and free text 
responses to examine attitudes and experiences to 
drug trial participation.
Motivating factors: “I wanted to improve my blood sugar control”: 
30%; “I thought it would be interesting”: 21%; “I wanted to help 
other people with diabetes”: 19%; “My mum/dad thought it would 
be a good idea”: 9%; “I wanted to know more about my diabetes”: 
6%; “My friend was doing it”: 2%; “I wanted to use the pen”: 4%; 
“I wanted to be helpful in any way I could”: 2%; “I wanted more 
flexibility with my insulin/diabetes”: 6%.
Discouraging factors: not mentioned.
Other outcomes: 81% would take part in a future trial; experiences 
during participation, information provided.
Confounding: trial participants are a self-selecting group 
and sample used in this study is small; therefore, may not be 
representative of the general pediatric population
Level of evidence: C
Critical appraisal: child friendly questionnaire used, only 
consenters questioned, high response rate; non-validated 
questionnaire.
caldwell, 2003
Study population: 33 parents with sick children from 
children’s hospital and with healthy children from 
local primary school.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: healthy children: 27%, acute 
illness: 18%, chronic illness: 15%, cancer: 18%, RCT 
participants: 21%; 73% with previous research 
experience.
Design: qualitative study; 4 focus groups and 5 
individual interviews to explore attitudes towards 
child’s participation in RCTs; data coded using 
constant comparative methods and further examined 
to identify emergent overarching themes.
Motivating factors: perceived benefits, doctor factors, child 
factors.
Discouraging factors: perceived risks, trial factors, parental factors.
Other outcomes: proportionality.
Confounding: not mentioned.
Level of evidence: +
Critical appraisal: comprehensive description of results; paid 
attention to different backgrounds and settings; no distinction 
between focus groups and individual interviews and no 
distinction based on previous research experience.
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cartwright, 2011
Study population: 16 parents of 12 infants born 
with complications who had participated in an RCT 
(immunotherapy, ventilation, hypothermia).
Inclusion criteria: parents read and speak English 
fluently; parents’ infants had participated in a RCT in 
the previous 18 months while receiving intensive care 
in the NICU.
Exclusion criteria: not mentioned.
Characteristics: 10 mothers (27-36 years), 6 fathers 
(27-36 years); all white Europeans, all consenters.
Design: qualitative study; semi-structured face-to-face 
interviews after trial participation; open-ended and 
closed questions.
Motivating factors: themes from interviews.
Discouraging factors: not mentioned.
Other outcomes: immediate reactions, interaction with clinician, 
implications of RCT, effect of RCT.
Confounding: parental responses may have been affected by time 
lag between participation and interview.
Level of evidence: +
Critical appraisal: small sample size, elaborate results from 
interviews, no discouraging factors mentioned.
cherill, 2010
Study population: 98 healthy children at secondary 
school and 117 children with a chronic illness at 
outpatient clinic or hospital.
Inclusion criteria: child and parent in agreement to 
participate.
Exclusion criteria: not mentioned.
Characteristics: healthy children: median age 13 (11-
16) years. Chronic ill children: median age: 14 (11-16) 
years. 
Design: quantitative study; written questionnaire 
about viewpoints of research in general (including 
drug trial) including closed questions and 3 
hypothetical scenarios.
Motivating factors: Helping others was the most common reason 
given for taking part in clinical trials. Altruistic nature of children in 
both groups was similar.
Discouraging factors: not mentioned.
Other outcomes: Alarming: 57-63% of children would participate 
in a cancer drug trials as a healthy volunteer.
Confounding: not mentioned.
Level of evidence: B
Critical appraisal: bad quality, only small part of results published; 
abstract and discussion mention altruistic motives, but not results 
not presented. 
Deatrick, 2002
Study population: 21 parents of children participating 
in phase 1 oncology trial.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: 19 mothers, 2 fathers; children: 2-18 
years. Only consenters.
Design: qualitative study; descriptive cross-sectional 
study with secondary analysis techniques to analyze 
existing qualitative data from two studies of parents’ 
decision-making at end of life for their children with 
cancer.
Motivating factors: prolong life for their child / delaying death; 
buying time for another therapy; providing treatment; working 
a miracle; desire to help other children with cancer in the future; 
practical concerns (including location and proximity of available 
treatment, ability to secure treatment in the near future and issues 
related to quality of life), child’s physical condition (good shape).
Discouraging factors: child’s physical condition (weak).
Other outcomes: all parents saw limited choices or no choices 
in the decisions about whether to enter their child in a phase 1 
clinical trial. 
Confounding: not mentioned.
Level of evidence: +
Critical appraisal: article only mentions some aspects of parents’ 




Study population: 68 parents who had volunteered 
their child for a randomized, double, blind, placebo-
controlled trial of ketotifen (new drug for asthma) and 
42 parents who had refused this participation.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: majority Caucasian, majority between 
(20-29 years of age).
Design: quantitative study; verbal questionnaire 
consisting of 48 structured and 2 open ended 
sections to assess perceptions, attitudes, and health 
seeking behavior of the parents.
Motivating factors: to benefit my own child: N=61; dissatisfaction 
with current treatment: N=56; to learn more about medical 
treatment: N=51; liked the people conducting the trial: N=49; 
to meet people: N=45; trust in the hospital: N=33; to gain better 
access to health care: N=26; advice of family doctor: N=10; advice 
of others: N=8; reimbursement of travel cost: N=8.
Discouraging factors: fear of side effects of the new drug: N=40; 
inconvenience of frequent visits: N=35; dislike of becoming 
involved: N=33; lack of time: N=23; distrust of modern medicine: 
N=22; loss of privacy: N=14; Not interested: N=10; distrust of the 
hospital: N=8; extra cost entailed: N=5.
Other outcomes: difference between consenters and non-
consenters: socio-demographic characteristics, health seeking 
behavior, availability of social support.
Confounding: no selection bias in recruitment.
Level of evidence: B
Critical appraisal: moment of questionnaire in relation to decision 
not clear. Large response rate, no response bias expected.
hoberman, 2013
Study population: 120 parents who were asked 
to provide consent for their child’s participation 
in a randomized controlled trial of antimicrobial 
prophylaxis for vesicoureteral reflux.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: 48 consenters, median age: 31 years; 
62 non-consenters, median age 33 years; majority 
Caucasian.
Design: quantitative study; written questionnaire 
consisting of Likert scales and VAS. Examining 
difference between consenters and non-consenters 
in 7 constructs governing the decision to provide 
consent. 
Motivating factors: significant differences between consenters 
and non-consenters: trust in research; perceiving researcher as 
friendly/professional; benefit to their child; benefit to others 
(altruism); importance of study.
Discouraging factors: significant differences between consenters 
and non-consenters: interference of study with standard of care; 
feelings of anxiety and decisional uncertainty.
Other outcomes: child-, parent- and study characteristics, parental 
perception of the study, parental understanding of study design, 
external influences, decision-making process.
Confounding: overrepresentation of higher levels of education 
in non-consenters; less than 50% response rate (no difference 
between consenters/non-consenters.
Level of evidence: B
Critical appraisal: good quality. Questionnaire based on previous 
research. But very low response rate and no in and exclusion 
criteria mentioned.
hoehn, 2005
Study population: 34 parents of 24 neonates having 
cardiothoracic surgery invited to participate in a 
study evaluating the impact of prenatal diagnosis on 
parental permission for neonatal cardiac surgery.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: 14 fathers, 20 mothers; majority 
Caucasian.
Design: qualitative study; Qualitative analysis of the 
unsolicited comments (spontaneously mentioned) of 
parents regarding reasons for agreeing or declining to 
participate in research studies.
Motivating factors: societal benefit (N=18/53%) (pro-reason); 
individual benefit to their infant (N=16/47%) (pro-reason); 
perception of no risk of harm (N=9/26%) (neutral reason).
Discouraging factors: risk of study participation (N=10/29%) 
(con-reason); Anti-experimentation (feeling like a guinea pig) 
(N=4/12%) (con-reason).
Other outcomes: comparison of reasons for consenters and non-
consenters.
Confounding: not mentioned.
Level of evidence: +
Critical appraisal: strong point: spontaneous comments, no 




Study population: 19 child-parent dyads enrolled in 
an RCT with investigational drug or an open-label trial 
with licensed drug (psychopharmacology)
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: children’s mean age: 11 years, range: 
7-15 years; all boys; 15 consenters, 3 non-consenters, 
1 undecided.
Design: qualitative study; interviews by use of 
MacArthur Competence Assessment Tool for Clinical 
Research; analyzed with qualitative content analysis.
Motivating factors: hopes for improvement of their own behavior 
based on experience (with benefit for themselves and/or for their 
families); Comfort (new medication easier to handle); explorative 
behavior/sensation seeking (the chance to test something new).
Discouraging factors: changes in treatment settings; Time spent; 
Burden of study examinations (blood-drawings); feeling like a 
guinea pig.
Other outcomes: proportionality, understanding, appreciation.
Confounding: IQ and experience influences reasoning. 
Level of evidence: +
Critical appraisal: comprehensive elaboration of interview results. 
Children and parents interviewed, but results of reasoning of 
parents not described, only reasons of children.
lebensburger, 2013
Study population: 14 parents or guardians of children 
(with SCD) with no prior experience with clinical trials 
or hydroxyurea therapy
Inclusion criteria: not mentioned
Exclusion criteria: not mentioned
Characteristics: 3 males, 11 females; average age: 42 
years (31-56); all African-American. 
Design: qualitative study; 3 focus groups addressing 
7 main questions and a mock recruitment pamphlet 
for a hypothetical feasibility trial of hydroxyurea for 
prevention of secondary silent cerebral infarcts.
Motivating factors: improvement child’s life, discuss trial with 
other participants, increased clinic visits
Discouraging factors: General mistrust of research studies, 
emotional issues (burden for child), practical issues (time required, 
missing work etc.), randomization, long term unknown risks, 
Other outcomes: -
Confounding: possibly response bias.
Level of evidence: +
Critical appraisal: Weak point: no in- and exclusion criteria and 
little info on patient characteristics. Strong point: accurate and 
visible coding of themes.
liaschenko, 2001
Study population: 12 fathers of children diagnosed 
with cancer and involved in a clinical cancer research 
study at a children’s hospital.
Inclusion criteria: fathers with a child who: was 
diagnosed with cancer, had participated in clinical 
research within last year, was at least 8 years of age, 
had at least one parent who was legally authorized to 
give informed consent.
Exclusion criteria: not mentioned.
Characteristics: majority Caucasian, children’s mean 
age: 13.5 years. All consenters.
Design: qualitative study; focused interviews in 
private setting to explore meanings of research and 
reasons for participation.
Motivating factors: altruism; no other option available; Possibility 
of and hope for direct improvement without significantly 
increasing the risk of more harm; Maximize the child’s chance of 
survival.
Discouraging factors: not mentioned.
Other outcomes: description of life context, description of 
meanings of research
Confounding: reasons for participation interact with meanings of 
participation and type of research.
Level of evidence: +
Critical appraisal: well defined methodology; Only brief 
description of results from interviews, very aggregated.
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macneill, 2013
Study population: 42 parents of children participating 
in a randomized double-blind placebo-controlled trial 
of Montelukast for preschool wheeze
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: 10 males, 32 females; mean age: 36 
years; 20 Bangladeshi, 10 white UK, 12 other. 
Design: qualitative study; semi-structured interviews 
to compare the motives and experiences of different 
ethnic groups.
Motivating factors: Benefit to child (21/42). Benefit to others 
(15/42); trust in the research team (3/42); Route to additional 
information, treatment and attention.
Discouraging factors: No benefit, adverse effects, randomization 
to placebo.
Other outcomes: experience of consent process; understanding 
research process, consulting others. Difference between ethnic 
groups.
Confounding: No non-consenters and Bangladeshi parents 
underrepresented.
Level of evidence: +
Critical appraisal: Good quality; transparent: coding example in 
article. Elaborate description of results.
masiye, 2008
Study population: 81 female guardians of children 
participating in the Intermittent Prevention Therapy 
post-discharge (IPTpd) Malaria Research
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: 39 from rural area, 42 urban area; 
mean age rural: 29 years, mean age urban: 28 years; 
education rural: 6 years, education urban: 9 years; All 
consenters. 
Design: qualitative study; 8 focus groups to assess the 
reasons why mothers enroll their children in malaria 
clinical research and how family members or relatives 
are involved in the decision-making process.
Motivating factors: majority wanted their children to receive 
better treatment, participants wanted to benefit from the material 
and monetary incentives that were given, sense of trust in the 
health workers, attention by health care workers
Discouraging factors: Not mentioned
Other outcomes: perspective on the informed consent process 
and role of partner in decision-making process.
Confounding: not mentioned
Level of evidence: +
Critical appraisal: sufficient quality; Weak point: no in- and 
exclusion criteria mentioned. Strong point: inclusion of themes 
and quotations of participants.
menon, 2012
Study population: 54 non-consenting legal guardians 
who were approached for consent for any ongoing 
PICU research.
Inclusion criteria: not mentioned.
Exclusion criteria: surveys and chart audits.
Characteristics: 54 non-consenters; Children’s age: 
0.6 years.
Design: Quantitative study; prospective, observational 
study with recording of demographic data and 
unsolicited reasons stated by legal guardians for 
consent refusal.
Motivating factors: not mentioned.
Discouraging factors: Guardian too stressed: N=24; Blood taking 
required for study: N=13; Medication administration required for 
study: N=3; Radiation required for study: N=2; Guardian does not 
agree with research: N=8; Already in another study: N=6
Discord between guardians: N=2; Child has been through enough: 
N=7
Other: N=28.
Other outcomes: description of patient and study demographics.
Confounding: not mentioned.
Level of evidence: B
Critical appraisal: Positive: unsolicited reasons, no suggestions. 
Only reasons for refusal stated by non-consenters.
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miller, 2013
Study population: 20 adolescents with cancer who 
were offered participation in a phase 1 trial.
Inclusion criteria: permission from parent and 
adolescent.
Exclusion criteria: not mentioned.
Characteristics: median age: 17.8 years; 7 participants: 
14-17 years, 13 participants: 18-21 years; majority 
male and Caucasian; all consenters.
Design: Quantitative study; verbal questionnaire 
with closed and open-ended questions to examine 
adolescents perspectives.
Motivating factors: Positive clinical effect: N=15 (75%); No other 
options: N=9 (45%); Positive impact on quality of life: N=8 
(40%); Few or fewer side effects: N=8 (40%); Logistics related to 
participation (e.g., ‘‘It’s easy to do.’’): N=6 (30%); Previous testing/
availability of trial drug: N=5 (25%); To help science and other 
children: N=4 (20%); Doctor’s recommendation: N=3 (15%); Other: 
N=5 (25%).
Discouraging factors: not mentioned.
Other outcomes: Experience of process, expectations.
Confounding: perceptions are likely not biased by trial 
participation or change in health status (due to little time 
between consent and interview).
Level of evidence: C
Critical appraisal: elaborate interpretation of results. Positive that 
reasons were not predefined, but an open question.
norris, 2010
Study population: 20 adolescents and their parents 
refused to participate in an RCT involving olanzapine 
for the adjunctive treatment of anorexia nervosa.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: all female, median age 15.4 years; all 
non-consenters.
Design: Quantitative study; secondary descriptive 
analysis of reasons provided by patients and their 
parents for refusal of study participation. already 
available data.
Motivating factors: not applicable
Discouraging factors: Adolescents: Not interested in taking 
any psychotropic medication / fears associated with effects of 
medication (i.e. weight gain): N=7; Refused randomization N=2; 
Fears associated with participation in research trial N=2. Parents: 
Not interested in or wanting child on any psychotropic medication 
/ fears associated with side effects of medication (i.e. potential for 
diabetes) N=7; Refused randomization N=2.
Other outcomes: 55% (n=11) of refusals were patient (adolescent) 
driven.
Confounding: not mentioned.
Level of evidence: C
Critical appraisal: Bad quality; little information, too broad 
description of reasons, small sample size, very specific population, 
with specific reasons for refusal (probably related to effect of trial 
(weight gain), not generalizable.
oppenheim, 2005
Study population: mother who accepted her daughter 
to be included in a phase 1-2 oncology trial.
Inclusion criteria: not applicable.
Exclusion criteria: not applicable.
Characteristics: mother of a child 7 years old treated 
since age of 2 for malignant germinal tumor, 
consented to trial.
Design: Qualitative study; secondary analysis of an 
interview of a mother with a psycho-oncologist to 
discuss relational, psychological and ethical issues of 
phase 1-2 trials.
Motivating factors: motivating themes identified in interview.
Discouraging factors: discouraging themes identified in interview.
Other outcomes: other themes.
Confounding: not mentioned.
Level of evidence: +




Study population: 23 caregivers of patients with SCD, 
16 pediatric patients with SCD and (13 AYA’s with SCD)
Inclusion criteria: fluent in English
Exclusion criteria: not mentioned
Characteristics: 21 male/2 female caregivers, median 
age: 42.1 years; 8 female/8 male children, median age: 
12.6 years; majority African American. Consenters and 
non-consenters.
Design: Qualitative study; semi-structured interviews 
asking about previous research experience and 
reasons to enroll and assessment of 2 vignettes 
(placebo-controlled drug trial and psychosocial 
study).
Motivating factors: parents consenting to drug vignette: potential 
benefit (42.9%), altruism (43.5%), trust (13.3%), manageable study 
demands; children consenting to drug vignette: potential benefit 
(37.5%), altruism (37.5%), manageable study demands.
Discouraging factors: parents dissenting to drug vignette: 
potential harm (71.9%), unmanageable study demands (28.1%); 
children dissenting to drug vignette: potential harm (55.6%), 
unmanageable study demands (44.4%).
Other outcomes: reasons for previous participation, ranking of 
statements. Weighing of proportionality.
Confounding: sampling bias. Results from hypothetical studies 
might not correlate with actual decision.
Level of evidence: +
Critical appraisal: Sufficient quality; no actual responses of 
participants visible, only coding groups. But elaborate results 
presented.
Pletch, 2001
Study population: 33 mothers of children diagnosed 
with cancer or DM1 and involved in clinical research 
studies (including drug trials).
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: 24 mothers of child with cancer 
(child’s mean age: 12.5 years), 9 mothers of child with 
DM1 (child’s mean age: 10.6 years); all consenters.
Design: Qualitative study; Semi-structured interviews 
with mothers. Narrative analysis techniques used to 
identify patterns in experiences.
Motivating factors: Cancer group: to save the life of their child, 
benefit they were looking was life over death; DM1: consider 
personal benefits that might accrue for their child, as well as 
societal benefits, contribution to improved knowledge about 
diabetes care for other children.
Discouraging factors: DM1: some mothers thought that 
diabetes was all the burden a child should be asked to bear, 
inconveniences.
Other outcomes: other themes related to experiences, 
proportionality.
Confounding: not mentioned.
Level of evidence: +
Critical appraisal: Positive: open questions about reasons, not 
predefined. Elaborate comparison between the two groups; No 
info about in- and exclusion criteria. Number of participants not 
consistent in article.
Pletch, 2001 (2)
Study population: 9 mothers of children with DM1 
and involved in clinical research (2 drug trials) at 
children’s hospital.
Inclusion criteria: child at least 9 years of age and prior 
experience with participating in a clinical trial.
Exclusion criteria: not mentioned.
Characteristics: Mean age mothers: 42 years, all 
European and high school graduates; mean age 
children: 10.6 years (range: 9-13 years).
Design: Qualitative study; semi-structured interviews 
with mothers to identify patterns influencing consent 
to clinical research.
Motivating factors: Continued well-being of their child; must be 
some direct and immediate advantage for their child (personal 
benefit); opportunities.
Discouraging factors: Risks.
Other outcomes: 3 steps in decision-making; interaction parent/
child.
Confounding: sample cannot be taken as representative of the 
general population of mothers of chronically ill children nor all 
mothers of children with diabetes.
Level of evidence: +
Critical appraisal: Strength: 2 members independently performed 
analysis, very elaborate description and analysis of results; 
Weakness: very homogenous group.
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read, 2009
Study population: 86 Adolescents and young adults 
diagnosed with cancer and 409 parents of children 
with cancer at 5 pediatric oncology centers.
Inclusion criteria: recall of being offered participation 
in health research; >12 years of age
Exclusion criteria: not mentioned.
Characteristics: AYA’s median age: 18 (12-22) years 
(50% consenters); parents median age: 40 (15-74) 
years (64% consenters).
Design: Quantitative study; validated postal 
questionnaires to describe personal factors that 
may influence decision to participate. Descriptive 
statistics and associations between demographic 
characteristics and attitudes were described.
Motivating factors: I thought it would help others: AYA: 67%, P: 
85%; I thought it would help me/my child: AYA: 26%, P: 60%; I 
thought it would not add too much discomfort: AYA: 19%, P: 20%; 
I felt pressure from my doctor to take part: AYA: 19%, P: 21%; I 
felt pressure from my family or friends to take part: AYA: 7%, P: 
3%; I thought it would not add too much time: AYA: 6%, P: 13%; I 
did not have any choice taking part in the study: AYA: 2%, P: NA; 
Other: AYA: 1%, P: 8%.
Discouraging factors: Study required too much of my time: AYA: 
45%, P: 13%; I had too much else to think about at the time: AYA: 
36%, P: 21%; I did not think it would help me: AYA: 18%, P: 13%; 
Study required me to undergo increased discomfort: AYA: 18%, 
P: 26%; I did not want to be a guinea pig: AYA: 9%, P: 11%; Study 
too hard to understand: AYA: 9%, P: 5%; I did not trust the person 
offering me the study: AYA: 0%, P: 3%; Too risky: AYA: 0%, P: 13%; 
Other: AYA: 1%, P: 37%.
Other outcomes: factors influencing participation of parents 
themselves in research.
Confounding: altruistic motives could have been influenced by 
social acceptability.
Level of evidence: B
Critical appraisal: Large sample size. Very little response on 
discouraging factors. AYA’s include minors and adults. 
rothmier, 2003
Study population: 44 parents or guardians of children 
less than 18 years of age who were currently involved 
in clinical asthma research.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: parents’ mean age: 40 years, majority 
Caucasian females; children’s age between 4 and 7 
years. All consenters
Design: Quantitative study; 2-page questionnaire 
administered in person containing 14 liker-type 
questions. Factors influencing parental consent were 
ranked on liker-scale.
Motivating factors: Most influential: Learn more about disease; 
Help medical knowledge; Newest drugs.
Discouraging factors: not mentioned.
Other outcomes: factors less convincing/ important influencing 
decision.
Confounding: not mentioned.
Level of evidence: C
Critical appraisal: Small sample size for quantitative study. 




Study population: 136 parents of children who were 
recruited for a multicenter randomized equivalence 
trial comparing oral and intravenous treatment for 
pneumonia.
Inclusion criteria: children aged 6 months to 16 
years with fever, respiratory symptoms or signs and 
radiologically confirmed pneumonia.
Exclusion criteria: not mentioned.
Characteristics: children’s median age: 2.0 years (6 
months-12 years). Consenters and non-consenters
Design: Quantitative study. Short postal questionnaire 
administered after trial participation, with free text 
questions and agree/disagree questions to assess 
what motivates parents to consent to an RCT.
Motivating factors: benefit to all children in the future: 32%; 
contribution to science: 27%; benefit to their own child: 19%; 
asked by a doctor: 13%; no reason not to: 7%.
Discouraging factors: wanting a specific treatment for their child 
/ unwilling to undergo randomization (N=25); Do not want to 
participate in a trial (N=2); too distressed by their child’s admission 
(N=2); PIF stated that the ethics committee would have access to 
their child’s data (N=1).
Other outcomes: factors influencing decision in future studies.
Confounding: possible overestimation of positive attitudes, due to 
low response rate; recall bias (different recall windows).
Level of evidence: C
Critical appraisal: good quality of questions (mix of open-ended 
and closed questions).
Little information about study population.
Tait, 2003
Study population: 505 parents/guardians who had 
been approached to allow their child to participate in 
any one of 18-ongoing clinical anesthesia or surgery 
studies.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: parents’ mean age: 37.1 years; child’s 
mean age: 7.2 years; 411 consenters, 94 non-
consenters.
Design: Quantitative study; questionnaire filled in by 
parents during participation of their child in trial to 
identify factors influencing their decision.
Motivating factors: positive predictors for consent: perceived 
benefits to child; perceived importance of study.
Discouraging factors: negative predictor for consent: perceived 
risk of study.
Other outcomes: factors influencing decision for future studies; 
interaction parent/child.
Confounding: not mentioned.
Level of evidence: B
Critical appraisal: Large sample size, large amount of data 
collected, elaborate description of results.
Tait, 1998
Study population: 246 parents/guardians who had 
been approached for permission to allow their 
child to participate in any one of several anesthesia 
research studies currently underway at the C.S. Mott 
Children’s Hospital. 
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: No demographic differences between 
consenters and non-consenters; 168 consenters, 78 
non-consenters.
Design: Quantitative study; written questionnaire 
detailing reasons for their decision. Reasons were 
analyzed by principal component analysis.
Motivating factors: Minimal risk to child: 86.1%; Other children 
might benefit: 83.7 %; Study was explained well: 77.9%; 
Understood the study: 77.5%; Study was important: 67.9%; 
Contribute to medical science: 69.1%; Risk was small in relation 
to the importance of the study: 68.8%; Child might benefit: 
51.2%; The researcher put you at ease: 44.7%; Sufficient time 
to decide: 36.1%; Child would receive “better” care: 13.0%; Felt 
uncomfortable saying “no”: 4.4 %; Felt obligated to consent: 3.1%.
Discouraging factors: Fear for safety of child: 61,6%; Potential risk 
to child: 59,7%; Randomized to placebo or drug: 40,8%; Another 
“thing“ to worry about: 35,6%; Fear of unknown: 35.2%; Study 
might interfere with care: 21,1%; Insufficient time to decide: 15,3%; 
Child would be a “guinea pig”: 15,3%; Distrust of medical system: 
5,6 %; Moral/religious reasons: 4,2 %; Did not understand study: 
2,8%; No privacy to decide: 2,8%; No financial compensation: 1,4%; 
Researcher made you feel uncomfortable: 1,4%.
Other outcomes: factors influencing decision for future studies.
Confounding: not mentioned.
Level of evidence: B
Critical appraisal: large sample size and large response rate. 
Reliability of questionnaire tested.
202 Addendum
Truong, 2011
Study population: (205 adult patients) and 48 parents 
of pediatric cancer patients participating in phase I, II, 
or III clinical trials of cancer-directed therapy.
Inclusion criteria: consent to a qualified cancer trial 
within the previous 14 days.
Exclusion criteria: consent obtained by an investigator 
of the present study, consent obtained in another 
language than English, email-address outside USA, 
participant removed from trial within 14 days, 
participant died.
Characteristics: parents’ mean age: 38.8 years, majority 
Caucasian and female; 20% phase I, 18% phase 2, 
961% phase 3. All consenters.
Design: Quantitative study; postal questionnaire 
including 9 statements of motivations for 
participation (with a focus on altruism).
Motivating factors: To help future patients: 50%; To help advance 
medical science: 49%; To receive medical benefits: 48%; I trust the 
doctor: 46%; I trust this hospital: 54%
To maintain hope: 54%.
Discouraging factors: not mentioned.
Other outcomes: Being motivated primarily by altruism was 
positively correlated with phase of trial.
Confounding: limited socio-demographic diversity, therefore 
limiting generalizability.
Level of evidence: C
Critical appraisal: predefined reasons (socially acceptable 
answering?); Focus on altruism in results, therefore other reasons 
are underexposed.
van stuijvenberg, 1998
Study population: 181 parents or guardians who had 
volunteered their child for a randomized, double 
blind, placebo-controlled trial of ibuprofen to prevent 
febrile seizure recurrences.
Inclusion criteria: children between 1 and 4 years old; 
with a recognized risk of febrile seizure recurrence; 
parents were Dutch or English speaking; child had 
visited the emergency room of the Sophia Children’s 
Hospital in Rotterdam or the Juliana Children’s 
Hospital in Den Haag because of a febrile seizure.
Exclusion criteria: not mentioned.
Characteristics: 181 mothers (median age: 32.6 years) 
and 155 fathers (median age: 35.6 years) of 181 
children; majority West-European; all consenters. 
Design: Quantitative study; postal questionnaire with 
structured and semi-structured questions to assess 
the quality of the informed consent process.
Motivating factors: Contribution to clinical science (n = 92; 51%); 
Benefit for their own child (n = 58; 32%); Give something in return 
for the care of their child (n = 12; 7%); Benefit for other children 
in future (n = 5; 3%); Benefit for the parent (n = 6; 3%); The doctor 
asked (n = 6; 3%); No major reason (n = 2; 1%).
Discouraging factors: not mentioned.
Other outcomes: comprehensibility of information, awareness of 
6 major trial characteristics, perception of the informed consent 
procedure; factors influencing decision for future studies.
Confounding: possible overestimation of positive experiences, 
possibility of socially desirable answers.
Level of evidence: C
Critical appraisal: Good quality; sufficient sample size, 
questionnaire partially validated. 
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vanhelst, 2013
Study population: 261 parents of children who 
participated in pediatric clinical research at Lille 
Clinical Investigation Centre of the Lille University 
Hospital.
Inclusion criteria: Pediatric clinical research study 
conducted between 2004 and 2007; Child aged 
between 1 and 18 years. 
Exclusion criteria: Pediatric clinical research studies 
involving neonates hospitalized in the intensive care 
unit; Children enrolled in oncology pediatric clinical 
research studies, who were a highly specific group 
of patients with an immediate, potentially poor 
outcome; Babies enrolled in industrial milk formula 
studies; Other studies involving children aged less 
than one year.
Characteristics: 126 parents of healthy children, 
99 ambulant sick children, 36 non-ambulant sick 
children. All consenters.
Design: Quantitative study; postal questionnaire 
with closed questions to identify motivating factors 
linked to child health status that affected consent to 
participation.
Motivating factors: Direct benefits to the parents’ own child of 
participating in the study; Benefits to the general population; Low 
risk to the child of participating in the study; Understanding the 
study and its regulation (percentages per group).
Discouraging factors: not mentioned.
Other outcomes: factors that improve parents’ acceptance for 
consent.
Confounding: not mentioned.
Level of evidence: B
Critical appraisal: Large sample size, not clear what kind of 
research it consists of, only 4 predefined reasons questioned.
Wagner, 2006
Study population: 90 youths and their parents 
who participated in the clinical treatment 
research program in child and adolescent 
psychopharmacology at an academic medical center.
Inclusion criteria: not mentioned.
Exclusion criteria: not mentioned.
Characteristics: children’s mean age: 12.37 years 
(range:6-17), 48% female, 72% Caucasian; parents’ 
mean age: 40.91 years, 82% female, 79% Caucasian; 
all consenters.
Design: Quantitative study; Written pre- and 
post-study questionnaire to assess attitudes and 
experiences prior to and upon completion of study.
Motivating factors: Parents: Get treatment for my child 60%, Find 
out about my child’s problem 30%, My child’s prior treatment 
was unsuccessful 5%, Financial reimbursement for visits 2%, 
Dissatisfied with my child’s prior treatment 1%, Treatment is free 
1%; Youths: To get help for my problem 43%, To find out what is 
bothering me: 20%, My parent told me to be in the study: 14%, I 
will get money when I come here: 11%, To help other people with 
problems: 4%, My doctor told me to be in the study: 4%, Other: 
3%, Treatment is free: 1%.
Discouraging factors: not mentioned. 
Other outcomes: post study questionnaire results.
Confounding: not mentioned.
Level of evidence: C
Critical appraisal: very different drug trials included; people could 
only give one reason for participation; probably other reasons 
matter for them also; pre and post questionnaire is a surplus value.
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Wendler, 2012
Study population: 177 adolescents participating in 
research at the NIH Clinical Center or Seattle Children’s 
Hospital and their parents.
Inclusion criteria: Adolescents 13 to 17 years of age, 
enrolled in the previous 6 months in a research study 
for any disorder or as healthy controls at the NIH 
Clinical Center or Seattle Children’s Hospital, spoke 
English or Spanish, had a parent or guardian who 
agreed to be interviewed; Parent or guardian of an 
eligible adolescent who agreed to be interviewed, 
spoke English or Spanish.
Exclusion criteria: when both parents were present, 
fathers were invited to participate.
Characteristics: adolescent’s mean age: 15.1 years; 
19.8% healthy, 5.1% minor illness, 75.1% significant 
illness; parents’ mean age: 45.3 years; all consenters
Design: Quantitative study; personal interviews 
(questionnaire) with parents and adolescents to 
conduct an explorative analysis to evaluate whether 
any of 13 potentially relevant, dichotomized variables 
were significant.
Motivating factors: “helping find better treatments for others who 
are ill” is pretty important or very important to their decision to 
enroll in research (for 84.7% of the adolescents and 87.1% of the 
parents).
Discouraging factors: not mentioned.
Other outcomes: willingness to undergo certain procedures.
Confounding: not mentioned.
Level of evidence: C
Critical appraisal: Article focusses on only one reason for 
participation (helping others), Other reasons were not questioned 
and explored; researchers do not mention the social desirability of 
the answer to their main question (helping others); large sample 
size.
Woodgate, 2010
Study population: 31 parents who had a child with a 
history of cancer at the outpatient pediatric cancer 
unit at the city’s primary cancer treatment center.
Inclusion criteria: Ability to speak and understand 
English; Parents of children with differing cancer 
diagnoses and at various stages of the treatment 
completion, from 6 months post diagnosis to 5 years 
after treatment completion.
Exclusion criteria: parents of newly diagnosed cancer 
patients.
Characteristics: parents’ age range: 27-51 years; 
child’s age range: 3-17 years; 29 consenters and 2 
non-consenters.
Design: Qualitative study; person-centered, individual, 
open-ended interviews. Analyzed with an interpretive 
descriptive qualitative method (identifying themes).
Motivating factors: doing “the best” for their child (all); the 
need to help other children with cancer and their families; not 
disappointing their child’s physician.
Discouraging factors: not mentioned.
Other outcomes: 6 themes identified: living a surreal event 
(finding it almost an impossible decision to make), wanting the 
best for my child, helping future families of children with cancer, 
coming to terms with my decision, making one difficult decision 
among many, experiencing a sense of trust.
Confounding: not mentioned.
Level of evidence: +
Critical appraisal: Good thing: open-ended question in interview, 
reasons were not predefined. But no special attention to 2 parents 
who refused participation in trial and their decision.
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Wynn, 2010
Study population: 796 parents of infants approached 
for BABY HUG trial (phase 3 RCT of hydroxyurea)
Inclusion criteria: infant <18 months of age, diagnosis 
of HbSS or HbSb thalassemia.
Exclusion criteria: not mentioned.
Characteristics: 487 (61%) non-consenters and 309 
(39%) consenters.
Design: Quantitative study; evaluation of an 
anonymized registry of potential subjects. Reasons 
participants stated for decision were categorized in 5 
categories.
Motivating factors: Desire to aid research in sickle cell anemia: 
51%; Hope that the child would be randomized to receive 
hydroxyurea: 51%; Desire to closer follow-up through increased 
clinic visits: 51%; Perceived the child to be ill and therefore hoped 
for clinical benefit from participation: 16%.
Discouraging factors: high frequency if required clinic visits, 
blood tests, and special studies: 25%; fear or distrust of research 
participation: 19%; limited access to transportation: 14%; 
perceived their child to be healthy and felt medicine was 
not needed at this time: 10%; wanted their child to receive 
hydroxyurea rather than possibly being randomized to receive 
placebo: 2%.
Other outcomes: reasons for not approaching.
Confounding: classification of responses may have resulted in 
some misinterpretation of reasons; 21% did not state a reason, 
could have caused bias.
Level of evidence: C
Critical appraisal: Good quality: large sample size, prospectively, 
answers were by free response; Minority group questioned, not 
generalizable.
Zupancic, 1997
Study population: 140 parents who had recently 
given or declined consent to one of three controlled 
trials (including drug trial) in the neonatal intensive 
care unit.
Inclusion criteria: not mentioned.
Exclusion criteria: Limited English skills.
Characteristics: child’s median age: 2 days; 103 
consenters, 37 non-consenters; no demographic 
differences.
Design: Quantitative study; cross-sectional written 
questionnaire consisting of 15 socio-demographic 
items and 13 scaled responses to statements. 
Responses were subjected to factor analysis to 
identify underlying constructs. The sample was 
then randomly split, and multiple regression was 
performed on each half.
Motivating factors: Factor analysis and multiple regression 
showed factor: “risk, benefit, and attitudes” to be significantly 
correlated with consent; consenters had lower parental estimates 
of risk and higher estimates of benefit, were more likely to report 
altruistic motives, freedom to make the decision independently 
and positive attitudes toward research.
Discouraging factors: not mentioned.
Other outcomes: Factor analysis and multiple regression showed 
no difference between consenters and non-consenters on “illness 
severity” or socio-demographic factors.
Confounding: not mentioned.
Level of evidence: B
Critical appraisal: Questionnaire was pretested, had good 
reliability and validity. Real consent decisions examined; 
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